US11903910B2 - Use of metformin and analogs thereof to reduce RAN protein levels in the treatment of neurological disorders - Google Patents

Use of metformin and analogs thereof to reduce RAN protein levels in the treatment of neurological disorders Download PDF

Info

Publication number
US11903910B2
US11903910B2 US16/650,721 US201816650721A US11903910B2 US 11903910 B2 US11903910 B2 US 11903910B2 US 201816650721 A US201816650721 A US 201816650721A US 11903910 B2 US11903910 B2 US 11903910B2
Authority
US
United States
Prior art keywords
certain embodiments
iii
alkyl
metformin
ran
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active, expires
Application number
US16/650,721
Other languages
English (en)
Other versions
US20200268691A1 (en
Inventor
Laura Ranum
Tao Zu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Florida Research Foundation Inc
Original Assignee
University of Florida Research Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Florida Research Foundation Inc filed Critical University of Florida Research Foundation Inc
Priority to US16/650,721 priority Critical patent/US11903910B2/en
Publication of US20200268691A1 publication Critical patent/US20200268691A1/en
Assigned to UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED reassignment UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: RANUM, LAURA, ZU, TAO
Application granted granted Critical
Publication of US11903910B2 publication Critical patent/US11903910B2/en
Active legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/11—Protein-serine/threonine kinases (2.7.11)
    • C12Y207/11001—Non-specific serine/threonine protein kinase (2.7.11.1), i.e. casein kinase or checkpoint kinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders

Definitions

  • Mutations of certain repeat expansions are associated with a number of different neurological diseases (e.g., C9ORFf72 amyotrophic lateral sclerosis (ALS), or C9ORFf72 frontotemporal dementia; myotonic dystrophy type 1 (DM1) and myotonic dystrophy type 2 (DM2); spinocerebellar ataxia types 1, 2, 3, 6, 7, 8, 10, 12, 17, 31, and 36; spinal bulbar muscular atrophy; dentatorubral-pallidoluysian atrophy (DRPLA); Huntington's disease (HD); Fragile X Tremor Ataxia Syndrome (FXTAS)); Fuch's endothelial corneal dystrophy (FECD); Huntington's disease-like 2 syndrome (HDL2); Fragile X syndrome (FXS); disorders related to 7p11.2 folate-sensitive fragile site FRA7A; disorders related to folate-
  • ALS amyotrophic lateral sclerosis
  • C9ORFf72 frontotemporal dementia e
  • RAN repeat associated non-ATG
  • RAN proteins are toxic and contribute to a growing number of diseases (Cleary and Ranum 2017). It therefore is important to develop therapeutic strategies that reduce the level of repeat associated non-ATG (RAN) proteins to treat neurological diseases caused by repeat expansion mutations.
  • compositions and methods for the treatment of neurological diseases associated with repeat associated non-ATG (RAN) proteins are described herein.
  • the disclosure also relates to the recognition that inhibiting Protein Kinase R (PKR) expression or activity inhibits RAN protein translation.
  • PKA Protein Kinase R
  • the disclosure is based, in part, on the discovery that mutations of repeat expansions (e.g., CAGG, CCTG, GGGGCC, GGCCCC, CAG, and CTG) are associated with a number of different neurological diseases (e.g., C9ORFf72 amyotrophic lateral sclerosis (ALS) or C9ORFf72 frontotemporal dementia; myotonic dystrophy type 1 (DM1) and myotonic dystrophy type 2 (DM2); spinocerebellar ataxia types 1, 2, 3, 6, 7, 8, 10, 12, 17, 31, and 36; spinal bulbar muscular atrophy; dentatorubral-pallidoluysian atrophy (DRPLA); Huntington's disease (HD); Fuch's endothelial corneal dystrophy (FECD); Fragile X Tremor Ataxia Syndrome (FXTAS); Huntington's disease-like 2 syndrome (HDL2); Fragile X syndrome (FXS); disorders related to 7p11.2 folate-sensitive fragile
  • RAN proteins repeat associated non-ATG translation proteins
  • polyalanine, polyserine, polyleucine, and polycysteine (polyAla, polySer, polyLeu and polyCys, respectively)—accumulate in the brains, tissue (e.g., blood, cerebrospinal fluid), and central nervous systems of subjects having Huntington's disease (HD).
  • C9ORF72 ALS or C9ORF72 FTD RAN proteins with dipeptide RAN proteins e.g., polyGlyPro (GP), polyGlyAla (GA), polyGlyArg (GR), polyProAla (PA) have been shown to accumulate in patient brains, blood and other tissues.
  • RAN proteins have been found in patients with Fragile X Tremor Ataxia Syndrome (FXTAS), myotonic dystrophy type 1 (DM1) and myotonic dystrophy type 2 (DM2).
  • FXTAS Fragile X Tremor Ataxia Syndrome
  • DM1 myotonic dystrophy type 1
  • DM2 myotonic dystrophy type 2
  • RAN proteins are also predicted to accumulate in patients with diseases caused by CAG.CTG repeat expansions including but not limited to spinocerebellar ataxia types 1, 2, 3, 6, 7, 8, 10, 12, 17, 31, and 36; spinal bulbar muscular atrophy (SBMA); dentatorubral-pallidoluysian atrophy (DRPLA); and Fuch's corneal endothelial dystrophy.
  • RAN proteins can be detected in a biological sample (e.g., blood, serum, tissue, or cerebrospinal fluid (CSF)) from a subject having or at risk of developing HD, C9ORF72 ALS, C9ORF72 FTD, DM1, DM2, FXTAS, SCA8; Huntington's disease-like 2 syndrome (HDL2); Fragile X syndrome (FXS); disorders related to 7p11.2 folate-sensitive fragile site FRA7A; disorders related to folate-sensitive fragile site 2q11 FRA2A; and Fragile XE syndrome (FRAXE); or other diseases caused by microsatellite repeat expansion mutations.
  • a biological sample e.g., blood, serum, tissue, or cerebrospinal fluid (CSF)
  • CSF cerebrospinal fluid
  • the present invention provides methods for treating and/or preventing a neurological disease associated with repeat expansions in a subject, the method comprising administering to the subject a therapeutically effective amount of a compound of Formula (I):
  • R 2A , R 3 , R 4 , R 6 , and R 7 are as defined herein.
  • Exemplary compounds of Formula (I) include, but are not limited to:
  • the present invention provides methods for treating and/or preventing a neurological disease associated with repeat expansions in a subject, the method comprising administering to the subject a therapeutically effective amount of metformin:
  • the present invention provides methods for treating and/or preventing a neurological disease associated with repeat expansions in a subject, the method comprising administering to the subject a therapeutically effective amount of a compound of Formula (II):
  • R 2′ , R 3 , R 4′ , R 6 , and R 7 are as defined herein.
  • Exemplary compounds of Formula (II) include, but are not limited to:
  • the present invention provides methods for treating and/or preventing a neurological disease associated with repeat expansions in a subject, the method comprising administering to the subject a therapeutically effective amount of a compound of Formula (III), (III-A), or (III-B):
  • R 4A , R 8 , and R 9 are as defined herein.
  • Exemplary compounds of Formulae (III), (III-A), and (III-B) include, but are not limited to:
  • Another aspect of the invention relates to methods of reducing the accumulation of repeat associated non-ATG protein (RAN) in a subject, tissue, or cell, the method comprising administering to the subject, or contacting the biological sample (e.g., tissue or cells) with an effective amount of a compound of Formula (I), (II), (III), (III-A), or (III-B) (e.g., metformin), or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, stereoisomer, derivative, or prodrug thereof, or a pharmaceutical composition thereof.
  • a compound of Formula (I), (II), (III), (III-A), or (III-B) e.g., metformin
  • a pharmaceutically acceptable salt, solvate, hydrate, tautomer, stereoisomer, derivative, or prodrug thereof e.g., metformin
  • the present invention also provides uses of a compound of Formula (I), (II), (III), (III-A), or (III-B) (e.g., metformin), or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, stereoisomer, derivative, or prodrug thereof, to treat and/or prevent a neurological disease associated with repeat expansions in a subject in need thereof.
  • a compound of Formula (I), (II), (III), (III-A), or (III-B) e.g., metformin
  • a pharmaceutically acceptable salt, solvate, hydrate, tautomer, stereoisomer, derivative, or prodrug thereof e.g., metformin
  • kits comprising a container with a compound of Formula (I), (II), (III), (III-A), or (III-B) (e.g., metformin), a pharmaceutically acceptable salt, solvate, hydrate, tautomer, stereoisomer, derivative, or prodrug, or a pharmaceutical composition thereof, as described herein.
  • the kits described herein may include a single dose or multiple doses of the compound or pharmaceutical composition.
  • the kits may be useful in a method of the disclosure.
  • the kit further includes instructions for using the compound or pharmaceutical composition.
  • a kit described herein may also include information (e.g. prescribing information) as required by a regulatory agency, such as the U.S. Food and Drug Administration (FDA).
  • FDA U.S. Food and Drug Administration
  • Compounds described herein can comprise one or more asymmetric centers, and thus can exist in various isomeric forms, e.g., enantiomers and/or diastereomers.
  • the compounds described herein can be in the form of an individual enantiomer, diastereomer, or geometric isomer, or can be in the form of a mixture of stereoisomers, including racemic mixtures and mixtures enriched in one or more stereoisomer.
  • Isomers can be isolated from mixtures by methods known to those skilled in the art, including chiral high pressure liquid chromatography (HPLC) and the formation and crystallization of chiral salts; or preferred isomers can be prepared by asymmetric syntheses.
  • HPLC high pressure liquid chromatography
  • C 1-6 is intended to encompass C 1 , C 2 , C 3 , C 4 , C 5 , C 6 , C 1-6 , C 1-5 , C 1-4 , C 1-3 , C 1-2 , C 2-6 , C 2-5 , C 2-4 , C 2-3 , C 3-6 , C 3-5 , C 3-4 , C 4-6 , C 4-5 , and C 5-6 .
  • Hydrocarbon chain refers to a substituted or unsubstituted divalent alkyl, alkenyl, or alkynyl group.
  • a hydrocarbon chain includes at least one chain, each node (“carbon unit”) of which including at least one carbon atom, between the two radicals of the hydrocarbon chain.
  • hydrocarbon chain —C A H(C B H 2 C C H 3 )— includes only one carbon unit C A .
  • C x hydrocarbon chain wherein x is a positive integer, refers to a hydrocarbon chain that includes x number of carbon unit(s) between the two radicals of the hydrocarbon chain. If there is more than one possible value of x, the smallest possible value of x is used for the definition of the hydrocarbon chain.
  • —CH(C 2 H 5 )— is a C 1 hydrocarbon chain, and
  • a hydrocarbon chain is a C 3 hydrocarbon chain.
  • a hydrocarbon chain may be saturated (e.g., —(CH 2 ) 4 —).
  • a hydrocarbon chain may also be unsaturated and include one or more C ⁇ C and/or C ⁇ C bonds anywhere in the hydrocarbon chain. For instance, —CH ⁇ CH—(CH 2 ) 2 —, —CH 2 —C ⁇ C—CH 2 —, and —C ⁇ C—CH ⁇ CH— are all examples of a unsubstituted and unsaturated hydrocarbon chain.
  • the hydrocarbon chain is unsubstituted (e.g., —(CH 2 ) 4 —). In certain embodiments, the hydrocarbon chain is substituted (e.g., —CH(C 2 H 5 )— and —CF 2 —). Any two substituents on the hydrocarbon chain may be joined to form an optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl ring. For instance
  • Alkyl refers to a radical of a straight-chain or branched saturated hydrocarbon group having from 1 to 20 carbon atoms (“C 1-20 alkyl”). In some embodiments, an alkyl group has 1 to 10 carbon atoms (“C 1-10 alkyl”). In some embodiments, an alkyl group has 1 to 9 carbon atoms (“C 1-9 alkyl”). In some embodiments, an alkyl group has 1 to 8 carbon atoms (“C 1-8 alkyl”). In some embodiments, an alkyl group has 1 to 7 carbon atoms (“C 1-7 alkyl”). In some embodiments, an alkyl group has 1 to 6 carbon atoms (“C 1-6 alkyl”).
  • an alkyl group has 1 to 5 carbon atoms (“C 1-5 alkyl”). In some embodiments, an alkyl group has 1 to 4 carbon atoms (“C 1-4 alkyl”). In some embodiments, an alkyl group has 1 to 3 carbon atoms (“C 1-3 alkyl”). In some embodiments, an alkyl group has 1 to 2 carbon atoms (“C 1-2 alkyl”). In some embodiments, an alkyl group has 1 carbon atom (“C 1 alkyl”). In some embodiments, an alkyl group has 2 to 6 carbon atoms (“C 2-6 alkyl”).
  • C 1-6 alkyl groups include methyl (C 1 ), ethyl (C 2 ), n-propyl (C 3 ), isopropyl (C 3 ), n-butyl (C 4 ), tert-butyl (C 4 ), sec-butyl (C 4 ), iso-butyl (C 4 ), n-pentyl (C 5 ), 3-pentanyl (C 5 ), amyl (C 5 ), neopentyl (C 5 ), 3-methyl-2-butanyl (C 5 ), tertiary amyl (C 5 ), and n-hexyl (C 6 ).
  • alkyl groups include n-heptyl (C 7 ), n-octyl (C 8 ) and the like. Unless otherwise specified, each instance of an alkyl group is independently optionally substituted, i.e., unsubstituted (an “unsubstituted alkyl”) or substituted (a “substituted alkyl”) with one or more substituents. In certain embodiments, the alkyl group is unsubstituted C 1-10 alkyl (e.g., —CH 3 ). In certain embodiments, the alkyl group is substituted C 1-10 alkyl.
  • Alkenyl refers to a radical of a straight-chain or branched hydrocarbon group having from 2 to 20 carbon atoms, one or more carbon-carbon double bonds, and no triple bonds (“C 2-20 alkenyl”). In some embodiments, an alkenyl group has 2 to 10 carbon atoms (“C 2-10 alkenyl”). In some embodiments, an alkenyl group has 2 to 9 carbon atoms (“C 2-9 alkenyl”). In some embodiments, an alkenyl group has 2 to 8 carbon atoms (“C 2-8 alkenyl”). In some embodiments, an alkenyl group has 2 to 7 carbon atoms (“C 2-7 alkenyl”).
  • an alkenyl group has 2 to 6 carbon atoms (“C 2-6 alkenyl”). In some embodiments, an alkenyl group has 2 to 5 carbon atoms (“C 2-5 alkenyl”). In some embodiments, an alkenyl group has 2 to 4 carbon atoms (“C 2-4 alkenyl”). In some embodiments, an alkenyl group has 2 to 3 carbon atoms (“C 2-3 alkenyl”). In some embodiments, an alkenyl group has 2 carbon atoms (“C 2 alkenyl”). The one or more carbon-carbon double bonds can be internal (such as in 2-butenyl) or terminal (such as in 1-butenyl).
  • Examples of C 2-4 alkenyl groups include ethenyl (C 2 ), 1-propenyl (C 3 ), 2-propenyl (C 3 ), 1-butenyl (C 4 ), 2-butenyl (C 4 ), butadienyl (C 4 ), and the like.
  • Examples of C 2-6 alkenyl groups include the aforementioned C 2-4 alkenyl groups as well as pentenyl (C 5 ), pentadienyl (C 5 ), hexenyl (C 6 ), and the like. Additional examples of alkenyl include heptenyl (C 7 ), octenyl (C 8 ), octatrienyl (C 8 ), and the like.
  • each instance of an alkenyl group is independently optionally substituted, i.e., unsubstituted (an “unsubstituted alkenyl”) or substituted (a “substituted alkenyl”) with one or more substituents.
  • the alkenyl group is unsubstituted C 2-10 alkenyl.
  • the alkenyl group is substituted C 2-10 alkenyl.
  • Alkynyl refers to a radical of a straight-chain or branched hydrocarbon group having from 2 to 20 carbon atoms, one or more carbon-carbon triple bonds, and optionally one or more double bonds (“C 2-20 alkynyl”).
  • an alkynyl group has 2 to 10 carbon atoms (“C 2-10 alkynyl”).
  • an alkynyl group has 2 to 9 carbon atoms (“C 2-9 alkynyl”).
  • an alkynyl group has 2 to 8 carbon atoms (“C 2-8 alkynyl”).
  • an alkynyl group has 2 to 7 carbon atoms (“C 2-7 alkynyl”).
  • an alkynyl group has 2 to 6 carbon atoms (“C 2-6 alkynyl”). In some embodiments, an alkynyl group has 2 to 5 carbon atoms (“C 2-5 alkynyl”). In some embodiments, an alkynyl group has 2 to 4 carbon atoms (“C 2-4 alkynyl”). In some embodiments, an alkynyl group has 2 to 3 carbon atoms (“C 2-3 alkynyl”). In some embodiments, an alkynyl group has 2 carbon atoms (“C 2 alkynyl”). The one or more carbon-carbon triple bonds can be internal (such as in 2-butynyl) or terminal (such as in 1-butynyl).
  • Examples of C 2-4 alkynyl groups include, without limitation, ethynyl (C 2 ), 1-propynyl (C 3 ), 2-propynyl (C 3 ), 1-butynyl (C 4 ), 2-butynyl (C 4 ), and the like.
  • Examples of C 2-6 alkenyl groups include the aforementioned C 2-4 alkynyl groups as well as pentynyl (C 5 ), hexynyl (C 6 ), and the like. Additional examples of alkynyl include heptynyl (C 7 ), octynyl (C 8 ), and the like.
  • each instance of an alkynyl group is independently optionally substituted, i.e., unsubstituted (an “unsubstituted alkynyl”) or substituted (a “substituted alkynyl”) with one or more substituents.
  • the alkynyl group is unsubstituted C 2-10 alkynyl.
  • the alkynyl group is substituted C 2-10 alkynyl.
  • Carbocyclyl or “carbocyclic” refers to a radical of a non-aromatic cyclic hydrocarbon group having from 3 to 10 ring carbon atoms (“C 3-10 carbocyclyl”) and ww ero heteroatoms in the non-aromatic ring system.
  • a carbocyclyl group has 3 to 8 ring carbon atoms (“C 3-8 carbocyclyl”).
  • a carbocyclyl group has 3 to 6 ring carbon atoms (“C 3-6 carbocyclyl”).
  • a carbocyclyl group has 3 to 6 ring carbon atoms (“C 3-6 carbocyclyl”).
  • a carbocyclyl group has 5 to 10 ring carbon atoms (“C 5-10 carbocyclyl”).
  • Exemplary C 3-6 carbocyclyl groups include, without limitation, cyclopropyl (C 3 ), cyclopropenyl (C 3 ), cyclobutyl (C 4 ), cyclobutenyl (C 4 ), cyclopentyl (C 5 ), cyclopentenyl (C 5 ), cyclohexyl (C 6 ), cyclohexenyl (C 6 ), cyclohexadienyl (C 6 ), and the like.
  • Exemplary C 3-8 carbocyclyl groups include, without limitation, the aforementioned C 3-6 carbocyclyl groups as well as cycloheptyl (C 7 ), cycloheptenyl (C 7 ), cycloheptadienyl (C 7 ), cycloheptatrienyl (C 7 ), cyclooctyl (C 8 ), cyclooctenyl (C 8 ), bicyclo[2.2.1]heptanyl (C 7 ), bicyclo[2.2.2]octanyl (C 8 ), and the like.
  • Exemplary C 3-10 carbocyclyl groups include, without limitation, the aforementioned C 3-8 carbocyclyl groups as well as cyclononyl (C 9 ), cyclononenyl (C 9 ), cyclodecyl (C 10 ), cyclodecenyl (C 10 ), octahydro-1H-indenyl (C 9 ), decahydronaphthalenyl (C 10 ), spiro[4.5]decanyl (C 10 ), and the like.
  • the carbocyclyl group is either monocyclic (“monocyclic carbocyclyl”) or contain a fused, bridged or spiro ring system such as a bicyclic system (“bicyclic carbocyclyl”) and can be saturated or can be partially unsaturated.
  • “Carbocyclyl” also includes ring systems wherein the carbocyclic ring, as defined above, is fused with one or more aryl or heteroaryl groups wherein the point of attachment is on the carbocyclic ring, and in such instances, the number of carbons continue to designate the number of carbons in the carbocyclic ring system.
  • each instance of a carbocyclyl group is independently optionally substituted, i.e., unsubstituted (an “unsubstituted carbocyclyl”) or substituted (a “substituted carbocyclyl”) with one or more substituents.
  • the carbocyclyl group is unsubstituted C 3-10 carbocyclyl.
  • the carbocyclyl group is a substituted C 3-10 carbocyclyl.
  • “carbocyclyl” is a monocyclic, saturated carbocyclyl group having from 3 to 10 ring carbon atoms (“C 3-10 cycloalkyl”). In some embodiments, a cycloalkyl group has 3 to 8 ring carbon atoms (“C 3-8 cycloalkyl”). In some embodiments, a cycloalkyl group has 3 to 6 ring carbon atoms (“C 3-6 cycloalkyl”). In some embodiments, a cycloalkyl group has 5 to 6 ring carbon atoms (“C 5-6 cycloalkyl”). In some embodiments, a cycloalkyl group has 5 to 10 ring carbon atoms (“C 5-10 cycloalkyl”).
  • C 5-6 cycloalkyl groups include cyclopentyl (C 5 ) and cyclohexyl (C 5 ).
  • Examples of C 3-6 cycloalkyl groups include the aforementioned C 5-6 cycloalkyl groups as well as cyclopropyl (C 3 ) and cyclobutyl (C 4 ).
  • Examples of C 3-8 cycloalkyl groups include the aforementioned C 3-6 cycloalkyl groups as well as cycloheptyl (C 7 ) and cyclooctyl (C 8 ).
  • each instance of a cycloalkyl group is independently unsubstituted (an “unsubstituted cycloalkyl”) or substituted (a “substituted cycloalkyl”) with one or more substituents.
  • the cycloalkyl group is unsubstituted C 3-10 cycloalkyl.
  • the cycloalkyl group is substituted C 3-10 cycloalkyl.
  • Heterocyclyl or “heterocyclic” refers to a radical of a 3- to 10-membered non-aromatic ring system having ring carbon atoms and 1 to 4 ring heteroatoms, wherein each heteroatom is independently selected from the group consisting of nitrogen, oxygen, sulfur, boron, phosphorus, and silicon (“3-10 membered heterocyclyl”).
  • the point of attachment can be a carbon or nitrogen atom, as valency permits.
  • a heterocyclyl group can either be monocyclic (“monocyclic heterocyclyl”) or a fused, bridged or spiro ring system such as a bicyclic system (“bicyclic heterocyclyl”), and can be saturated or can be partially unsaturated.
  • Heterocyclyl bicyclic ring systems can include one or more heteroatoms in one or both rings.
  • Heterocyclyl also includes ring systems wherein the heterocyclic ring, as defined above, is fused with one or more carbocyclyl groups wherein the point of attachment is either on the carbocyclyl or heterocyclic ring, or ring systems wherein the heterocyclic ring, as defined above, is fused with one or more aryl or heteroaryl groups, wherein the point of attachment is on the heterocyclic ring, and in such instances, the number of ring members continue to designate the number of ring members in the heterocyclic ring system.
  • each instance of heterocyclyl is independently optionally substituted, i.e., unsubstituted (an “unsubstituted heterocyclyl”) or substituted (a “substituted heterocyclyl”) with one or more substituents.
  • the heterocyclyl group is unsubstituted 3-10 membered heterocyclyl. In certain embodiments, the heterocyclyl group is substituted 3-10 membered heterocyclyl.
  • a heterocyclyl group is a 5-10 membered non-aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms, wherein each heteroatom is independently selected from the group consisting of nitrogen, oxygen, sulfur, boron, phosphorus, and silicon (“5-10 membered heterocyclyl”).
  • a heterocyclyl group is a 5-8 membered non-aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms, wherein each heteroatom is independently selected from the group consisting of nitrogen, oxygen, and sulfur (“5-8 membered heterocyclyl”).
  • a heterocyclyl group is a 5-6 membered non-aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms, wherein each heteroatom is independently selected from the group consisting of nitrogen, oxygen, and sulfur (“5-6 membered heterocyclyl”).
  • the 5-6 membered heterocyclyl has 1-3 ring heteroatoms selected from nitrogen, oxygen, and sulfur.
  • the 5-6 membered heterocyclyl has 1-2 ring heteroatoms selected from nitrogen, oxygen, and sulfur.
  • the 5-6 membered heterocyclyl has one ring heteroatom selected from nitrogen, oxygen, and sulfur.
  • Exemplary 3-membered heterocyclyl groups containing one heteroatom include, without limitation, azirdinyl, oxiranyl, and thiiranyl.
  • Exemplary 4-membered heterocyclyl groups containing one heteroatom include, without limitation, azetidinyl, oxetanyl and thietanyl.
  • Exemplary 5-membered heterocyclyl groups containing one heteroatom include, without limitation, tetrahydrofuranyl, dihydrofuranyl, tetrahydrothiophenyl, dihydrothiophenyl, pyrrolidinyl, dihydropyrrolyl, and pyrrolyl-2,5-dione.
  • Exemplary 5-membered heterocyclyl groups containing two heteroatoms include, without limitation, dioxolanyl, oxasulfuranyl, disulfuranyl, and oxazolidin-2-one.
  • Exemplary 5-membered heterocyclyl groups containing three heteroatoms include, without limitation, triazolinyl, oxadiazolinyl, and thiadiazolinyl.
  • Exemplary 6-membered heterocyclyl groups containing one heteroatom include, without limitation, piperidinyl, tetrahydropyranyl, dihydropyridinyl, and thianyl.
  • Exemplary 6-membered heterocyclyl groups containing two heteroatoms include, without limitation, piperazinyl, morpholinyl, dithianyl, and dioxanyl. Exemplary 6-membered heterocyclyl groups containing two heteroatoms include, without limitation, triazinanyl. Exemplary 7-membered heterocyclyl groups containing one heteroatom include, without limitation, azepanyl, oxepanyl and thiepanyl. Exemplary 8-membered heterocyclyl groups containing one heteroatom include, without limitation, azocanyl, oxecanyl and thiocanyl.
  • Exemplary 5-membered heterocyclyl groups fused to a C 6 aryl ring include, without limitation, indolinyl, isoindolinyl, dihydrobenzofuranyl, dihydrobenzothienyl, benzoxazolinonyl, and the like.
  • Exemplary 6-membered heterocyclyl groups fused to an aryl ring include, without limitation, tetrahydroquinolinyl, tetrahydroisoquinolinyl, and the like.
  • Aryl refers to a radical of a monocyclic or polycyclic (e.g., bicyclic or tricyclic) 4n+2 aromatic ring system (e.g., having 6, 10, or 14 pi electrons shared in a cyclic array) having 6-14 ring carbon atoms and zero heteroatoms provided in the aromatic ring system (“C 6-14 aryl”).
  • an aryl group has six ring carbon atoms (“C 6 aryl”; e.g., phenyl).
  • an aryl group has ten ring carbon atoms (“C 10 aryl”; e.g., naphthyl such as 1-naphthyl and 2-naphthyl).
  • an aryl group has fourteen ring carbon atoms (“C 14 aryl”; e.g., anthracyl).
  • Aryl also includes ring systems wherein the aryl ring, as defined above, is fused with one or more carbocyclyl or heterocyclyl groups wherein the radical or point of attachment is on the aryl ring, and in such instances, the number of carbon atoms continue to designate the number of carbon atoms in the aryl ring system.
  • each instance of an aryl group is independently optionally substituted, i.e., unsubstituted (an “unsubstituted aryl”) or substituted (a “substituted aryl”) with one or more substituents.
  • the aryl group is unsubstituted C 6-14 aryl.
  • the aryl group is substituted C 6-14 aryl.
  • Alkyl is a subset of alkyl and aryl and refers to an optionally substituted alkyl group substituted by an optionally substituted aryl group. In certain embodiments, the aralkyl is optionally substituted benzyl. In certain embodiments, the aralkyl is benzyl. In certain embodiments, the aralkyl is optionally substituted phenethyl. In certain embodiments, the aralkyl is phenethyl.
  • Heteroaryl refers to a radical of a 5-10 membered monocyclic or bicyclic 4n+2 aromatic ring system (e.g., having 6 or 10 pi electrons shared in a cyclic array) having ring carbon atoms and 1-4 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from the group consisting of nitrogen, oxygen and sulfur (“5-10 membered heteroaryl”).
  • the point of attachment can be a carbon or nitrogen atom, as valency permits.
  • Heteroaryl bicyclic ring systems can include one or more heteroatoms in one or both rings.
  • Heteroaryl includes ring systems wherein the heteroaryl ring, as defined above, is fused with one or more carbocyclyl or heterocyclyl groups wherein the point of attachment is on the heteroaryl ring, and in such instances, the number of ring members continue to designate the number of ring members in the heteroaryl ring system. “Heteroaryl” also includes ring systems wherein the heteroaryl ring, as defined above, is fused with one or more aryl groups wherein the point of attachment is either on the aryl or heteroaryl ring, and in such instances, the number of ring members designates the number of ring members in the fused (aryl/heteroaryl) ring system.
  • Bicyclic heteroaryl groups wherein one ring does not contain a heteroatom e.g., indolyl, quinolinyl, carbazolyl, and the like
  • the point of attachment can be on either ring, i.e., either the ring bearing a heteroatom (e.g., 2-indolyl) or the ring that does not contain a heteroatom (e.g., 5-indolyl).
  • a heteroaryl group is a 5-10 membered aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from the group consisting of nitrogen, oxygen, and sulfur (“5-10 membered heteroaryl”).
  • a heteroaryl group is a 5-8 membered aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from the group consisting of nitrogen, oxygen, and sulfur (“5-8 membered heteroaryl”).
  • a heteroaryl group is a 5-6 membered aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from the group consisting of nitrogen, oxygen, and sulfur (“5-6 membered heteroaryl”).
  • the 5-6 membered heteroaryl has 1-3 ring heteroatoms selected from nitrogen, oxygen, and sulfur.
  • the 5-6 membered heteroaryl has 1-2 ring heteroatoms selected from nitrogen, oxygen, and sulfur.
  • the 5-6 membered heteroaryl has 1 ring heteroatom selected from nitrogen, oxygen, and sulfur.
  • each instance of a heteroaryl group is independently optionally substituted, i.e., unsubstituted (an “unsubstituted heteroaryl”) or substituted (a “substituted heteroaryl”) with one or more substituents.
  • the heteroaryl group is unsubstituted 5-14 membered heteroaryl. In certain embodiments, the heteroaryl group is substituted 5-14 membered heteroaryl.
  • Exemplary 5-membered heteroaryl groups containing one heteroatom include, without limitation, pyrrolyl, furanyl and thiophenyl.
  • Exemplary 5-membered heteroaryl groups containing two heteroatoms include, without limitation, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, and isothiazolyl.
  • Exemplary 5-membered heteroaryl groups containing three heteroatoms include, without limitation, triazolyl, oxadiazolyl, and thiadiazolyl.
  • Exemplary 5-membered heteroaryl groups containing four heteroatoms include, without limitation, tetrazolyl.
  • Exemplary 6-membered heteroaryl groups containing one heteroatom include, without limitation, pyridinyl.
  • Exemplary 6-membered heteroaryl groups containing two heteroatoms include, without limitation, pyridazinyl, pyrimidinyl, and pyrazinyl.
  • Exemplary 6-membered heteroaryl groups containing three or four heteroatoms include, without limitation, triazinyl and tetrazinyl, respectively.
  • Exemplary 7-membered heteroaryl groups containing one heteroatom include, without limitation, azepinyl, oxepinyl, and thiepinyl.
  • Exemplary 5,6-bicyclic heteroaryl groups include, without limitation, indolyl, isoindolyl, indazolyl, benzotriazolyl, benzothiophenyl, isobenzothiophenyl, benzofuranyl, benzoisofuranyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzoxadiazolyl, benzthiazolyl, benzisothiazolyl, benzthiadiazolyl, indolizinyl, and purinyl.
  • Exemplary 6,6-bicyclic heteroaryl groups include, without limitation, naphthyridinyl, pteridinyl, quinolinyl, isoquinolinyl, cinnolinyl, quinoxalinyl, phthalazinyl, and quinazolinyl.
  • Heteroaralkyl is a subset of alkyl and heteroaryl and refers to an optionally substituted alkyl group substituted by an optionally substituted heteroaryl group.
  • Partially unsaturated refers to a group that includes at least one double or triple bond.
  • a “partially unsaturated” ring system is further intended to encompass rings having multiple sites of unsaturation but is not intended to include aromatic groups (e.g., aryl or heteroaryl groups) as defined herein.
  • aromatic groups e.g., aryl or heteroaryl groups
  • saturated refers to a group that does not contain a double or triple bond, i.e., contains all single bonds.
  • Alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl groups, which are divalent bridging groups are further referred to using the suffix -ene, e.g., alkylene, alkenylene, alkynylene, carbocyclylene, heterocyclylene, arylene, and heteroarylene.
  • Alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl groups are optionally substituted (e.g., “substituted” or “unsubstituted” alkyl, “substituted” or “unsubstituted” alkenyl, “substituted” or “unsubstituted” alkynyl, “substituted” or “unsubstituted” carbocyclyl, “substituted” or “unsubstituted” heterocyclyl, “substituted” or “unsubstituted” aryl or “substituted” or “unsubstituted” heteroaryl group).
  • substituted means that at least one hydrogen present on a group (e.g., a carbon or nitrogen atom) is replaced with a permissible substituent, e.g., a substituent which upon substitution results in a stable compound, e.g., a compound which does not spontaneously undergo transformation such as by rearrangement, cyclization, elimination, or other reaction.
  • a “substituted” group has a substituent at one or more substitutable positions of the group, and when more than one position in any given structure is substituted, the substituent is either the same or different at each position.
  • substituted is contemplated to include substitution with all permissible substituents of organic compounds, any of the substituents described herein that results in the formation of a stable compound.
  • the present invention contemplates any and all such combinations in order to arrive at a stable compound.
  • heteroatoms such as nitrogen may have hydrogen substituents and/or any suitable substituent as described herein which satisfy the valencies of the heteroatoms and results in the formation of a stable moiety.
  • Exemplary carbon atom substituents include, but are not limited to, halogen, —CN, —NO 2 , —N 3 , —SO 2 H, —SO 3 H, —OH, —OR aa , —ON(R bb ) 2 , —N(R bb ) 2 , —N(R bb ) 3 + X ⁇ , —N(OR cc )R bb , —SH, —SR aa , —SSR cc , —C( ⁇ O)R aa , —CO 2 H, —CHO, —C(OR cc ) 2 , —CO 2 R aa , —OC( ⁇ O)R aa , —OCO 2 R aa , —C( ⁇ O)N(R bb ) 2 , —OC( ⁇ O)N(R bb ) 2 , —NR bb C
  • each instance of R aa is, independently, selected from C 1-10 alkyl, C 1-10 perhaloalkyl, C 2-10 alkenyl, C 2-10 alkynyl, heteroC 1-10 alkyl, heteroC 2-10 alkenyl, heteroC 2-10 alkynyl, C 3-10 carbocyclyl, 3-14 membered heterocyclyl, C 6-14 aryl, and 5-14 membered heteroaryl, or two R aa groups are joined to form a 3-14 membered heterocyclyl or 5-14 membered heteroaryl ring, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 R dd groups;
  • each instance of R bb is, independently, selected from hydrogen, —OH, —OR aa , —N(R cc ) 2 , —CN, —C( ⁇ O)R aa , —C( ⁇ O)N(R cc ) 2 , —CO 2 R aa , —SO 2 R aa , —C( ⁇ NR cc )OR aa , —C( ⁇ NR cc )N(R cc ) 2 , —SO 2 N(R cc ) 2 , —SO 2 R cc , —SO 2 OR cc , —SOR aa , —C( ⁇ S)N(R cc ) 2 , —C( ⁇ O)SR cc , —C( ⁇ S)SR cc , —P( ⁇ O)(R aa ) 2 , —P( ⁇ O)(OR cc ) 2
  • each instance of R cc is, independently, selected from hydrogen, C 1-10 alkyl, C 1-10 perhaloalkyl, C 2-10 alkenyl, C 2-10 alkynyl, heteroC 1-10 alkyl, heteroC 2-10 alkenyl, heteroC 2-10 alkynyl, C 3-10 carbocyclyl, 3-14 membered heterocyclyl, C 6-14 aryl, and 5-14 membered heteroaryl, or two R cc groups are joined to form a 3-14 membered heterocyclyl or 5-14 membered heteroaryl ring, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 R dd groups;
  • each instance of R dd is, independently, selected from halogen, —CN, —NO 2 , —N 3 , —SO 2 H, —SO 3 H, —OH, —OR ee , —ON(R ff ) 2 , —N(R ff ) 2 , —N(R ff ) 3 + X ⁇ , —N(OR ee )R ff , —SH, —SR ee , —SSR ee , —C( ⁇ O)R ee , —CO 2 H, —CO 2 R ee , —OC( ⁇ O)R ee , —OCO 2 R ee , —C( ⁇ O)N(R ff ) 2 , —OC( ⁇ O)N(R ff ) 2 , —NR ff C( ⁇ O)R ee , —NR ff CO 2 R
  • each instance of R ee is, independently, selected from C 1-6 alkyl, C 1-6 perhaloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, heteroC 1-6 alkyl, heteroC 2-6 alkenyl, heteroC 2-6 alkynyl, C 3-10 carbocyclyl, C 6-10 aryl, 3-10 membered heterocyclyl, and 3-10 membered heteroaryl, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 R gg groups;
  • each instance of R ff is, independently, selected from hydrogen, C 1-6 alkyl, C 1-6 perhaloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, heteroC 1-6 alkyl, heteroC 2-6 alkenyl, heteroC 2-6 alkynyl, C 3-10 carbocyclyl, 3-10 membered heterocyclyl, C 6-10 aryl and 5-10 membered heteroaryl, or two R ff groups are joined to form a 3-10 membered heterocyclyl or 5-10 membered heteroaryl ring, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 R gg groups; and
  • each instance of R gg is, independently, halogen, —CN, —NO 2 , —N 3 , —SO 2 H, —SO 3 H, —OH, —OC 1-6 alkyl, —ON(C 1-6 alkyl) 2 , —N(C 1-6 alkyl) 2 , —N(C 1-6 alkyl) 3 + X ⁇ , —NH(C 1-6 alkyl) 2 + X ⁇ , —NH 2 (C- 1-6 alkyl) + X ⁇ , —NH 3 + X ⁇ , —N(OC 1-6 alkyl)(C 1-6 alkyl), —N(OH)(C 1-6 alkyl), —NH(OH), —SH, —SC 1-6 alkyl, —SS(C 1-6 alkyl), —C( ⁇ O)(C 1-6 alkyl), —CO 2 H, —CO 2 (C 1-6 alkyl), —OC( ⁇ O
  • a “counterion” or “anionic counterion” is a negatively charged group associated with a positively charged group in order to maintain electronic neutrality.
  • An anionic counterion may be monovalent (i.e., including one formal negative charge).
  • An anionic counterion may also be multivalent (i.e., including more than one formal negative charge), such as divalent or trivalent.
  • Exemplary counterions include halide ions (e.g., F ⁇ , Cl ⁇ , Br ⁇ , I ⁇ ), NO 3 ⁇ , ClO 4 ⁇ , OH ⁇ , H 2 PO 4 ⁇ , HCO 3 ⁇ , HSO 4 ⁇ , sulfonate ions (e.g., methansulfonate, trifluoromethanesulfonate, p-toluenesulfonate, benzenesulfonate, 10-camphor sulfonate, naphthalene-2-sulfonate, naphthalene-1-sulfonic acid-5-sulfonate, ethan-1-sulfonic acid-2-sulfonate, and the like), carboxylate ions (e.g., acetate, propanoate, benzoate, glycerate, lactate, tartrate, glycolate, gluconate, and the like), BF 4
  • Exemplary counterions which may be multivalent include CO 3 2 ⁇ , HPO 4 2 ⁇ , PO 4 3 ⁇ , B 4 O 7 2 ⁇ , SO 4 2 ⁇ , S 2 O 3 2 ⁇ , carboxylate anions (e.g., tartrate, citrate, fumarate, maleate, malate, malonate, gluconate, succinate, glutarate, adipate, pimelate, suberate, azelate, sebacate, salicylate, phthalates, aspartate, glutamate, and the like), and carboranes.
  • carboxylate anions e.g., tartrate, citrate, fumarate, maleate, malate, malonate, gluconate, succinate, glutarate, adipate, pimelate, suberate, azelate, sebacate, salicylate, phthalates, aspartate, glutamate, and the like
  • carboranes e.g., tartrate, citrate, fumarate, maleate, mal
  • Halo or “halogen” refers to fluorine (fluoro, —F), chlorine (chloro, —Cl), bromine (bromo, —Br), or iodine (iodo, —I).
  • acyl refers to a group having the general formula —C( ⁇ O)R X1 , —C( ⁇ O)OR X1 , —C( ⁇ O)—O—C( ⁇ O)R X1 , —C( ⁇ O)SR X1 , —C( ⁇ O)N(R X1 ) 2 , —C( ⁇ S)R X1 , —C( ⁇ S)N(R X1 ) 2 , and —C( ⁇ S)S(R X1 ), —C( ⁇ NR X1 )R X1 , —C( ⁇ NR X1 )OR X1 , —C( ⁇ NR X1 )SR X1 , and —C( ⁇ NR X1 )N(R X1 ) 2 , wherein R X1 is hydrogen; halogen; substituted or unsubstituted hydroxyl; substituted or unsubstituted thiol;
  • acyl groups include aldehydes (—CHO), carboxylic acids (—CO 2 H), ketones, acyl halides, esters, amides, imines, carbonates, carbamates, and ureas.
  • Acyl substituents include, but are not limited to, any of the substituents described herein, that result in the formation of a stable moiety (e.g., aliphatic, alkyl, alkenyl, alkynyl, heteroaliphatic, heterocyclic, aryl, heteroaryl, acyl, oxo, imino, thiooxo, cyano, isocyano, amino, azido, nitro, hydroxyl, thiol, halo, aliphaticamino, heteroaliphaticamino, alkylamino, heteroalkylamino, arylamino, heteroarylamino, alkylaryl, arylalkyl, aliphaticoxy, heteroaliphaticoxy, alkyl
  • Alkoxy or “alkoxyl” refers to a radical of the formula: —O-alkyl.
  • Nitrogen atoms can be substituted or unsubstituted as valency permits, and include primary, secondary, tertiary, and quaternary nitrogen atoms.
  • Exemplary nitrogen atom substituents include, but are not limited to, hydrogen, —OH, —OR aa , —N(R cc ) 2 , —CN, —C( ⁇ O)R aa , —C( ⁇ O)N(R cc ) 2 , —CO 2 R aa , —SO 2 R aa , —C( ⁇ NR bb )R aa , —C( ⁇ NR cc )OR aa , —C( ⁇ NR cc )N(R cc ) 2 , —SO 2 N(R cc ) 2 , —SO 2 R cc , —SO 2 OR cc , —SOR aa , —C( ⁇ S)N(R
  • the substituent present on a nitrogen atom is a nitrogen protecting group (also referred to as an amino protecting group).
  • Nitrogen protecting groups include, but are not limited to, —OH, —OR aa , —N(R cc ) 2 , —C( ⁇ O)R aa , —C( ⁇ O)N(R cc ) 2 , —CO 2 R aa , —SO 2 R aa , —C( ⁇ NR cc )R aa , —C( ⁇ NR cc )OR aa , —C( ⁇ NR cc )N(R cc ) 2 , —SO 2 N(R cc ) 2 , —SO 2 R cc , —SO 2 OR cc , —SOR aa , —C( ⁇ S)N(R cc ) 2 , —C( ⁇ O)SR cc , —C(C(
  • Nitrogen protecting groups are well known in the art and include those described in detail in Protecting Groups in Organic Synthesis , T. W. Greene and P. G. M. Wuts, 3 rd edition, John Wiley & Sons, 1999, incorporated herein by reference.
  • nitrogen protecting groups such as amide groups (e.g., —C( ⁇ O)R aa ) include, but are not limited to, formamide, acetamide, chloroacetamide, trichloroacetamide, trifluoroacetamide, phenylacetamide, 3-phenylpropanamide, picolinamide, 3-pyridylcarboxamide, N-benzoylphenylalanyl derivative, benzamide, p-phenylbenzamide, o-nitophenylacetamide, o-nitrophenoxyacetamide, acetoacetamide, (N′-dithiobenzyloxyacylamino)acetamide, 3-(p-hydroxyphenyl)propanamide, 3-(o-nitrophenyl)propanamide, 2-methyl-2-(o-nitrophenoxy)propanamide, 2-methyl-2-(o-phenylazophenoxy)propanamide, 4-chlorobutanamide, 3-methyl-3-nitrobutanamide, o-nitro
  • Nitrogen protecting groups such as carbamate groups include, but are not limited to, methyl carbamate, ethyl carbamante, 9-fluorenylmethyl carbamate (Fmoc), 9-(2-sulfo)fluorenylmethyl carbamate, 9-(2,7-dibromo)fluoroenylmethyl carbamate, 2,7-di-t-butyl-[9-(10,10-dioxo-10,10,10,10-tetrahydrothioxanthyl)]methyl carbamate (DBD-Tmoc), 4-methoxyphenacyl carbamate (Phenoc), 2,2,2-trichloroethyl carbamate (Troc), 2-trimethylsilylethyl carbamate (Teoc), 2-phenylethyl carbamate (hZ), 1-(1-adamantyl)-1-methylethyl carbamate
  • Nitrogen protecting groups such as sulfonamide groups include, but are not limited to, p-toluenesulfonamide (Ts), benzenesulfonamide, 2,3,6,-trimethyl-4-methoxybenzenesulfonamide (Mtr), 2,4,6-trimethoxybenzenesulfonamide (Mtb), 2,6-dimethyl-4-methoxybenzenesulfonamide (Pme), 2,3,5,6-tetramethyl-4-methoxybenzenesulfonamide (Mte), 4-methoxybenzenesulfonamide (Mbs), 2,4,6-trimethylbenzenesulfonamide (Mts), 2,6-dimethoxy-4-methylbenzenesulfonamide (iMds), 2,2,5,7,8-pentamethylchroman-6-sulfonamide (Pmc), methanesulfonamide
  • Ts p-toluenesulfonamide
  • nitrogen protecting groups include, but are not limited to, phenothiazinyl-(10)-acyl derivative, N′-p-toluenesulfonylaminoacyl derivative, N′-phenylaminothioacyl derivative, N-benzoylphenylalanyl derivative, N-acetylmethionine derivative, 4,5-diphenyl-3-oxazolin-2-one, N-phthalimide, N-dithiasuccinimide (Dts), N-2,3-diphenylmaleimide, N-2,5-dimethylpyrrole, N-1,1,4,4-tetramethyldisilylazacyclopentane adduct (STABASE), 5-substituted 1,3-dimethyl-1,3,5-triazacyclohexan-2-one, 5-substituted 1,3-dibenzyl-1,3,5-triazacyclohexan-2-one, 1-substituted 3,5-dinitro-4
  • the substituent present on an oxygen atom is an oxygen protecting group (also referred to herein as an “hydroxyl protecting group”).
  • Oxygen protecting groups include, but are not limited to, —R aa , —N(R bb ) 2 , —C( ⁇ O)SR aa , —C( ⁇ O)R aa , —CO 2 R aa , —C( ⁇ O)N(R bb ) 2 , —C( ⁇ NR bb )R aa , —C( ⁇ NR bb )OR aa , —C( ⁇ NR bb )N(R bb ) 2 , —S( ⁇ O)R aa , —SO 2 R aa , —Si(R aa ) 3 , —P(R cc ) 2 , —P(R cc ) 3 + X ⁇ , —P(OR cc
  • Oxygen protecting groups are well known in the art and include those described in detail in Protecting Groups in Organic Synthesis , T. W. Greene and P. G. M. Wuts, 3 rd edition, John Wiley & Sons, 1999, incorporated herein by reference.
  • oxygen protecting groups include, but are not limited to, methyl, methoxylmethyl (MOM), methylthiomethyl (MTM), t-butylthiomethyl, (phenyldimethylsilyl)methoxymethyl (SMOM), benzyloxymethyl (BOM), p-methoxybenzyloxymethyl (PMBM), (4-methoxyphenoxy)methyl (p-AOM), guaiacolmethyl (GUM), t-butoxymethyl, 4-pentenyloxymethyl (POM), siloxymethyl, 2-methoxyethoxymethyl (MEM), 2,2,2-trichloroethoxymethyl, bis(2-chloroethoxy)methyl, 2-(trimethylsilyl)ethoxymethyl (SEMOR), tetrahydropyranyl (THP), 3-bromotetrahydropyranyl, tetrahydrothiopyranyl, 1-methoxycyclohexyl, 4-methoxytetrahydropyranyl (MTHP), 4-meth
  • the substituent present on a sulfur atom is a sulfur protecting group (also referred to as a “thiol protecting group”).
  • Sulfur protecting groups include, but are not limited to, —R aa , —N(R bb ) 2 , —C( ⁇ O)SR aa , —C( ⁇ O)R aa , —CO 2 R aa , —C( ⁇ O)N(R bb ) 2 , —C( ⁇ NR bb )R aa , —C( ⁇ NR bb )OR aa , —C( ⁇ NR bb )N(R bb ) 2 , —S( ⁇ O)R aa , —SO 2 R aa , —Si(R aa ) 3 , —P(R cc ) 2 , —P(R cc ) 3 + X ⁇ , —P(OR c
  • Sulfur protecting groups are well known in the art and include those described in detail in Protecting Groups in Organic Synthesis , T. W. Greene and P. G. M. Wuts, 3 rd edition, John Wiley & Sons, 1999, incorporated herein by reference.
  • LG is an art-understood term referring to a molecular fragment that departs with a pair of electrons in a heterolytic bond cleavage, wherein the molecular fragment is an anion or neutral molecule.
  • a leaving group can be an atom or a group capable of being displaced by a nucleophile. See, for example, Smith, March Advanced Organic Chemistry 6th ed. (501-502).
  • Exemplary leaving groups include, but are not limited to, halo (e.g., chloro, bromo, iodo) and activated substituted hydroxyl groups (e.g., —OC( ⁇ O)SR aa , —OC( ⁇ O)R aa , —OCO 2 R aa , —OC( ⁇ O)N(R bb ) 2 , —OC( ⁇ NR bb )R aa , —OC( ⁇ NR bb )OR aa , —OC( ⁇ NR bb )N(R bb ) 2 , —OS( ⁇ O)R aa , —OSO 2 R aa , —OP(R cc ) 2 , —OP(R cc ) 3 , —OP( ⁇ O) 2 R aa , —OP( ⁇ O)(R aa ) 2 , —OP( ⁇ O)(OR cc
  • Suitable leaving groups include, but are not limited to, halogen (such as F, Cl, Br, or I (iodine)), alkoxycarbonyloxy, aryloxycarbonyloxy, alkanesulfonyloxy, arenesulfonyloxy, alkyl-carbonyloxy (e.g., acetoxy), arylcarbonyloxy, aryloxy, methoxy, N,O-dimethylhydroxylamino, pixyl, and haloformates.
  • halogen such as F, Cl, Br, or I (iodine
  • the leaving group is a sulfonic acid ester, such as toluenesulfonate (tosylate, —OTs), methanesulfonate (mesylate, —OMs), p-bromobenzenesulfonyloxy (brosylate, —OBs), or trifluoromethanesulfonate (triflate, —OTf).
  • the leaving group is a brosylate, such as p-bromobenzenesulfonyloxy.
  • the leaving group is a nosylate, such as 2-nitrobenzenesulfonyloxy.
  • the leaving group is a sulfonate-containing group. In some embodiments, the leaving group is a tosylate group.
  • the leaving group may also be a phosphineoxide (e.g., formed during a Mitsunobu reaction) or an internal leaving group such as an epoxide or cyclic sulfate.
  • Other non-limiting examples of leaving groups are water, amines, ammonia, alcohols, ether moieties, sulfur-containing moieties, thioether moieties, zinc halides, magnesium moieties, diazonium salts, and copper moieties.
  • pharmaceutically acceptable salt refers to those salts which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit/risk ratio.
  • Pharmaceutically acceptable salts are well known in the art. For example, Berge et al., describe pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences, 1977, 66, 1-19, incorporated herein by reference.
  • Pharmaceutically acceptable salts of the compounds of this invention include those derived from suitable inorganic and organic acids and bases.
  • Examples of pharmaceutically acceptable, nontoxic acid addition salts are salts of an amino group formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, and perchloric acid or with organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid, or malonic acid or by using other methods known in the art such as ion exchange.
  • inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, and perchloric acid
  • organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid, or malonic acid or by using other methods known in the art such as ion exchange.
  • salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate,
  • Salts derived from appropriate bases include alkali metal, alkaline earth metal, ammonium and N + (C 1-4 alkyl) 4 ⁇ salts.
  • Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like.
  • Further pharmaceutically acceptable salts include, when appropriate, nontoxic ammonium, quaternary ammonium, and amine cations formed using counterions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, lower alkyl sulfonate, and aryl sulfonate.
  • solvate refers to forms of the compound that are associated with a solvent, usually by a solvolysis reaction. This physical association may include hydrogen bonding.
  • solvents include water, methanol, ethanol, acetic acid, DMSO, THF, diethyl ether, and the like.
  • Compounds described herein, including, for example, metformin may be prepared, e.g., in crystalline form, and may be solvated.
  • Suitable solvates include pharmaceutically acceptable solvates and further include both stoichiometric solvates and non-stoichiometric solvates.
  • the solvate will be capable of isolation, for example, when one or more solvent molecules are incorporated in the crystal lattice of a crystalline solid.
  • “Solvate” encompasses both solution-phase and isolable solvates.
  • Representative solvates include hydrates, ethanolates, and methanolates.
  • hydrate refers to a compound that is associated with water.
  • the number of the water molecules contained in a hydrate of a compound is in a definite ratio to the number of the compound molecules in the hydrate. Therefore, a hydrate of a compound may be represented, for example, by the general formula R ⁇ x H 2 O, wherein R is the compound and wherein x is a number greater than 0.
  • a given compound may form more than one type of hydrates, including, e.g., monohydrates (x is 1), lower hydrates (x is a number greater than 0 and smaller than 1, e.g., hemihydrates (R ⁇ 0.5 H 2 O)), and polyhydrates (x is a number greater than 1, e.g., dihydrates (R ⁇ 2 H 2 O) and hexahydrates (R ⁇ 6 H 2 O)).
  • monohydrates x is 1
  • lower hydrates x is a number greater than 0 and smaller than 1, e.g., hemihydrates (R ⁇ 0.5 H 2 O)
  • polyhydrates x is a number greater than 1, e.g., dihydrates (R ⁇ 2 H 2 O) and hexahydrates (R ⁇ 6 H 2 O)
  • tautomers or “tautomeric” refers to two or more interconvertible compounds resulting from at least one formal migration of a hydrogen atom and at least one change in valency (e.g., a single bond to a double bond, a triple bond to a single bond, or vice versa).
  • the exact ratio of the tautomers depends on several factors, including temperature, solvent, and pH. Tautomerizations (i.e., the reaction providing a tautomeric pair) may catalyzed by acid or base.
  • Exemplary tautomerizations include keto-to-enol, amide-to-imide, lactam-to-lactim, enamine-to-imine, and enamine-to-(a different enamine) tautomerizations.
  • stereoisomers that are not mirror images of one another are termed “diastereomers” and those that are non-superimposable mirror images of each other are termed “enantiomers.”
  • enantiomers When a compound has an asymmetric center, for example, it is bonded to four different groups, a pair of enantiomers is possible.
  • An enantiomer can be characterized by the absolute configuration of its asymmetric center and is described by the R- and S-sequencing rules of Cahn and Prelog, or by the manner in which the molecule rotates the plane of polarized light and designated as dextrorotatory or levorotatory (i.e., as (+) or ( ⁇ )-isomers respectively).
  • a chiral compound can exist as either individual enantiomer or as a mixture thereof. A mixture containing equal proportions of the enantiomers is called a “racemic mixture.”
  • prodrugs refers to compounds that have cleavable groups and become by solvolysis or under physiological conditions the compounds described herein, which are pharmaceutically active in vivo. Such examples include, but are not limited to, choline ester derivatives and the like, N-alkylmorpholine esters and the like. Other derivatives of the compounds described herein have activity in both their acid and acid derivative forms, but in the acid sensitive form often offer advantages of solubility, tissue compatibility, or delayed release in the mammalian organism (see, Bundgard, H., Design of Prodrugs , pp. 7-9, 21-24, Elsevier, Amsterdam 1985).
  • Prodrugs include acid derivatives well known to practitioners of the art, such as, for example, esters prepared by reaction of the parent acid with a suitable alcohol, or amides prepared by reaction of the parent acid compound with a substituted or unsubstituted amine, or acid anhydrides, or mixed anhydrides. Simple aliphatic or aromatic esters, amides, and anhydrides derived from acidic groups pendant on the compounds described herein are particular prodrugs. In some cases it is desirable to prepare double ester type prodrugs such as (acyloxy)alkyl esters or ((alkoxycarbonyl)oxy)alkylesters.
  • C 1 -C 8 alkyl, C 2 -C 8 alkenyl, C 2 -C 8 alkynyl, aryl, C 7 -C 12 substituted aryl, and C 7 -C 12 arylalkyl esters of the compounds described herein may be preferred.
  • a “subject” to which administration is contemplated includes, but is not limited to, humans (i.e., a male or female of any age group, e.g., a pediatric subject (e.g., infant, child, adolescent) or adult subject (e.g., young adult, middle-aged adult, or senior adult)) and/or other non-human animals, for example, mammals (e.g., primates (e.g., cynomolgus monkeys, rhesus monkeys); commercially relevant mammals such as cattle, pigs, horses, sheep, goats, cats, and/or dogs) and birds (e.g., commercially relevant birds such as chickens, ducks, geese, and/or turkeys).
  • mammals e.g., primates (e.g., cynomolgus monkeys, rhesus monkeys); commercially relevant mammals such as cattle, pigs, horses, sheep, goats, cats, and/or dogs) and birds (
  • the animal is a mammal.
  • the animal may be a male or female and at any stage of development.
  • a non-human animal may be a transgenic animal or genetically engineered animal (e.g., a transgenic mouse).
  • a “patient” refers to a human subject in need of treatment of a disease (e.g., a neurological disease or neurodegenerative disease), which may include, but is not limited to, human subjects with microsatellite repeat expansion mutations.
  • administer refers to implanting, absorbing, ingesting, injecting, inhaling, or otherwise introducing an inventive compound, or a pharmaceutical composition thereof.
  • treatment refers to reversing, alleviating, delaying the onset of, or inhibiting the progress of a “pathological condition” (e.g., a disease, disorder, or condition, or one or more signs or symptoms thereof) described herein.
  • pathological condition e.g., a disease, disorder, or condition, or one or more signs or symptoms thereof
  • treatment may be administered after one or more signs or symptoms have developed or have been observed.
  • treatment may be administered in the absence of signs or symptoms of the disease or condition.
  • treatment may be administered to a susceptible individual prior to the onset of symptoms (e.g., in light of a history of symptoms and/or in light of genetic or other susceptibility factors). Treatment may also be continued after symptoms have resolved, for example, to delay or prevent a neurological disease associated with repeat expansions, or to reduce the accumulation of RAN protein in a subject, tissue, or cell.
  • a “therapeutically effective amount” of a compound described herein is an amount sufficient to provide a therapeutic benefit in the treatment of a condition or to delay or minimize one or more symptoms associated with the condition.
  • a therapeutically effective amount of a compound means an amount of therapeutic agent, alone or in combination with other therapies, which provides a therapeutic benefit in the treatment of the condition.
  • the term “therapeutically effective amount” can encompass an amount that improves overall therapy, reduces or avoids symptoms, signs, or causes of the condition, and/or enhances the therapeutic efficacy of another therapeutic agent.
  • a therapeutically effective amount is effective for treating a disease.
  • a therapeutically effective amount is effective for treating an neurological disease associated with repeat expansions.
  • a therapeutically effective amount is effective for treating a neurodegenerative disease associated with repeat expansions. In certain embodiments, a therapeutically effective amount is an amount effective in reducing repeat expansions. In certain embodiments, a therapeutically effective amount is an amount effective in reducing the transcription of RNAs that produce RAN proteins. In certain embodiments, a therapeutically effective amount is an amount effective in reducing the translation of RAN proteins. In certain embodiments, a therapeutically effective amount is an amount effective in reducing the level of one or more RAN proteins in a subject. In certain embodiments, a therapeutically effective amount is an amount effective in reducing the level of one or more RAN proteins and treating a neurological disease associated with repeat expansions.
  • a therapeutically effective amount is an amount effective in reducing the level of one or more RAN proteins and treating a neurological disease associated with RAN protein accumulation. In certain embodiments, a therapeutically effective amount is an amount effective in reducing the accumulation of RAN proteins. In certain embodiments, a therapeutically effective amount is effective for treating amyotrophic lateral sclerosis (ALS). In certain embodiments, a therapeutically effective amount is effective for treating frontotemporal dementia (FTD). In certain embodiments, a therapeutically effective amount is effective for treating C9ORFf72 ALS. In certain embodiments, a therapeutically effective amount is effective for treating C9ORFf72 FTD. In certain embodiments, a therapeutically effective amount is effective for treating spinocerebellar ataxia.
  • ALS amyotrophic lateral sclerosis
  • FTD frontotemporal dementia
  • a therapeutically effective amount is effective for treating C9ORFf72 ALS.
  • a therapeutically effective amount is effective for treating C9ORFf72 FTD. In certain embodiments
  • a therapeutically effective amount is effective for treating spinocerebellar ataxia type 1, spinocerebellar ataxia type 2, spinocerebellar ataxia type 3, or spinocerebellar ataxia type 8. In certain embodiments, a therapeutically effective amount is effective for treating a spinocerebellar ataxia type 6, spinocerebellar ataxia type 7, spinocerebellar ataxia type 10, spinocerebellar ataxia type 12, spinocerebellar ataxia type 17, spinocerebellar ataxia type 31, or spinocerebellar ataxia type 36. In certain embodiments, a therapeutically effective amount is effective for treating myotonic dystrophy.
  • a therapeutically effective amount is effective for treating myotonic dystrophy type 1, myotonic dystrophy type 2, or Fuch's corneal endothelial dystrophy. In certain embodiments, a therapeutically effective amount is effective for treating spinal bulbar muscular atrophy. In certain embodiments, a therapeutically effective amount is effective for treating dentatorubral-pallidoluysian atrophy. In certain embodiments, a therapeutically effective amount is effective for treating Huntington's disease. In certain embodiments, a therapeutically effective amount is effective for treating Fragile X Tremor Ataxia Syndrome (FXTAS).
  • FXTAS Fragile X Tremor Ataxia Syndrome
  • a therapeutically effective amount is effective for Huntington's disease-like 2 syndrome (HDL2); Fragile X syndrome (FXS); disorders related to 7p11.2 folate-sensitive fragile site FRA7A; disorders related to folate-sensitive fragile site 2q11 FRA2A; or Fragile XE syndrome (FRAXE).
  • HDL2 Huntington's disease-like 2 syndrome
  • FXS Fragile X syndrome
  • disorders related to 7p11.2 folate-sensitive fragile site FRA7A disorders related to folate-sensitive fragile site 2q11 FRA2A
  • Fragile XE syndrome Fragile XE syndrome
  • a “prophylactically effective amount” of a compound described herein is an amount sufficient to prevent a condition, or one or more symptoms associated with the condition or prevent its recurrence.
  • a prophylactically effective amount of a compound means an amount of a therapeutic agent, alone or in combination with other agents, which provides a prophylactic benefit in the prevention of the condition.
  • the term “prophylactically effective amount” can encompass an amount that improves overall prophylaxis or enhances the prophylactic efficacy of another prophylactic agent.
  • a prophylactically effective amount is effective for preventing a neurological disease associated with repeat expansions.
  • a prophylactically effective amount is effective for preventing a neurological disease associated with RAN protein accumulation.
  • a prophylactically effective amount is effective for preventing a neurodegenerative disease associated with repeat expansions. In certain embodiments, a prophylactically effective amount is effective in preventing C9ORFf72 amyotrophic lateral sclerosis (ALS) or C9ORFf72 frontotemporal dementia; myotonic dystrophy type 1 (DM1) and myotonic dystrophy type 2 (DM2); spinocerebellar ataxia types 1, 2, 3, 6, 7, 8, 10, 12, 17, 31, and 36; spinal bulbar muscular atrophy; dentatorubral-pallidoluysian atrophy (DRPLA); Huntington's disease; Fuch's endothelial corneal dystrophy (FECD); Fragile X Tremor Ataxia Syndrome (FXTAS); Huntington's disease-like 2 syndrome (HDL2); Fragile X syndrome (FXS); disorders related to 7p11.2 folate-sensitive fragile site FRA7A; disorders related to folate-sensitive fragile site 2q11 FRA
  • ALS
  • a prophylactically effective amount is effective in reducing the level of RAN proteins in tissues from subjects with gene mutations that can cause C9orf72 amyotrophic lateral sclerosis (ALS) or C9orf72 frontotemporal dementia; myotonic dystrophy type 1 (DM1) and myotonic dystrophy type 2 (DM2); spinocerebellar ataxia types 1, 2, 3, 6, 7, 8, 10, 12, 17, 31, and 36; spinal bulbar muscular atrophy; dentatorubral-pallidoluysian atrophy (DRPLA); Huntington's disease; Fuch's endothelial corneal dystrophy (FECD); Fragile X Tremor Ataxia Syndrome (FXTAS); Huntington's disease-like 2 syndrome (HDL2); Fragile X syndrome (FXS); disorders related to 7p11.2 folate-sensitive fragile site FRA7A; disorders related to folate-sensitive fragile site 2q11 FRA2A; or Fragile XE syndrome (FRAX
  • a prophylactically effective amount is effective in preventing the accumulation of RAN proteins in tissues from subjects with gene mutations that can cause C9orf72 amyotrophic lateral sclerosis (ALS) or C9orf72 frontotemporal dementia; myotonic dystrophy type 1 (DM1) and myotonic dystrophy type 2 (DM2); spinocerebellar ataxia types 1, 2, 3, 6, 7, 8, 10, 12, 17, 31, and 36; spinal bulbar muscular atrophy; dentatorubral-pallidoluysian atrophy (DRPLA); Huntington's disease; Fuch's endothelial corneal dystrophy (FECD); Fragile X Tremor Ataxia Syndrome (FXTAS)); Huntington's disease-like 2 syndrome (HDL2); Fragile X syndrome (FXS); disorders related to 7p11.2 folate-sensitive fragile site FRA7A; disorders related to folate-sensitive fragile site 2q11 FRA2A; or Fragile XE syndrome (FRA
  • tissue sample refers to any sample including tissue samples (such as tissue sections and needle biopsies of a tissue); cell samples (e.g., cytological smears (such as Pap or blood smears) or samples of cells obtained by microdissection); samples of whole organisms (such as samples of yeasts or bacteria); or cell fractions, fragments or organelles (such as obtained by lysing cells and separating the components thereof by centrifugation or otherwise).
  • tissue samples such as tissue sections and needle biopsies of a tissue
  • cell samples e.g., cytological smears (such as Pap or blood smears) or samples of cells obtained by microdissection) or samples of cells obtained by microdissection
  • samples of whole organisms such as samples of yeasts or bacteria
  • cell fractions, fragments or organelles such as obtained by lysing cells and separating the components thereof by centrifugation or otherwise.
  • biological samples include blood, serum, urine, semen, fecal matter, cerebrospinal fluid, interstitial fluid, mucus, tears, sweat, pus, biopsied tissue (e.g., obtained by a surgical biopsy or needle biopsy), nipple aspirates, milk, vaginal fluid, saliva, swabs (such as buccal swabs), or any material containing biomolecules that is derived from a first biological sample.
  • Biological samples also include those biological samples that are transgenic, such as transgenic oocyte, sperm cell, blastocyst, embryo, fetus, donor cell, or cell nucleus.
  • Biological samples further include white blood cells in peripheral blood, or brain lysates and cerebrospinal fluid.
  • a “protein” or “peptide” comprises a polymer of amino acid residues linked together by peptide bonds.
  • the term refers to proteins, polypeptides, and peptides of any size, structure, or function. Typically, a protein will be at least three amino acids long.
  • a protein may refer to an individual protein or a collection of proteins. Inventive proteins preferably contain only natural amino acids, although non-natural amino acids (i.e., compounds that do not occur in nature but that can be incorporated into a polypeptide chain) and/or amino acid analogs as are known in the art may alternatively be employed.
  • amino acids in an inventive protein may be modified, for example, by the addition of a chemical entity such as a carbohydrate group, a hydroxyl group, a phosphate group, a farnesyl group, an isofarnesyl group, a fatty acid group, a linker for conjugation or functionalization, or other modification.
  • a protein may also be a single molecule or may be a multi-molecular complex.
  • a protein may be a fragment of a naturally occurring protein or peptide.
  • a protein may be naturally occurring, recombinant, or synthetic, or any combination of these.
  • a “RAN protein (repeat-associated non-ATG translated protein)” is a polypeptide translated from sense or antisense RNA sequences carrying a nucleotide expansion without the requirement for an AUG initiation codon.
  • RAN proteins comprise “expansion repeats” or “repeat expansions” of an amino acid, termed poly amino acid repeats.
  • AAAAAAAAAAAAAAAAAAAAAAAA poly-Alanine
  • LLLLLLLLLLLLLLLLLLLL poly-Leucine
  • SSSSSSSSSSSSSSSSSSSSSSSSSSSS poly-Serine
  • CCCCCCCCCCCCCCCCCCCC poly-Cysteine
  • SEQ ID NO: 4 are poly amino acid repeats that are each 20 amino acid residues in length.
  • RAN proteins can have a poly amino acid repeat of at least 25, at least 30, at least 40, at least 50, at least 60, at least 70, at least 80, at least 90, at least 100, or at least 200 amino acid residues in length.
  • a RAN protein has a poly amino acid repeat more than 200 amino acid residues in length.
  • RAN proteins are translated from abnormal repeat expansions (e.g., CAG repeats) of DNA.
  • RAN proteins comprise expansion repeats of one or amino acid, termed poly amino acid repeats (e.g., di-amino acid repeats).
  • RAN protein accumulation e.g., in the nucleus or cytoplasm of a cell disrupts cellular function and induces cellular toxicity.
  • translation and accumulation of RAN proteins is associated with a disease, for example, a neurological disease, neurodegenerative disease, or neurodegenerative disorder.
  • diseases associated with RAN protein translation and accumulation include but are not limited to C9ORFf72 ALS, C9ORFf72 FTD, myotonic dystrophy type 1 (DM1) and myotonic dystrophy type 2 (DM2), spinocerebellar ataxia types 1, 2, 3, 6, 7, 8, 10, 12, 17, 31, and 36; spinal bulbar muscular atrophy; dentatorubral-pallidoluysian atrophy (DRPLA); Huntington's disease (HD); Fuch's endothelial corneal dystrophy (FECD); Fragile X Tremor Ataxia Syndrome (FXTAS); Huntington's disease-like 2 syndrome (HDL2); Fragile X syndrome (FXS); disorders related to 7p11.2 folate-sensitive fragile site FRA7A; disorders related to folate-sensitive fragile site 2q11 FRA2A; and Fra
  • a “repeat expansion” is a mutation which increases the number of times that a short nucleotide sequence is repeated. Exemplary repeat expansions are provided above in the definition of “RAN protein.”
  • C9ORFf72 amyotrophic lateral sclerosis or “C9ORFf72 ALS” refers to amyotrophic lateral sclerosis associated with a hexanucleotide repeat expansion mutation in the chromosome 9 open reading frame 72 (C9ORFf72) gene.
  • C9ORFf72 frontotemporal dementia or “C9ORFf72 FTD” refers to frontotemporal dementia associated with a hexanucleotide expansion mutation in the C9ORFf72 gene.
  • Neurodegenerative diseases refers to a type of neurological disease marked by the loss of nerve cells.
  • neurodegenerative diseases include but are not limited to C9ORFf72 ALS, C9ORFf72 FTD, myotonic dystrophy type 1 (DM1) and myotonic dystrophy type 2 (DM2), spinocerebellar ataxia types 1, 2, 3, 6, 7, 8, 10, 12, 17, 31, and 36; spinal bulbar muscular atrophy; dentatorubral-pallidoluysian atrophy (DRPLA); Huntington's disease (HD); Fuch's endothelial corneal dystrophy (FECD); Fragile X Tremor Ataxia Syndrome (FXTAS); Huntington's disease-like 2 syndrome (HDL2); Fragile X syndrome (FXS); disorders related to 7p11.2 folate-sensitive fragile site FRA7A; disorders related to folate-sensitive fragile site 2q11 FRA2A; and Fragile XE syndrome (FRAXE).
  • Neuromuscular diseases refer to a type of neurological disease marked by pathologies of the nerves or neuromuscular junctions.
  • FIG. 1 B shows that metformin inhibits RAN translation in multiple reading frames in cells that have been transfected with constructs containing CAG, CCTG, or GGGGCC repeat expansion motifs.
  • the lane labeled KMQ has a methionine encoding ATG immediately 5′ to the CAG repeat expansion and located within the polyGln reading frame.
  • the KKQ vector contains a CAG expansion without an AUG initiation codon, and indicates: Ser-Flag, Ala-HA, Gln-Myc.
  • constructs contain epitope tags that are incorporated into the C-terminal regions of the ATG-initiated poly-Gln and non-ATG initiated RAN proteins (poly-Gln, poly-Leu-Pro-Ala-Cys and poly-Gly-Pro) which are expressed across these repeat expansions.
  • the lane labeled CCTG expresses the following RAN proteins: LPAC-Flag, LPAC-HA, and LPAC-Myc.
  • the lane labeled G4C2 is designed to detect the following RAN proteins: GP-Flag, GR-HA, and GA-Myc.
  • Treatment of the transfected HEK293T cells with metformin shows reduced RAN protein levels of the following RAN proteins of poly-LPAC (poly-Leucine-Proline-Alanine-Cysteine in all three reading frames, poly-Ala, and poly-GP (poly-glycine-proline).
  • poly-LPAC poly-Leucine-Proline-Alanine-Cysteine in all three reading frames
  • poly-Ala poly-Ala
  • poly-GP poly-glycine-proline
  • FIG. 2 shows that steady state levels of RAN proteins expressed by the C9ORF72 expansion mutation were reduced in vivo in a human study subject before and after taking metformin (500 mg or 1000 mg per day Metformin Hydrochloride Extended Release Tablets) as prescribed by the subject's physician.
  • metformin 500 mg or 1000 mg per day Metformin Hydrochloride Extended Release Tablets
  • GP glycine-proline
  • FIGS. 3 A- 3 J show metformin inhibits PKR and reduces RAN proteins and ameliorates disease in C9orf72 ALS/FTD BAC transgenic mice (C9-BAC) mice.
  • FIG. 3 A shows a protein blot indicating that metformin reduces RAN protein expression in HEK293T cells transiently transfected with CAG, CCTG, CAGG, and G4C2 expansion constructs.
  • FIG. 3 B shows data indicating that metformin reduces levels of p-PKR (T446 and T451) in cells transfected with repeat expansion constructs.
  • FIG. 3 C is a schematic diagram showing the study design for two metformin treatment groups, with treatment at 5 mM metformin from 2 to 5 months of age or from six to 9 months of age.
  • FIG. 3 D shows data quantifying GA aggregates and indicates a reduction in GA aggregates in mice treated with 5 mM metformin in their drinking water from 2-5 months compared to untreated C9-500 mice.
  • FIG. 3 E shows quantification of GFAP staining, indicating decreased levels of reactive gliosis in C9-500 metformin treated mice compared to C9-500 control animals.
  • FIG. 3 F shows DigiGait analyses indicating that of eight parameters that differed between untreated C9-500 and NT controls, 6 of these parameters improved in C9-500 animals treated with metformin.
  • FIG. 3 G shows open field analyses showing decreased center time in C9-500 animals that is normalized in C9-500 animals treated with metformin.
  • FIG. 3 H shows data from MSD assays indicating soluble GP levels are reduced in C9-500 animals treated with metformin compared to C9-500 controls.
  • FIG. 3 I shows GA aggregates are reduced in C9-500 animals treated with metformin compared to C9-500 controls.
  • FIG. 3 J is a schematic showing that chronic activation of the PKR pathway by repeat expansion RNAs favors RAN translation through the integrated stress response and eIF2t phosphorylation.
  • FIG. 4 shows metformin and related drugs phenformin and buformin inhibit PKR and reduce GP RAN protein levels in a dose-dependent manner.
  • Top panel protein blots showing metformin, phenformin, and buformin reduce RAN GP protein levels in HEK293T cells transiently transfected with G4C2 expansion constructs in a dose dependent manner.
  • Bottom panel metformin, phenformin, and bufomin reduce levels of p-PKR (T446 and T451) in cells transfected with a G4C2 repeat expansion construct.
  • FIGS. 5 A- 5 B show metformin inhibits RAN translation in multiple reading frames in cells that have been transfected with constructs containing CAG, CCTG, or GGGGCC repeat expansion motifs. Protein blots were run on protein lysates from HEK293T cells transfected with various repeat expansion constructs shown in FIG. 5 A .
  • the lane labeled KMQ has a methionine encoding ATG immediately 5′ to the CAG repeat expansion and located within the polyGln reading frame.
  • the KKQ vector contains a CAG expansion without an AUG initiation codon, and indicates: Ser-Flag, Ala-HA, Gln-Myc.
  • constructs contain epitope tags that are incorporated into the C-terminal regions of the ATG-initiated poly-Gln and non-ATG initiated RAN proteins (poly-Gln, poly-Leu-Pro-Ala-Cys and poly-Gly-Pro) which are expressed across these repeat expansions.
  • the lane labeled CCTG expresses the following RAN proteins: LPAC-Flag, LPAC-HA, and LPAC-Myc.
  • the lane labeled G4C2 is designed to detect the following RAN proteins: GP-Flag, GR-HA, and GA-Myc.
  • Treatment of the transfected HEK293T cells with metformin shows reduced RAN protein levels of the following RAN proteins of poly-LPAC (poly-Leucine-Proline-Alanine-Cysteine in all three reading frames, poly-Ala, and poly-GP (poly-glycine-proline).
  • poly-LPAC poly-Leucine-Proline-Alanine-Cysteine in all three reading frames
  • poly-Ala poly-Ala
  • poly-GP poly-glycine-proline
  • FIG. 6 B shows a schematic diagram showing the study design for two metformin treatment groups, with treatment from 2 to 5 months (Group A) or from 6 to 10 months of age (Group B).
  • FIG. 6 C shows quantification of GA aggregates shows a reduction in GA aggregates in metformin treated compared to untreated C9-BAC mice.
  • FIG. 6 D shows soluble GP levels are reduced Group B but not Group A C9-BAC animals treated with metformin compared to controls.
  • FIG. 6 E shows DigiGait analyses showing 6 of 8 parameters that differed between untreated C9-BAC and non-transgenic (NT) littermate controls improved in C9-BAC animals treated with metformin.
  • FIG. 6 F shows exemplary data of three DigiGait parameters.
  • FIG. 6 G shows open-field analyses showing increased center time in C9-BAC animals treated with metformin.
  • FIGS. 6 G and 6 H show decreased reactive gliosis as measured by GFAP staining ( FIG. 6 H ) in metformin treated vs. untreated C9-BAC animals ( FIG. 6 I ).
  • Statistical analyses were performed using two-tailed t-test (panels a-f, i), *P ⁇ 0.05, **P ⁇ 0.01, ***P ⁇ 0.001.
  • FIG. 6 F and FIG. 6 G statistical analyses were performed using one-way ANOVA with Tukey analyses for multiple comparisons *P ⁇ 0.05, **P ⁇ 0.01, ***P ⁇ 0.001.
  • the present invention provides compositions, methods, uses, and kits for using compounds of Formulae (I), (II), (III), (III-A), and (III-B) (e.g., metformin, buformin, phenformin) to treat and/or preventing a neurological disease associated with repeat expansions in a subject in need thereof.
  • Metformin is used to inhibit RAN translation.
  • the neurological disease to be treated is associated with repeat expansions.
  • the neurological disease is associated with repeat expansion mutations that undergo RAN protein translation.
  • the neurological disease is associated with the expression of RAN proteins.
  • the disclosure provides a method for administering to a subject a therapeutically effective amount of a compound of Formula (I), (II), (III), (III-A), or (III-B) (e.g., metformin, buformin, phenformin), or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, stereoisomer, derivative, or prodrug thereof.
  • a therapeutically effective amount of a compound of Formula (I), (II), (III), (III-A), or (III-B) e.g., metformin, buformin, phenformin
  • a pharmaceutically acceptable salt, solvate, hydrate, tautomer, stereoisomer, derivative, or prodrug thereof e.g., metformin
  • the disclosure provides a method for administering to the biological sample (e.g., cells or tissue) a therapeutically effective amount of a compound described herein (e.g., metformin), or a pharmaceutically acceptable salt, solvate,
  • a biological sample includes, but is not limited to, cells, tissue, cerebrospinal fluid, blood, or tissue biopsy samples from a subject.
  • the method comprises treating a neurological disease associated with repeat expansions in a subject (e.g., C9ORFf72 amyotrophic lateral sclerosis (ALS) or C9ORFf72 frontotemporal dementia; myotonic dystrophy type 1 (DM1) and myotonic dystrophy type 2 (DM2); spinocerebellar ataxia types 1, 2, 3, 6, 7, 8, 10, 12, 17, 31, and 36; spinal bulbar muscular atrophy; dentatorubral-pallidoluysian atrophy (DRPLA); Huntington's disease (HD); Fuch's endothelial corneal dystrophy (FECD); Fragile X Tremor Ataxia Syndrome (FXTAS)); Huntington's disease-like 2 syndrome (HDL2); Fragile X syndrome (FXS); FRAXA; disorders related to 7p11.2 folate-sensitive
  • the method comprises treating a neurological disease associated with repeat expansions in a biological sample (e.g., cells) from a patient with the disease, the method comprising contacting the biological sample with a therapeutically effective amount of a compound of Formula (I), (II), (III), (III-A), or (III-B) (e.g., metformin), or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, stereoisomer, derivative, or prodrug thereof.
  • a biological sample e.g., cells
  • a biological sample e.g., cells
  • a therapeutically effective amount of a compound of Formula (I), (II), (III), (III-A), or (III-B) e.g., metformin
  • a pharmaceutically acceptable salt, solvate, hydrate, tautomer, stereoisomer, derivative, or prodrug thereof e.g., metformin
  • the method comprises treating a neurological disease associated with repeat expansions in a biological sample from a patient with the disease, the method comprising contacting the biological sample with a therapeutically effective amount of a compound of Formula (I), (II), (III), (III-A), or (III-B) (e.g., metformin), or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, stereoisomer, derivative, or prodrug thereof.
  • a compound of Formula (I), (II), (III), (III-A), or (III-B) e.g., metformin
  • a pharmaceutically acceptable salt, solvate, hydrate, tautomer, stereoisomer, derivative, or prodrug thereof e.g., metformin
  • the method comprises treating a neurological disease associated with repeat expansions in a tissue from a patient with the disease, the method comprising contacting the tissue with a therapeutically effective amount of a compound of Formula (I), (II), (III), (III-A), or (III-B) (e.g., metformin), or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, stereoisomer, derivative, or prodrug thereof.
  • a compound of Formula (I), (II), (III), (III-A), or (III-B) e.g., metformin
  • a pharmaceutically acceptable salt, solvate, hydrate, tautomer, stereoisomer, derivative, or prodrug thereof e.g., metformin
  • the method comprises treating a neurological disease associated with the accumulation of RAN proteins in a subject, the method comprising administering to the subject a therapeutically effective amount of a compound of Formula (I), (II), (III), (III-A), or (III-B) (e.g., metformin), or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, stereoisomer, derivative, or prodrug thereof.
  • a compound of Formula (I), (II), (III), (III-A), or (III-B) e.g., metformin
  • a pharmaceutically acceptable salt, solvate, hydrate, tautomer, stereoisomer, derivative, or prodrug thereof e.g., metformin
  • Another aspect of the invention relates to methods of treating a neurological disease associated with repeat expansions in a subject or cell, by administering to the subject or contacting the biological sample (e.g., cells or tissue) with a therapeutically effective amount of a compound of Formula (I), (II), (III), (III-A), or (III-B) (e.g., metformin), or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, stereoisomer, derivative, or prodrug thereof, whereby the method comprises modulating RAN protein translation.
  • the method comprises modulating the steady state levels of RAN proteins.
  • the method comprises reducing the accumulation of RAN protein in a subject.
  • the method comprises reducing the accumulation of RAN protein in a tissue. In certain embodiments, the method comprises reducing the accumulation of RAN protein in a cell. In certain embodiments, the modulating comprises negative regulation of RAN protein translation. In certain embodiments, the modulating comprises inhibition of RAN protein translation. In certain embodiments, the modulating comprises negative regulation of RAN protein translation and reduced accumulation of RAN protein in a cell. In certain embodiments, the modulating comprises negative regulation of RAN protein accumulation in a cell or in patient tissue. In certain embodiments, the modulating comprises changes related to translation of RAN proteins. In certain embodiments, the modulating comprises changes related to turnover of RAN proteins.
  • the method comprises reducing the level of one or more repeat associated non-ATG (RAN) proteins in a cell, tissue, biological sample, or subject. In certain embodiments, the method comprises reducing the translation of RAN proteins in a cell, tissue, biological sample, or subject. In certain embodiments, the method comprises reducing the accumulation of RAN proteins in a cell, tissue, biological sample, or subject.
  • RAN repeat associated non-ATG
  • the method comprises reducing the level of one or more RAN proteins in a cell, tissue, biological sample, or subject by administering to the subject or contacting the cell, tissue, or biological sample, with a compound of Formula (I), (II), (III), (III-A), or (III-B) (e.g., metformin), or a pharmaceutically acceptable salt, solvate, or hydrate, tautomer, stereoisomer, derivative, or prodrug.
  • a compound of Formula (I), (II), (III), (III-A), or (III-B) e.g., metformin
  • a pharmaceutically acceptable salt, solvate, or hydrate, tautomer, stereoisomer, derivative, or prodrug e.g., metformin
  • the levels of any RAN protein may be reduced using a compound of Formula (I), (II), (III), (III-A), or (III-B) (e.g., metformin), or a pharmaceutically acceptable salt, solvate, or hydrate, tautomer, stereoisomer, derivative, or prodrug.
  • the levels of any RAN protein comprises, in certain embodiments, the steady state levels of one or more RAN proteins.
  • the one or more RAN proteins are selected from the group consisting of poly-Leucine-Proline-Alanine-Cysteine, poly-Glutamine-Alanine-Glycine-Arginine, poly-Glycine-Proline, poly-Glycine-Alanine, poly-Glycine-Arginine, poly-Proline-Alanine, poly-Proline-Arginine, poly-Alanine, poly-Leucine, poly-Serine, poly-Cysteine, poly-Glutamine, poly-Arginine, poly-Glycine, poly-Proline, poly-Isoleucine-Leucine-Phenylalanine-Tyrosine-Serine, Poly-Tryptophan-Asparagine-Glycine-Methionine-Glutamine, poly-Phenylalanine-Histidine-Serine-Isoleucine-Proline, poly-Glycine-Leucine, poly-Tryptophan-Alanine, poly-
  • the method comprises reducing the level of the RAN protein, poly-Leucine-Proline-Alanine-Cysteine. In certain embodiments, the method comprises reducing the level of the RAN protein, poly-Glutamine-Alanine-Glycine-Arginine. In certain embodiments, the method comprises reducing the level of the RAN protein, poly-Glycine-Proline. In certain embodiments, the method comprises reducing the level of the RAN protein poly-Glycine-Alanine. In certain embodiments, the method comprises reducing the level of the RAN protein, poly-Glycine-Arginine. In certain embodiments, the method comprises reducing the level of the RAN protein, poly-Proline-Alanine.
  • the method comprises reducing the level of the RAN protein, poly-Proline-Arginine. In certain embodiments, the method comprises reducing the level of RAN proteins that are poly-Glycine-Leucine, poly-Tryptophan-Alanine, poly-Glutamine-Alanine, poly-Glycine-Proline, and/or poly-Proline-Arginine. In certain embodiments, the method comprises reducing the level of the RAN protein, poly-Alanine. In certain embodiments, the method comprises reducing the level of the RAN protein, poly-Leucine. In certain embodiments, the method comprises reducing the level of the RAN protein, poly-Serine.
  • the method comprises reducing the level of the RAN protein, poly-Cysteine. In certain embodiments, the method comprises reducing the level of the RAN protein, poly-Glutamine. In certain embodiments, the method comprises reducing the level of RAN proteins that are poly-Glutamine, which are associated with spinocerebellar ataxia type 12.
  • the method comprises reducing the level of RAN proteins that are poly-Alanine, poly-Leucine, poly-Serine, and/or poly-Cysteine, which are associated with DM1, spinocerebellar ataxia types 1, 2, 3, 6, 7, 8, 12, 17; spinal bulbar muscular atrophy; dentatorubral-pallidoluysian atrophy (DRPLA), and Huntington's disease.
  • DM1 spinocerebellar ataxia types 1, 2, 3, 6, 7, 8, 12, 17
  • spinal bulbar muscular atrophy spinal bulbar muscular atrophy
  • dentatorubral-pallidoluysian atrophy DRPLA
  • Huntington's disease Huntington's disease.
  • the method comprises reducing the level of RAN proteins that are poly-Glutamine, poly-Alanine, poly-Leucine, poly-Serine, and/or poly-Cysteine, which are associated with Huntington's disease-like 2 syndrome (HDL2); and Fuch's endothelial corneal dystrophy (FECD).
  • HDL2 Huntington's disease-like 2 syndrome
  • FECD Fuch's endothelial corneal dystrophy
  • the method comprises reducing the level of RAN proteins that are poly-Arginine, poly-Glycine, poly-Alanine, and/or poly-Proline, which are associated with Fragile X syndrome (FXS); FRAXA; disorders related to 7p11.2 folate-sensitive fragile site FRA7A; disorders related to folate-sensitive fragile site 2q11 FRA2A; and Fragile XE syndrome (FRAXE).
  • FXS Fragile X syndrome
  • FRAXA Fragile X syndrome
  • FRAXA Fragile X syndrome
  • FRA7A disorders related to 7p11.2 folate-sensitive fragile site
  • FRA7A disorders related to folate-sensitive fragile site 2q11 FRA2A
  • FFAXE Fragile XE syndrome
  • the method comprises reducing the level of RAN proteins that are poly-Alanine, poly-Leucine, poly-Serine, poly-Cysteine, or poly-Leu-Pro-Ala-Cys, which are
  • the method comprises reducing the level of RAN proteins that are poly-Gln-Ala-Gly-Arg, which are associated with DM2. In certain embodiments, the method comprises reducing the level of RAN proteins that are poly-Gly-Pro, poly-Gly-Arg, poly-Gly-Ala, poly-Pro-Ala, or poly-Pro-Arg, which are associated with sense C9ORFf72 ALS and C9ORFf72 FTD.
  • the method comprises reducing the level of RAN proteins that are poly-Pro-Ala, poly-Pro-Arg, poly-Gly-Pro, poly-Pro-Ala, or poly-Pro-Arg, which are associated with antisense C9ORFf72 ALS and antisense C9ORFf72 FTD.
  • the method comprises reducing the level of RAN proteins that are Poly-Tryptophan-Asparagine-Glycine-Methionine-Glutamine or poly-Phenylalanine-Histidine-Serine-Isoleucine-Proline, which are associated with spinocerebellar ataxia type 31.
  • the method comprises reducing the level of RAN proteins that are poly-Isoleucine-Leucine-Phenylalanine-Tyrosine-Serine, which are associated with spinocerebellar ataxia type 10.
  • Another aspect of the invention relates to methods of reducing the accumulation of repeat associated non-ATG protein (RAN) in a subject, tissue, or cell, the method comprising administering to the subject or cell a therapeutically effective amount of a compound of Formula (I), (II), (III), (III-A), or (III-B) (e.g., metformin), or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, stereoisomer, derivative, or prodrug thereof, or a pharmaceutical composition thereof.
  • a compound of Formula (I), (II), (III), (III-A), or (III-B) e.g., metformin
  • a pharmaceutically acceptable salt, solvate, hydrate, tautomer, stereoisomer, derivative, or prodrug thereof e.g., metformin
  • the number of poly-amino acid repeats in the RAN protein is at least 35. In certain embodiments, the number of poly-amino acid repeats in the RAN protein is at least 45. In certain embodiments, the number of poly-amino acid repeats in the RAN protein is at least 50. In certain embodiments, the number of poly-amino acid repeats in the RAN protein is at least 70. In certain embodiments, the number of poly-amino acid repeats in the RAN protein is at least 80. In certain embodiments, the number of poly-amino acid repeats in the RAN protein is at least 90. In certain embodiments, the number of poly-amino acid repeats in the RAN protein is at least 100.
  • the number of poly-amino acid repeats in the RAN protein is at least 120. In certain embodiments, the number of poly-amino acid repeats in the RAN protein is at least 150. In certain embodiments, the number of poly-amino acid repeats in the RAN protein is at least 200. In certain embodiments, the number of poly-amino acid repeats in the RAN protein is at least 250.
  • the neurological disease to be treated is associated with repeat expansions (e.g., repeat expansion mutations that undergo RAN protein translation). In certain embodiments, the neurological disease is associated with the expression of RAN proteins.
  • the repeat expansions comprise GGGGCC expansions and GGCCCC expansions. In certain embodiments, the repeat expansions comprise GGGGCC expansions. In certain embodiments, the repeat expansions comprise GGCCCC expansions. In certain embodiments, the repeat expansions comprise CAG expansions and CTG expansions. In certain embodiments, the repeat expansions comprise CAG expansions. In certain embodiments, the repeat expansions comprise CTG expansions. In certain embodiments, the repeat expansions comprise CAGG expansions and CCTG expansions. In certain embodiments, the repeat expansions comprise CAGG expansions. In certain embodiments, the repeat expansions comprise CCTG expansions.
  • the neurological disease being treated is a neurodegenerative disorder. In certain embodiments, the neurological disease being treated is a neuromuscular disorder. In certain embodiments, the neurological disease is associated with GGGGCC expansions and/or GGCCCC expansions. In certain embodiments, the neurological disease is associated with GGGGCC expansions and GGCCCC expansions. In certain embodiments, the neurological disease is associated with GGGGCC expansions. In certain embodiments, the neurological disease is associated with GGCCCC expansions. In certain embodiments, the neurological disease associated with GGGGCC expansions and/or GGCCCC expansions is amyotrophic lateral sclerosis (ALS).
  • ALS amyotrophic lateral sclerosis
  • the neurological disease associated with GGGGCC expansions and/or GGCCCC expansions is frontotemporal dementia (FTD).
  • the neurological disease associated with GGGGCC expansions and/or GGCCCC expansions is C9ORFf72 ALS.
  • the neurological disease is associated with GGGGCC expansions and/or GGCCCC expansions C9ORFf72 FTD.
  • the neurological disease is associated with CAG expansions and/or CTG expansions. In certain embodiments, the neurological disease is associated with CAG expansions and CTG expansions. In certain embodiments, the neurological disease is associated with CAG expansions. In certain embodiments, the neurological disease is associated with CTG expansions. In certain embodiments, the neurological disease associated with CAG expansions and/or CTG expansions is spinocerebellar ataxia (SCA). In certain embodiments, the neurological disease is associated with TGGAA expansions. In certain embodiments, the neurological disease associated with TGGAA expansions is spinocerebellar ataxia. In certain embodiments, the neurological disease associated with TGGAA expansions is spinocerebellar ataxia type 31.
  • the neurological disease is associated with GGCCTG expansions. In certain embodiments, the neurological disease associated with GGCCTG expansions is spinocerebellar ataxia type 36. In certain embodiments, the neurological disease is associated with TGGGCC expansions. In certain embodiments, the neurological disease is associated with 5′ TGGGCC expansions. In certain embodiments, the neurological disease associated with TGGGCC expansions is spinocerebellar ataxia type 36. In certain embodiments, the neurological disease associated with 5′ TGGGCC expansions is spinocerebellar ataxia type 36. In certain embodiments, the neurological disease is associated with GGCCCA expansions of another DNA strand.
  • the neurological disease is associated with 5′ GGCCCA expansions of another DNA strand. In certain embodiments, the neurological disease associated with 5′ GGCCCA expansions of another DNA strand is spinocerebellar ataxia type 36. In certain embodiments, the neurological disease is associated with ATCCT expansions In certain embodiments, the neurological disease is associated with 5′ ATCCT expansions. In certain embodiments, the neurological disease associated with ATCCT expansions is spinocerebellar ataxia type 10. In certain embodiments, the neurological disease associated with 5′ ATCCT expansions is spinocerebellar ataxia type 10. In certain embodiments, the neurological disease is associated with AGGAT expansions of another DNA strand. In certain embodiments, the neurological disease is associated with 5′ AGGAT expansions of another DNA strand. In certain embodiments, the neurological disease associated with AGGAT expansions of another DNA strand is spinocerebellar ataxia type 10.
  • the neurological disease associated with 5′ AGGAT expansions of another DNA strand is spinocerebellar ataxia type 10.
  • the spinocerebellar ataxia is spinocerebellar ataxia type 1, spinocerebellar ataxia type 2, spinocerebellar ataxia type 3, or spinocerebellar ataxia type 8.
  • the spinocerebellar ataxia is spinocerebellar ataxia type 1.
  • the spinocerebellar ataxia is spinocerebellar ataxia type 2.
  • the spinocerebellar ataxia is spinocerebellar ataxia type 3.
  • the spinocerebellar ataxia is spinocerebellar ataxia type 8.
  • the spinocerebellar ataxia is spinocerebellar ataxia type 6, spinocerebellar ataxia type 7, spinocerebellar ataxia type 10, spinocerebellar ataxia type 12, spinocerebellar ataxia type 17, spinocerebellar ataxia type 31, or spinocerebellar ataxia type 36.
  • the spinocerebellar ataxia is spinocerebellar ataxia type 6.
  • the spinocerebellar ataxia is spinocerebellar ataxia type 7.
  • the spinocerebellar ataxia is spinocerebellar ataxia type 10.
  • the spinocerebellar ataxia is spinocerebellar ataxia type 12. In certain embodiments, the spinocerebellar ataxia is spinocerebellar ataxia type 17. In certain embodiments, the spinocerebellar ataxia is spinocerebellar ataxia type 31. In certain embodiments, the spinocerebellar ataxia is spinocerebellar ataxia type 36. In certain embodiments, the neurological disease is myotonic dystrophy type 1 or Fuch's corneal endothelial dystrophy. In certain embodiments, the neurological disease is myotonic dystrophy type 1. In certain embodiments, the neurological disease is Fuch's corneal endothelial dystrophy.
  • the neurological disease is associated with CAGG expansions and/or CCTG expansions. In embodiments, the neurological disease is associated with CAGG expansions and CCTG expansions. In embodiments, the neurological disease is associated with CAGG expansions. In embodiments, the neurological disease is associated with CCTG expansions. In certain embodiments, the neurological disease associated with CAGG expansions and/or CCTG expansions is myotonic dystrophy type 2. In certain embodiments, the neurological disease is associated with RAN protein accumulation.
  • the neurological disease is a neurodegenerative disorder, and is associated with a RAN protein where the number of poly-amino acid repeats in the RAN protein is at least 35. In certain embodiments, the neurological disease is a neurodegenerative disorder, and is associated with a RAN protein where the number of poly-amino acid repeats in the RAN protein is at least 50. In certain embodiments, the neurological disease is a neurodegenerative disorder, and is associated with a RAN protein where the number of poly-amino acid repeats in the RAN protein is at least 70. In certain embodiments, the neurological disease is spinal bulbar muscular atrophy or dentatorubral-pallidoluysian atrophy. In certain embodiments, the neurological disease is spinal bulbar muscular atrophy. In certain embodiments, the neurological disease is dentatorubral-pallidoluysian atrophy.
  • the neurological disease is Huntington's disease.
  • the neurological disease is Fragile X Tremor Ataxia Syndrome (FXTAS).
  • the neurological disease is Huntington's disease-like 2 syndrome (HDL2); Fragile X syndrome (FXS); disorders related to 7p11.2 folate-sensitive fragile site FRA7A; disorders related to folate-sensitive fragile site 2q11 FRA2A; or Fragile XE syndrome (FRAXE).
  • the present invention provides methods of diagnosing a patient with a neurological disease associated with repeat expansions, the methods comprising performing an assay to detect levels of RAN proteins in the patient; and diagnosing the patient with a neurological disease associated with repeat expansions based upon the presence of the at least one RAN protein.
  • the present invention also provides uses of a compound of Formula (I), (II), (III), (III-A), or (III-B) (e.g., metformin), or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, stereoisomer, derivative, or prodrug thereof, to treat and/or prevent a neurological disease associated with repeat expansions in a subject in need thereof.
  • a compound of Formula (I), (II), (III), (III-A), or (III-B) e.g., metformin
  • a pharmaceutically acceptable salt, solvate, hydrate, tautomer, stereoisomer, derivative, or prodrug thereof e.g., metformin
  • the present invention also provides uses of a compound of Formula (I), (II), (III), (III-A), or (III-B) (e.g., metformin), or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, stereoisomer, derivative, or prodrug thereof, to treat and/or prevent a neurological disease associated with RAN protein accumulation in a subject in need thereof.
  • a compound of Formula (I), (II), (III), (III-A), or (III-B) e.g., metformin
  • a pharmaceutically acceptable salt, solvate, hydrate, tautomer, stereoisomer, derivative, or prodrug thereof e.g., metformin
  • the present invention provides uses of a compound of Formula (I), (II), (III), (III-A), or (III-B) (e.g., metformin), or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, stereoisomer, derivative, or prodrug thereof, to reduce the levels of RAN protein in a subject or biological sample (e.g., cells or tissue).
  • a compound of Formula (I), (II), (III), (III-A), or (III-B) e.g., metformin
  • a pharmaceutically acceptable salt, solvate, hydrate, tautomer, stereoisomer, derivative, or prodrug thereof e.g., metformin
  • the present invention provides uses of a compound of Formula (I), (II), (III), (III-A), or (III-B) (e.g., metformin), or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, stereoisomer, derivative, or prodrug thereof, to reduce the accumulation of RAN protein in a subject or biological sample (e.g., cells or tissue).
  • a compound of Formula (I), (II), (III), (III-A), or (III-B) e.g., metformin
  • a pharmaceutically acceptable salt, solvate, hydrate, tautomer, stereoisomer, derivative, or prodrug thereof e.g., metformin
  • the present invention provides uses of a compound of Formula (I), (II), (III), (III-A), or (III-B) (e.g., metformin), or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, stereoisomer, derivative, or prodrug thereof, to treat and/or prevent a neurological disease associated with repeat expansions in a subject in need thereof, and/or in a biological sample (e.g., cells or tissue), whereby the method comprises modulating (e.g., inhibiting) RAN protein translation.
  • a compound of Formula (I), (II), (III), (III-A), or (III-B) e.g., metformin
  • a pharmaceutically acceptable salt, solvate, hydrate, tautomer, stereoisomer, derivative, or prodrug thereof e.g., metformin
  • a pharmaceutically acceptable salt, solvate, hydrate, tautomer, stereoisomer, derivative, or prodrug thereof e.g.
  • the present invention provides uses of a compound of Formula (I), (II), (III), (III-A), or (III-B) (e.g., metformin), or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, stereoisomer, derivative, or prodrug thereof, to treat and/or prevent a neurological disease associated with RAN protein accumulation in a subject in need thereof, and/or in a biological sample (e.g., cells or tissue), whereby the method comprises modulating (e.g., inhibiting) RAN protein translation.
  • a compound of Formula (I), (II), (III), (III-A), or (III-B) e.g., metformin
  • a pharmaceutically acceptable salt, solvate, hydrate, tautomer, stereoisomer, derivative, or prodrug thereof e.g., metformin
  • a pharmaceutically acceptable salt, solvate, hydrate, tautomer, stereoisomer, derivative, or prodrug thereof e.g
  • the present invention provides uses of a compound of Formula (I), (II), (III), (III-A), or (III-B) (e.g., metformin), or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, stereoisomer, derivative, or prodrug thereof, to treat and/or prevent a neurological disease associated with repeat expansions (e.g., poly(GP) and/or poly(PR) RAN proteins) in a subject in need thereof, and/or in a biological sample (e.g., cells or tissue),
  • a subject in need thereof is a patient with expansion mutations or microsatellite repeat expansion mutations.
  • the present disclosure also provides pharmaceutical compositions comprising a compound of Formula (I), (II), (III), (III-A), or (III-B) (e.g., metformin) and optionally a pharmaceutically acceptable excipient.
  • the pharmaceutical composition comprises a compound of Formula (I), (II), (III), (III-A), or (III-B) (e.g., metformin), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.
  • a compound of Formula (I), (II), (III), (III-A), or (III-B) (e.g., metformin) is provided in an effective amount in the pharmaceutical composition.
  • the effective amount is a therapeutically effective amount.
  • the effective amount is a prophylactically effective amount.
  • a therapeutically effective amount is an amount effective in reducing repeat expansions.
  • a therapeutically effective amount is an amount effective in reducing the transcription of RNAs that produce RAN proteins.
  • a therapeutically effective amount is an amount effective in reducing the translation of RAN proteins.
  • a therapeutically effective amount is an amount effective in reducing the level of one or more RAN proteins in a subject. In certain embodiments, a therapeutically effective amount is an amount effective for treating a neurological disease associated with repeat expansions. In certain embodiments, a therapeutically effective amount is an amount effective in reducing the level of one or more RAN proteins and treating a neurological disease associated with repeat expansions. In certain embodiments, a therapeutically effective amount is an amount effective in reducing the level of one or more RAN proteins and treating a neurological disease associated with RAN protein accumulation. In certain embodiments, a therapeutically effective amount is an amount effective in reducing the accumulation of RAN proteins.
  • the effective amount is an amount effective in reducing the level of RAN proteins by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or at least 98%. In certain embodiments, the effective amount is an amount effective in reducing the translation of RAN proteins by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or at least 98%.
  • compositions described herein can be prepared by any method known in the art of pharmacology.
  • preparatory methods include bringing the compound described herein (i.e., the “active ingredient”) into association with a carrier or excipient, and/or one or more other accessory ingredients, and then, if necessary and/or desirable, shaping, and/or packaging the product into a desired single- or multi-dose unit.
  • compositions can be prepared, packaged, and/or sold in bulk, as a single unit dose, and/or as a plurality of single unit doses.
  • a “unit dose” is a discrete amount of the pharmaceutical composition comprising a predetermined amount of the active ingredient.
  • the amount of the active ingredient is generally equal to the dosage of the active ingredient which would be administered to a subject and/or a convenient fraction of such a dosage, such as one-half or one-third of such a dosage.
  • Relative amounts of the active ingredient, the pharmaceutically acceptable excipient, and/or any additional ingredients in a pharmaceutical composition described herein will vary, depending upon the identity, size, and/or condition of the subject treated and further depending upon the route by which the composition is to be administered.
  • the composition may comprise between 0.1% and 100% (w/w) active ingredient.
  • compositions used in the manufacture of provided pharmaceutical compositions include inert diluents, dispersing and/or granulating agents, surface active agents and/or emulsifiers, disintegrating agents, binding agents, preservatives, buffering agents, lubricating agents, and/or oils. Excipients such as cocoa butter and suppository waxes, coloring agents, coating agents, sweetening, flavoring, and perfuming agents may also be present in the composition.
  • Exemplary diluents include calcium carbonate, sodium carbonate, calcium phosphate, dicalcium phosphate, calcium sulfate, calcium hydrogen phosphate, sodium phosphate lactose, sucrose, cellulose, microcrystalline cellulose, kaolin, mannitol, sorbitol, inositol, sodium chloride, dry starch, cornstarch, powdered sugar, and mixtures thereof.
  • Exemplary granulating and/or dispersing agents include potato starch, corn starch, tapioca starch, sodium starch glycolate, clays, alginic acid, guar gum, citrus pulp, agar, bentonite, cellulose, and wood products, natural sponge, cation-exchange resins, calcium carbonate, silicates, sodium carbonate, cross-linked poly(vinyl-pyrrolidone) (crospovidone), sodium carboxymethyl starch (sodium starch glycolate), carboxymethyl cellulose, cross-linked sodium carboxymethyl cellulose (croscarmellose), methylcellulose, pregelatinized starch (starch 1500), microcrystalline starch, water insoluble starch, calcium carboxymethyl cellulose, magnesium aluminum silicate (Veegum), sodium lauryl sulfate, quaternary ammonium compounds, and mixtures thereof.
  • crospovidone cross-linked poly(vinyl-pyrrolidone)
  • sodium carboxymethyl starch sodium starch glycolate
  • Exemplary surface active agents and/or emulsifiers include natural emulsifiers (e.g., acacia, agar, alginic acid, sodium alginate, tragacanth, chondrux, cholesterol, xanthan, pectin, gelatin, egg yolk, casein, wool fat, cholesterol, wax, and lecithin), colloidal clays (e.g., bentonite (aluminum silicate) and Veegum (magnesium aluminum silicate)), long chain amino acid derivatives, high molecular weight alcohols (e.g., stearyl alcohol, cetyl alcohol, oleyl alcohol, triacetin monostearate, ethylene glycol distearate, glyceryl monostearate, and propylene glycol monostearate, polyvinyl alcohol), carbomers (e.g., carboxy polymethylene, polyacrylic acid, acrylic acid polymer, and carboxyvinyl polymer), carrageenan, cellulos
  • Exemplary binding agents include starch (e.g., cornstarch and starch paste), gelatin, sugars (e.g., sucrose, glucose, dextrose, dextrin, molasses, lactose, lactitol, mannitol, etc.), natural and synthetic gums (e.g., acacia, sodium alginate, extract of Irish moss, panwar gum, ghatti gum, mucilage of isapol husks, carboxymethylcellulose, methylcellulose, ethylcellulose, hydroxyethylcellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, microcrystalline cellulose, cellulose acetate, poly(vinyl-pyrrolidone), magnesium aluminum silicate (Veegum®), and larch arabogalactan), alginates, polyethylene oxide, polyethylene glycol, inorganic calcium salts, silicic acid, polymethacrylates, waxes, water, alcohol, and/or mixtures
  • Exemplary preservatives include antioxidants, chelating agents, antimicrobial preservatives, antifungal preservatives, antiprotozoan preservatives, alcohol preservatives, acidic preservatives, and other preservatives.
  • the preservative is an antioxidant.
  • the preservative is a chelating agent.
  • antioxidants include alpha tocopherol, ascorbic acid, acorbyl palmitate, butylated hydroxyanisole, butylated hydroxytoluene, monothioglycerol, potassium metabisulfite, propionic acid, propyl gallate, sodium ascorbate, sodium bisulfite, sodium metabisulfite, and sodium sulfite.
  • Exemplary chelating agents include ethylenediaminetetraacetic acid (EDTA) and salts and hydrates thereof (e.g., sodium edetate, disodium edetate, trisodium edetate, calcium disodium edetate, dipotassium edetate, and the like), citric acid and salts and hydrates thereof (e.g., citric acid monohydrate), fumaric acid and salts and hydrates thereof, malic acid and salts and hydrates thereof, phosphoric acid and salts and hydrates thereof, and tartaric acid and salts and hydrates thereof.
  • EDTA ethylenediaminetetraacetic acid
  • salts and hydrates thereof e.g., sodium edetate, disodium edetate, trisodium edetate, calcium disodium edetate, dipotassium edetate, and the like
  • citric acid and salts and hydrates thereof e.g., citric acid mono
  • antimicrobial preservatives include benzalkonium chloride, benzethonium chloride, benzyl alcohol, bronopol, cetrimide, cetylpyridinium chloride, chlorhexidine, chlorobutanol, chlorocresol, chloroxylenol, cresol, ethyl alcohol, glycerin, hexetidine, imidurea, phenol, phenoxyethanol, phenylethyl alcohol, phenylmercuric nitrate, propylene glycol, and thimerosal.
  • antifungal preservatives include butyl paraben, methyl paraben, ethyl paraben, propyl paraben, benzoic acid, hydroxybenzoic acid, potassium benzoate, potassium sorbate, sodium benzoate, sodium propionate, and sorbic acid.
  • Exemplary alcohol preservatives include ethanol, polyethylene glycol, phenol, phenolic compounds, bisphenol, chlorobutanol, hydroxybenzoate, and phenylethyl alcohol.
  • Exemplary acidic preservatives include vitamin A, vitamin C, vitamin E, beta-carotene, citric acid, acetic acid, dehydroacetic acid, ascorbic acid, sorbic acid, and phytic acid.
  • preservatives include tocopherol, tocopherol acetate, deteroxime mesylate, cetrimide, butylated hydroxyanisol (BHA), butylated hydroxytoluened (BHT), ethylenediamine, sodium lauryl sulfate (SLS), sodium lauryl ether sulfate (SLES), sodium bisulfite, sodium metabisulfite, potassium sulfite, potassium metabisulfite, Glydant® Plus, Phenonip®, methylparaben, Germall® 115, Germaben® II, Neolone®, Kathon®, and Euxyl®.
  • Exemplary buffering agents include citrate buffer solutions, acetate buffer solutions, phosphate buffer solutions, ammonium chloride, calcium carbonate, calcium chloride, calcium citrate, calcium glubionate, calcium gluceptate, calcium gluconate, D-gluconic acid, calcium glycerophosphate, calcium lactate, propanoic acid, calcium levulinate, pentanoic acid, dibasic calcium phosphate, phosphoric acid, tribasic calcium phosphate, calcium hydroxide phosphate, potassium acetate, potassium chloride, potassium gluconate, potassium mixtures, dibasic potassium phosphate, monobasic potassium phosphate, potassium phosphate mixtures, sodium acetate, sodium bicarbonate, sodium chloride, sodium citrate, sodium lactate, dibasic sodium phosphate, monobasic sodium phosphate, sodium phosphate mixtures, tromethamine, magnesium hydroxide, aluminum hydroxide, alginic acid, pyrogen-free water, isotonic saline, Ringer
  • Exemplary lubricating agents include magnesium stearate, calcium stearate, stearic acid, silica, talc, malt, glyceryl behanate, hydrogenated vegetable oils, polyethylene glycol, sodium benzoate, sodium acetate, sodium chloride, leucine, magnesium lauryl sulfate, sodium lauryl sulfate, and mixtures thereof.
  • Exemplary natural oils include almond, apricot kernel, avocado, babassu, bergamot, black current seed, borage, cade, camomile, canola, caraway, carnauba, castor, cinnamon, cocoa butter, coconut, cod liver, coffee, corn, cotton seed, emu, eucalyptus, evening primrose, fish, flaxseed, geraniol, gourd, grape seed, hazel nut, hyssop, isopropyl myristate, jojoba, kukui nut, lavandin, lavender, lemon, litsea cubeba, macademia nut, mallow, mango seed, meadowfoam seed, mink, nutmeg, olive, orange, orange roughy, palm, palm kernel, peach kernel, peanut, poppy seed, pumpkin seed, rapeseed, rice bran, rosemary, safflower, sandalwood, sasquana, savoury, sea buckt
  • Exemplary synthetic oils include, but are not limited to, butyl stearate, caprylic triglyceride, capric triglyceride, cyclomethicone, diethyl sebacate, dimethicone 360, isopropyl myristate, mineral oil, octyldodecanol, oleyl alcohol, silicone oil, and mixtures thereof.
  • Liquid dosage forms for oral and parenteral administration include pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs.
  • the liquid dosage forms may comprise inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (e.g., cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof.
  • inert diluents commonly used in the art such as, for example, water or other solvents, so
  • the oral compositions can include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.
  • adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.
  • the conjugates described herein are mixed with solubilizing agents such as Cremophor®, alcohols, oils, modified oils, glycols, polysorbates, cyclodextrins, polymers, and mixtures thereof.
  • solubilizing agents such as Cremophor®, alcohols, oils, modified oils, glycols, polysorbates, cyclodextrins, polymers, and mixtures thereof.
  • the exemplary liquid dosage forms in certain embodiments are formulated for ease of swallowing, or for administration via feeding tube.
  • Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules.
  • the active ingredient is mixed with at least one inert, pharmaceutically acceptable excipient or carrier such as sodium citrate or dicalcium phosphate and/or (a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and silicic acid, (b) binders such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidinone, sucrose, and acacia, (c) humectants such as glycerol, (d) disintegrating agents such as agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate, (e) solution retarding agents such as paraffin, (f) absorption accelerators such as quaternary ammonium compounds, (g) wetting agents such as, for example, cetyl alcohol and glycerol mono
  • Solid compositions of a similar type can be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.
  • the solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings and other coatings well known in the art of pharmacology. They may optionally comprise opacifying agents and can be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner.
  • encapsulating compositions which can be used include polymeric substances and waxes.
  • Solid compositions of a similar type can be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polethylene glycols and the like.
  • the active ingredient can be in a micro-encapsulated form with one or more excipients as noted above.
  • the solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings, release controlling coatings, and other coatings well known in the pharmaceutical formulating art.
  • the active ingredient can be admixed with at least one inert diluent such as sucrose, lactose, or starch.
  • Such dosage forms may comprise, as is normal practice, additional substances other than inert diluents, e.g., tableting lubricants and other tableting aids such a magnesium stearate and microcrystalline cellulose.
  • the dosage forms may comprise buffering agents. They may optionally comprise opacifying agents and can be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner.
  • encapsulating agents which can be used include polymeric substances and waxes.
  • compositions suitable for administration to humans are principally directed to pharmaceutical compositions which are suitable for administration to humans, it will be understood by the skilled artisan that such compositions are generally suitable for administration to animals of all sorts. Modification of pharmaceutical compositions suitable for administration to humans in order to render the compositions suitable for administration to various animals is well understood, and the ordinarily skilled veterinary pharmacologist can design and/or perform such modification with ordinary experimentation.
  • a compound of Formula (I), (II), (III), (III-A), or (III-B) (e.g., metformin) provided herein is typically formulated in dosage unit form for ease of administration and uniformity of dosage. It will be understood, however, that the total daily usage of the compositions described herein will be decided by a physician within the scope of sound medical judgment.
  • the specific therapeutically effective dose level for any particular subject or organism will depend upon a variety of factors including the disease being treated and the severity of the disorder; the activity of the specific active ingredient employed; the specific composition employed; the age, body weight, general health, sex, and diet of the subject; the time of administration, route of administration, and rate of excretion of the specific active ingredient employed; the duration of the treatment; drugs used in combination or coincidental with the specific active ingredient employed; and like factors well known in the medical arts.
  • a compound of Formula (I), (II), (III), (III-A), or (III-B) e.g., metformin
  • compositions thereof provided herein can be administered by any route, including enteral (e.g., oral), parenteral, intravenous, intramuscular, intra-arterial, intramedullary, intrathecal, subcutaneous, intraventricular, transdermal, interdermal, rectal, intravaginal, intraperitoneal, topical (as by powders, ointments, creams, and/or drops), mucosal, nasal, bucal, sublingual; by intratracheal instillation, bronchial instillation, and/or inhalation; and/or as an oral spray, nasal spray, and/or aerosol.
  • enteral e.g., oral
  • parenteral intravenous, intramuscular, intra-arterial, intramedullary
  • intrathecal subcutaneous, intraventricular, transdermal, interdermal, rectal, intravaginal,
  • Specifically contemplated routes are oral administration, intravenous administration (e.g., systemic intravenous injection), regional administration via blood and/or lymph supply, and/or direct administration to an affected site.
  • intravenous administration e.g., systemic intravenous injection
  • regional administration via blood and/or lymph supply e.g., via blood and/or lymph supply
  • direct administration e.g., direct administration to an affected site.
  • the most appropriate route of administration will depend upon a variety of factors including the nature of the agent (e.g., its stability in the environment of the gastrointestinal tract), and/or the condition of the subject (e.g., whether the subject is able to tolerate oral administration).
  • the compound or pharmaceutical composition described herein is suitable for topical administration to the eye of a subject.
  • any two doses of the multiple doses include different or substantially the same amounts of a compound described herein.
  • the frequency of administering the multiple doses to the subject or applying the multiple doses to the biological sample, tissue, or cell is three doses a day, two doses a day, one dose a day, one dose every other day, one dose every third day, one dose every week, one dose every two weeks, one dose every three weeks, or one dose every four weeks.
  • the frequency of administering the multiple doses to the subject or applying the multiple doses to the biological sample, tissue, or cell is one dose per day.
  • the frequency of administering the multiple doses to the subject or applying the multiple doses to the biological sample, tissue, or cell is two doses per day.
  • the frequency of administering the multiple doses to the subject or applying the multiple doses to the biological sample, tissue, or cell is three doses per day.
  • the duration between the first dose and last dose of the multiple doses is one day, two days, four days, one week, two weeks, three weeks, one month, two months, three months, four months, six months, eight months, nine months, one year, two years, three years, four years, five years, seven years, ten years, fifteen years, twenty years, or the lifetime of the subject, tissue, or cell.
  • the duration between the first dose and last dose of the multiple doses is three months, six months, or one year.
  • the duration between the first dose and last dose of the multiple doses is the lifetime of the subject, tissue, or cell.
  • a dose (e.g., a single dose, or any dose of multiple doses) described herein includes independently between 0.1 ⁇ g and 1 ⁇ g, between 0.001 mg and 0.01 mg, between 0.01 mg and 0.1 mg, between 0.1 mg and 1 mg, between 1 mg and 3 mg, between 3 mg and 10 mg, between 10 mg and 30 mg, between 30 mg and 100 mg, between 100 mg and 300 mg, between 300 mg and 1,000 mg, or between 1 g and 10 g, inclusive, of a compound described herein.
  • a dose described herein includes independently between 1 mg and 3 mg, inclusive, of a compound described herein. In certain embodiments, a dose described herein includes independently between 3 mg and 10 mg, inclusive, of a compound described herein. In certain embodiments, a dose described herein includes independently between 10 mg and 30 mg, inclusive, of a compound described herein. In certain embodiments, a dose described herein includes independently between 30 mg and 100 mg, inclusive, of a compound described herein.
  • the method comprises administering to the subject a therapeutically effective amount of a compound of Formula (I):
  • each instance of is a single bond or double bond, as valency permits;
  • each instance of R 2A is independently hydrogen, optionally substituted acyl, optionally substituted alkyl, or a nitrogen protecting group;
  • R 3 is hydrogen, optionally substituted alkyl, or a nitrogen protecting group
  • each instance of R 4 is independently hydrogen, optionally substituted alkyl, or a nitrogen protecting group, or absent, as valency permits; or, optionally, one instance of R 4 is taken together with R 3 and the intervening atoms to form an optionally substituted 5 to 7-membered heterocyclic ring;
  • R 4 when one instance of R 4 is taken together with R 3 and the intervening atoms to form an optionally substituted 5 to 7-membered heterocyclic ring, connecting the nitrogen of the moiety —N(R 6 ) 3 and the carbon of the moiety —C(NR 4 ) 2 is a double bond, as valency permits;
  • each instance of R 6 is independently hydrogen, optionally substituted alkyl, a nitrogen protecting group, or absent, as valency permits;
  • R 7 is hydrogen, optionally substituted alkyl, a nitrogen protecting group or absent, as valency permits.
  • the compound of Formula (I) is of Formula (I-A):
  • each instance of R 2A is independently hydrogen, optionally substituted alkyl, or a nitrogen protecting group.
  • the method comprises administering to the subject a therapeutically effective amount of metformin:
  • the method comprises administering to the subject a therapeutically effective amount of a compound of Formula (II):
  • each instance of is a single bond or double bond, as valency permits;
  • R 2′ is hydrogen, halogen, or —N(R 2A ) 2 ;
  • each instance of R 2A is independently hydrogen, optionally substituted acyl, optionally substituted alkyl, or a nitrogen protecting group;
  • R 3 is hydrogen, optionally substituted alkyl, or a nitrogen protecting group
  • R 4′ is hydrogen, —N(R 4 ) 2 , or
  • each instance of R 4 is independently hydrogen, optionally substituted alkyl, or a nitrogen protecting group, or absent, as valency permits; or, optionally, when R 4′ is —N(R 4 ) 2 , one instance of R 4 is taken together with R 3 and the intervening atoms to form an optionally substituted 5 to 7-membered heterocyclic ring;
  • each instance of R 4A is independently hydrogen, optionally substituted alkyl, or a nitrogen protecting group
  • each instance of R 6 is independently hydrogen, optionally substituted alkyl, a nitrogen protecting group, or absent, as valency permits;
  • R 7 is hydrogen, optionally substituted alkyl, a nitrogen protecting group, or absent, as valency permits.
  • each instance of is a single bond or a double bond, as valency permits. In certain embodiments, at least one instance of is a single bond. In certain embodiments, at least one instance of is a double bond.
  • Formula (II) includes substituent R 2′ .
  • R 2′ is hydrogen.
  • R 2′ is halogen (e.g., F, Cl, Br, or I).
  • R 2′ is I.
  • R 2′ is —N(R 2A ) 2 , and each instance of R 2A is independently hydrogen, optionally substituted acyl, optionally substituted alkyl, or a nitrogen protecting group (e.g., —NMe 2 ).
  • R 2′ is —NMe 2 .
  • R 2′ is —N(R 2A ) 2 , and each instance of R 2A is independently hydrogen or optionally substituted alkyl.
  • R 2′ is —(N 15 )(R 2A ) 2 , and each instance of R 2A is independently hydrogen or optionally substituted alkyl.
  • R 2A is as defined herein.
  • Formula (I) includes two instances of substituent R 2A
  • Formula (II) includes zero or more instances of substituent R 2A .
  • at least one instance of R 2A is hydrogen. In certain embodiments, both instances of R 2A are hydrogen. In certain embodiments, at least one instance of R 2A is deuterium. In certain embodiments, both instances of R 2A are deuterium. In certain embodiments, at least one instance of R 2A is optionally substituted acyl (e.g., —C( ⁇ O)Me). In certain embodiments, at least one instance of R 2A is optionally substituted alkyl (e.g., substituted or unsubstituted C 1-6 alkyl).
  • At least one instance of R 2A is optionally substituted C 1-6 alkyl. In certain embodiments, at least one instance of R 2A is substituted C 1-6 alkyl. In certain embodiments, at least one instance of R 2A is unsubstituted C 1-6 alkyl. In certain embodiments, at least one instance of R 2A is unsubstituted methyl. In certain embodiments, two instances of R 2A are unsubstituted methyl. In certain embodiments, at least one instance of R 2A is unsubstituted methyl or unsubstituted ethyl. In certain embodiments, at least one instance of R 2A is optionally substituted methyl.
  • At least one instance of R 2A is —CH 2 (D). In certain embodiments, at least one instance of R 2A is unsubstituted methyl. In certain embodiments, at least one instance of R 2A is —CD 3 . In certain embodiments, both instances of R 2A are —CD 3 . In certain embodiments, at least one instance of R 2A is unsubstituted ethyl. In certain embodiments, at least one instance of R 2A is optionally substituted ethyl. In certain embodiments, at least one instance of R 2A is substituted ethyl. In certain embodiments, at least one instance of R 2A is of the formula:
  • At least one instance of R 2A is optionally substituted n-propyl. In certain embodiments, at least one instance of R 2A is unsubstituted n-propyl. In certain embodiments, at least one instance of R 2A is a nitrogen protecting group (e.g., benzyl (Bn), t-butyl carbonate (BOC or Boc), benzyl carbamate (Cbz), 9-fluorenylmethyl carbonate (Fmoc), trifluoroacetyl, triphenylmethyl, acetyl, or p-toluenesulfonamide (Ts)).
  • benzyl Bn
  • BOC or Boc t-butyl carbonate
  • Boc benzyl carbamate
  • Fmoc 9-fluorenylmethyl carbonate
  • Ts p-toluenesulfonamide
  • Formulae (I) and (II) include substituent R 3 .
  • R 3 is hydrogen.
  • at least one instance of R 3 is optionally substituted alkyl (e.g., substituted or unsubstituted C 1-6 alkyl).
  • R 3 is optionally substituted C 1-6 alkyl.
  • R 3 is unsubstituted C 1-6 alkyl.
  • R 3 is unsubstituted methyl or unsubstituted ethyl.
  • R 3 is unsubstituted methyl.
  • R 3 is optionally substituted methyl.
  • R 3 is optionally substituted ethyl.
  • R 3 is unsubstituted ethyl.
  • R 3 is a nitrogen protecting group (e.g., benzyl (Bn), t-butyl carbonate (BOC or Boc), benzyl carbamate (Cbz), 9-fluorenylmethyl carbonate (Fmoc), trifluoroacetyl, triphenylmethyl, acetyl, or p-toluenesulfonamide (Ts)).
  • Formula (II) includes substituent R 4′ .
  • R 4′ is hydrogen.
  • R 4′ is —N(R 4 ) 2 , and each instance of R 4 is independently hydrogen, optionally substituted alkyl, or a nitrogen protecting group, or absent, as valency permits.
  • R 4′ is
  • R 4 is independently hydrogen or optionally substituted alkyl.
  • R 4′ is
  • R 4 is as defined herein.
  • Formulae (I) and (II) each include one or more instances of substituent R 4 . In certain embodiments, one instance of R 4 is absent. In certain embodiments, Formulae (I) and (II) each include two instances of substituent R 4 . In certain embodiments, Formulae (I) and (II) each include three instances of substituent R 4 .
  • each instance of R 4 is independently hydrogen, optionally substituted alkyl, or a nitrogen protecting group, or absent, as valency permits; or, optionally, one instance of R 4 is taken together with R 3 and the intervening atoms to form an optionally substituted 5 to 7-membered heterocyclic ring; or optionally, when one instance of R 4 is taken together with R 3 and the intervening atoms to form an optionally substituted 5 to 7-membered heterocyclic ring, is a double bond, as valency permits.
  • at least one instance of R 4 is hydrogen.
  • both instances of R 4 are hydrogen.
  • at least one instance of R 4 is deuterium.
  • both instances of R 4 are deuterium.
  • at least one instance of R 4 is optionally substituted alkyl (e.g., substituted or unsubstituted C 1-6 alkyl).
  • at least one instance of R 4 is optionally substituted C 1-6 alkyl.
  • at least one instance of R 4 is unsubstituted C 1-6 alkyl.
  • at least one instance of R 4 is unsubstituted methyl or unsubstituted ethyl.
  • at least one instance of R 4 is optionally substituted methyl.
  • at least one instance of R 4 is —CH 2 (D).
  • At least one instance of R 4 is unsubstituted methyl. In certain embodiments, two instances of R 4 are unsubstituted methyl. In certain embodiments, at least one instance of R 4 is —CD 3 . In certain embodiments, both instances of R 4 are —CD 3 . In certain embodiments, at least one instance of R 4 is unsubstituted ethyl.
  • At least one instance of R 4 is a nitrogen protecting group (e.g., benzyl (Bn), t-butyl carbonate (BOC or Boc), benzyl carbamate (Cbz), 9-fluorenylmethyl carbonate (Fmoc), trifluoroacetyl, triphenylmethyl, acetyl, or p-toluenesulfonamide (Ts)).
  • one instance of R 4 is taken together with R 3 and the intervening atoms to form an optionally substituted 6-membered heterocyclic ring.
  • the compound of Formula (I) is of the formula:
  • the compound of Formula (I) is of the formula:
  • Formulae (I) and (II) each include one or more instances of substituent R 6 . In certain embodiments, one instance of R 6 is absent. In certain embodiments, Formulae (I) and (II) each include two instances of substituent R 6 . In certain embodiments, Formulae (I) and (II) each include three instances of substituent R 6 . In certain embodiments, each instance of R 6 is independently hydrogen, optionally substituted alkyl, a nitrogen protecting group, or absent, as valency permits. In certain embodiments, at least one instance of R 6 is hydrogen. In certain embodiments, two instances of R 6 are hydrogen. In certain embodiments, at least one instance of R 6 is deuterium. In certain embodiments, two instances of R 6 are deuterium.
  • At least one instance of R 6 is optionally substituted alkyl (e.g., substituted or unsubstituted C 1-6 alkyl). In certain embodiments, at least one instance of R 6 is optionally substituted C 1-6 alkyl. In certain embodiments, two instances of R 6 are optionally substituted C 1-6 alkyl. In certain embodiments, three instances of R 6 are optionally substituted C 1-6 alkyl, and the moiety:
  • At least one instance of R 6 is unsubstituted C 1-6 alkyl. In certain embodiments, at least one instance of R 6 is unsubstituted methyl or unsubstituted ethyl. In certain embodiments, at least one instance of R 6 is optionally substituted methyl. In certain embodiments, at least one instance of R 6 is —CH 2 (D). In certain embodiments, at least one instance of R 6 is unsubstituted methyl. In certain embodiments, two instances of R 6 are unsubstituted methyl. In certain embodiments, at least one instance of R 6 is —(C-11)H 3 or —(C-13)H 3 .
  • At least one instance of R 6 is —(C-11)H 3 . In certain embodiments, at least one instance of R 6 is —(C-13)H 3 . In certain embodiments, at least one instance of R 6 is —CD 3 . In certain embodiments, both instances of R 6 are —CD 3 . In certain embodiments, at least one instance of R 6 is unsubstituted ethyl.
  • At least one instance of R 6 is a nitrogen protecting group (e.g., benzyl (Bn), t-butyl carbonate (BOC or Boc), benzyl carbamate (Cbz), 9-fluorenylmethyl carbonate (Fmoc), trifluoroacetyl, triphenylmethyl, acetyl, or p-toluenesulfonamide (Ts)).
  • a nitrogen protecting group e.g., benzyl (Bn), t-butyl carbonate (BOC or Boc), benzyl carbamate (Cbz), 9-fluorenylmethyl carbonate (Fmoc), trifluoroacetyl, triphenylmethyl, acetyl, or p-toluenesulfonamide (Ts)
  • Formulae (I) and (II) each include substituent R 7 .
  • R 7 is independently hydrogen, optionally substituted alkyl, a nitrogen protecting group, or absent, as valency permits. In certain embodiments, R 7 is absent. In certain embodiments, R 7 is hydrogen. In certain embodiments, R 7 is deuterium. In certain embodiments, R 7 is optionally substituted alkyl (e.g., substituted or unsubstituted C 1-6 alkyl). In certain embodiments, R 7 is optionally substituted C 1-6 alkyl. In certain embodiments, R 7 is unsubstituted C 1-6 alkyl. In certain embodiments, R 7 is unsubstituted methyl or unsubstituted ethyl.
  • R 7 is optionally substituted methyl. In certain embodiments, R 7 is —CH 2 (D). In certain embodiments, R 7 is unsubstituted methyl. In certain embodiments, R 7 is —CD 3 . In certain embodiments, R 7 is unsubstituted ethyl. In certain embodiments, R 7 is a nitrogen protecting group (e.g., benzyl (Bn), t-butyl carbonate (BOC or Boc), benzyl carbamate (Cbz), 9-fluorenylmethyl carbonate (Fmoc), trifluoroacetyl, triphenylmethyl, acetyl, or p-toluenesulfonamide (Ts)).
  • benzyl Bn
  • t-butyl carbonate BOC or Boc
  • Boc benzyl carbamate
  • Fmoc 9-fluorenylmethyl carbonate
  • Ts p-toluenesulfonamide
  • the compound of Formula (I) is of the formula:
  • x is 0 or 1
  • R 10 is halogen, optionally substituted alkyl, —NH 2 , —NH (optionally substituted alkyl), or —N(optionally substituted alkyl) 2 .
  • the compound of Formula (I) is of the formula:
  • the compound of Formula (I) is of the formula:
  • the compound of Formula (I) is of the formula:
  • the compound of Formula (I) is of the formula:
  • the compound of Formula (I) is of the formula:
  • the compound of Formula (I) is of the formula:
  • the compound of Formula (I) is of the formula:
  • the compound of Formula (I) is of the formula:
  • the compound of Formula (I) is of the formula:
  • the compound of Formula (I) is of the formula:
  • the compound of Formula (II) is of the formula:
  • x is 0 or 1
  • R 10 is halogen, optionally substituted alkyl, —NH 2 , —NH (optionally substituted alkyl), or —N(optionally substituted alkyl) 2 .
  • the compound of Formula (II) is of the formula:
  • the compound of Formula (II) is of the formula:
  • the compound of Formula (II) is of the formula:
  • the compound of Formula (II) is of the formula:
  • Formulae (I) and (II) include zero or more instances of substituent R 10 .
  • x is 0. In certain embodiments, x is 1.
  • at least one instance of R 10 is halogen (e.g., F, Cl, Br, or I). In certain embodiments, at least one instance of R 10 is I.
  • at least one instance of R 10 is optionally substituted alkyl (e.g., substituted or unsubstituted C 1-6 alkyl). In certain embodiments, at least one instance of R 10 is optionally substituted C 1-6 alkyl. In certain embodiments, at least one instance of R 10 is unsubstituted C 1-6 alkyl.
  • At least one instance of R 10 is unsubstituted methyl or unsubstituted ethyl. In certain embodiments, at least one instance of R 10 is unsubstituted methyl. In certain embodiments, at least one instance of R 10 is optionally substituted methyl. In certain embodiments, at least one instance of R 10 is optionally substituted ethyl. In certain embodiments, at least one instance of R 10 is unsubstituted ethyl. In certain embodiments, at least one instance of R 10 is —NH 2 .
  • At least one instance of R 10 is —N(optionally substituted alkyl) 2 (e.g., —N(substituted or unsubstituted C 1-6 alkyl) 2 ). In certain embodiments, at least one instance of R 10 is —NH (optionally substituted alkyl) 2 (e.g., —NH (substituted or unsubstituted C 1-6 alkyl).
  • a compound of Formula (I) or (II) is of the formula:
  • R 5 is optionally substituted acyl, unsubstituted alkyl, unsubstituted carbocyclyl, or optionally substituted aryl;
  • each instance of R 5A is independently —O(optionally substituted alkyl), —OH, —NH 2 , —NH (optionally substituted alkyl), or —N(optionally substituted alkyl) 2 ;
  • n 0, 1, 2, 3, or 4.
  • R 5 is optionally substituted acyl, unsubstituted alkyl, unsubstituted carbocyclyl, or optionally substituted aryl. In certain embodiments, R 5 is optionally substituted acyl (e.g., —C( ⁇ O)Me). In certain embodiments, R 5 is unsubstituted alkyl (e.g., unsubstituted C 1-6 alkyl). In certain embodiments, R 5 is unsubstituted carbocyclyl (e.g., substituted or unsubstituted, 3- to 7-membered, monocyclic carbocyclyl comprising zero, one, or two double bonds in the carbocyclic ring system).
  • R 5 is unsubstituted cyclohexyl. In certain embodiments, R 5 is optionally substituted aryl. In certain embodiments, R 5 is optionally substituted phenyl. In certain embodiments, R 5 is unsubstituted phenyl. In certain embodiments, R 5 is optionally substituted benzyl. In certain embodiments, R 5 is unsubstituted benzyl.
  • each instance of R 5A is independently —O(optionally substituted alkyl), —OH, —NH 2 , or —N(optionally substituted alkyl) 2 .
  • at least one instance of R 5A is —O(optionally substituted alkyl) (e.g., —O(optionally substituted C 1-6 alkyl)).
  • at least one instance of R 5A is —OMe.
  • At least one instance of R 5A is —OH. In certain embodiments, at least one instance of R 5A is —NH 2 . In certain embodiments, at least one instance of R 5A is —N(optionally substituted alkyl) 2 (e.g., —N(optionally substituted C 1-6 alkyl) 2 ). In certain embodiments, at least one instance of R 5A is —NMe 2 . In certain embodiments, at least one instance of R 5A is —NH (optionally substituted alkyl).
  • a compound of Formulae (I) or (II) is of the formula:
  • At least one hydrogen atom is deuterium.
  • at least one carbon atom is C-11.
  • at least one carbon atom is C-13.
  • at least one nitrogen atom is N-15.
  • a compound of Formulae (I) or (II) is of the formula:
  • the compound of Formula (I) is of the formula:
  • the compound of Formula (I) is of the formula:
  • the compound of Formula (I) is of the formula:
  • the compound of Formula (I) is of the formula:
  • the compound of Formula (I) is of the formula:
  • the compound of Formula (II) is of the formula:
  • the method comprises administering to the subject a therapeutically effective amount of a compound of Formula (III), (III-A), or (III-B):
  • each instance of R 4A is independently hydrogen, optionally substituted alkyl, a nitrogen protecting group, or —CN;
  • each instance of R 8 is independently hydrogen, optionally substituted alkyl, or a nitrogen protecting group
  • R 9 is hydrogen, optionally substituted alkyl, —CN, or a nitrogen protecting group.
  • Formulae (III), (III-A), and (III-B) each include substituent R 4A .
  • R 4A is as described herein.
  • each instance of R 4A is independently hydrogen, optionally substituted alkyl, a nitrogen protecting group, or —CN.
  • at least one instance of R 4A is hydrogen.
  • two instances of R 4A are hydrogen.
  • at least one instance of R 4A is optionally substituted alkyl (e.g., substituted or unsubstituted C 1-6 alkyl).
  • at least one instance of R 4A is optionally substituted C 1-6 alkyl.
  • two instances of R 4A are optionally substituted C 1-6 alkyl. In certain embodiments, at least one instance of R 4A is unsubstituted C 1-6 alkyl. In certain embodiments, at least one instance of R 4A is unsubstituted methyl or unsubstituted ethyl. In certain embodiments, at least one instance of R 4A is optionally substituted methyl. In certain embodiments, at least one instance of R 4A is unsubstituted methyl. In certain embodiments, at least one instance of R 4A is unsubstituted ethyl.
  • At least one instance of R 4A is a nitrogen protecting group (e.g., benzyl (Bn), t-butyl carbonate (BOC or Boc), benzyl carbamate (Cbz), 9-fluorenylmethyl carbonate (Fmoc), trifluoroacetyl, triphenylmethyl, acetyl, or p-toluenesulfonamide (Ts)).
  • at least one instance of R 4A is —CN.
  • Formulae (III), (III-A), and (III-B) each include one or more instances of substituent R 8 .
  • each instance of R 8 is independently hydrogen, optionally substituted alkyl, or a nitrogen protecting group.
  • at least one instance of R 8 is hydrogen.
  • two instances of R 8 are hydrogen.
  • at least one instance of R 8 is optionally substituted alkyl (e.g., substituted or unsubstituted C 1-6 alkyl).
  • at least one instance of R 8 is optionally substituted C 1-6 alkyl.
  • two instances of R 8 are optionally substituted C 1-6 alkyl.
  • At least one instance of R 8 is unsubstituted C 1-6 alkyl. In certain embodiments, at least one instance of R 8 is unsubstituted methyl or unsubstituted ethyl. In certain embodiments, at least one instance of R 8 is optionally substituted methyl. In certain embodiments, at least one instance of R 8 is unsubstituted methyl. In certain embodiments, at least one instance of R 8 is unsubstituted ethyl.
  • At least one instance of R 8 is a nitrogen protecting group (e.g., benzyl (Bn), t-butyl carbonate (BOC or Boc), benzyl carbamate (Cbz), 9-fluorenylmethyl carbonate (Fmoc), trifluoroacetyl, triphenylmethyl, acetyl, or p-toluenesulfonamide (Ts)).
  • a nitrogen protecting group e.g., benzyl (Bn), t-butyl carbonate (BOC or Boc), benzyl carbamate (Cbz), 9-fluorenylmethyl carbonate (Fmoc), trifluoroacetyl, triphenylmethyl, acetyl, or p-toluenesulfonamide (Ts)
  • Formulae (III), (III-A), and (III-B) each include substituent R 9 .
  • R 9 is hydrogen, optionally substituted alkyl, —CN, or a nitrogen protecting group.
  • R 9 is hydrogen.
  • R 9 is optionally substituted alkyl (e.g., substituted or unsubstituted C 1-6 alkyl).
  • R 9 is optionally substituted C 1-6 alkyl.
  • R 9 is unsubstituted C 1-6 alkyl.
  • R 9 is unsubstituted methyl or unsubstituted ethyl.
  • R 9 is optionally substituted methyl.
  • R 9 is unsubstituted methyl. In certain embodiments, R 9 is unsubstituted ethyl. In certain embodiments, R 9 is —CN. In certain embodiments, R 9 is a nitrogen protecting group (e.g., benzyl (Bn), t-butyl carbonate (BOC or Boc), benzyl carbamate (Cbz), 9-fluorenylmethyl carbonate (Fmoc), trifluoroacetyl, triphenylmethyl, acetyl, or p-toluenesulfonamide (Ts)).
  • benzyl Bn
  • t-butyl carbonate BOC or Boc
  • Boc benzyl carbamate
  • Fmoc 9-fluorenylmethyl carbonate
  • Ts p-toluenesulfonamide
  • the compound of Formula (III), (III-A), or (III-B) is of the formula:
  • a compound of Formula (I), (II), (III), (III-A), or (III-B), or a pharmaceutically acceptable salt thereof is formulated as a tablet with hydrochloride.
  • a compound of Formula (I), (II), (III), (III-A), or (III-B) e.g., metformin
  • a compound described herein is formulated as a tablet with hydrobromic acid. In certain embodiments, a compound described herein is formulated as a tablet with phosphoric acid. In certain embodiments, a compound described herein is formulated as a tablet with sulfuric acid. In certain embodiments, a compound described herein is formulated as a tablet with perchloric acid. In certain embodiments, a compound described herein is formulated as a tablet with an organic acid such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid, or malonic acid. In certain embodiments, a compound described herein is formulated as a tablet using other methods known in the art such as ion exchange.
  • a compound of Formula (I), (II), (III), (III-A), or (III-B) are formulated as a tablet with HBr.
  • metformin is formulated as a metformin hydrochloride tablet.
  • a compound of Formula (I), (II), (III), (III-A), or (III-B) is formulated as a metformin hydrochloride extended release tablet.
  • metformin is formulated as a metformin succinate or metformin fumurate salt.
  • a a compound of Formula (I), (II), (III), (III-A), or (III-B) (e.g., metformin) and compositions thereof, in certain embodiments, is administered via an enteral (e.g., oral) route.
  • a compound of Formula (I), (II), (III), (III-A), or (III-B) (e.g., metformin) is administered in doses of 500 mg metformin twice a day or doses of 850 mg metformin once a day.
  • a compound of Formula (I), (II), (III), (III-A), or (III-B) is administered in doses of at least 825 mg metformin three times a day.
  • a compound of Formula (I), (II), (III), (III-A), or (III-B) is administered in doses of 825 mg metformin three times a day.
  • a compound of Formula (I), (II), (III), (III-A), or (III-B) is administered in doses of 500 mg metformin once a day.
  • a compound of Formula (I), (II), (III), (III-A), or (III-B) is administered in doses of 1000 mg once a day. Doses of a compound of Formulae (I), (II), (III), (III-A), or (III-B) (e.g., metformin), in certain embodiments, are given with meals.
  • the method comprises administering to the subject a compound of Formula (I), (II), (III), (III-A), or (III-B) (e.g., metformin) over a period between 10 days to 30 days.
  • the duration between the first dose and last dose of the multiple doses of a compound of Formula (I), (II), (III), (III-A), or (III-B) is 10 days, 11 days, 12 days, 13 days, 14 days, 15 days, 16 days, 17 days, 18 days, 19 days, 20 days, 21 days, 22 days, 23 days, 24 days, 25 days, 26 days, 27 days, 28 days, 29 days, or 30 days.
  • the duration between the first dose and last dose of the multiple doses of a compound of Formula (I), (II), (III), (III-A), or (III-B) is at least the following number of days: 10 days, 11 days, 12 days, 13 days, 14 days, 15 days, 16 days, 17 days, 18 days, 19 days, 20 days, 21 days, 22 days, 23 days, 24 days, 25 days, 26 days, 27 days, 28 days, 29 days, or 30 days.
  • the duration between the first dose and last dose of the multiple doses of metformin is 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, multiple months, at least one year, multiple years, at least one decade, or multiple decades.
  • the doses of a compound of Formula (I), (II), (III), (III-A), or (III-B) are administered indefinitely. In certain embodiments, the doses of metformin are administered over a lifetime of the subject.
  • a dose described herein is at least 500 mg, 600 mg, 650 mg, 750 mg, 700 mg, 800 mg, 825 mg, 850 mg, 900 mg, 950 mg, 1000 mg, 1500 mg, 2000 mg, 2500 mg, 3000 mg, 3500 mg, 4000 mg, 5000 mg, 8000 mg, 9000 mg, or 10,000 mg of a compound of Formula (I), (II), (III), (III-A), or (III-B) (e.g., metformin).
  • a compound of Formula (I), (II), (III), (III-A), or (III-B) e.g., metformin
  • the duration between the first dose and last dose of the multiple doses of a compound of Formula (I), (II), (III), (III-A), or (III-B) is based on the duration required to prevent the accumulation of RAN proteins in a subject. In certain embodiments, the duration between the first dose and last dose of the multiple doses of a compound of Formula (I), (II), (III), (III-A), or (III-B) (e.g., metformin) is based on the duration required to reduce the level of RAN proteins in a subject.
  • the multiple doses of a compound of Formula (I), (II), (III), (III-A), or (III-B) are administered as prophylactic treatment to reduce the level of RAN proteins in a subject.
  • the prophylactic treatment is long-term, in certain embodiments.
  • the multiple doses of a compound of Formula (I), (II), (III), (III-A), or (III-B) are administered as long-term therapeutic treatment to reduce the level of RAN proteins in a subject.
  • the subject in certain embodiments, has a microsatellite expansion mutation including but not limited to mutations that cause: C9orf72 ALS or C9orf72 FTD, myotonic dystrophy type 1 (DM1) and myotonic dystrophy type 2 (DM2); spinocerebellar ataxia types 1, 2, 3, 6, 7, 8, 10, 12, 17, 31, and 36; spinal bulbar muscular atrophy; dentatorubral-pallidoluysian atrophy (DRPLA); Huntington's disease (HD); Fragile X Tremor Ataxia Syndrome (FXTAS); Huntington's disease-like 2 syndrome (HDL2); Fragile X syndrome (FXS); disorders related to 7p11.2 folate-sensitive fragile site FRA7A; disorders related to folate-sensitive fragile site 2q11 FRA2A; and Fragile XE syndrome (FRAXE).
  • C9orf72 ALS or C9orf72 FTD myotonic dystrophy type 1 (DM1) and myotonic dys
  • Dose ranges as described herein provide guidance for the administration of provided pharmaceutical compositions to an adult.
  • the amount to be administered to, for example, a child or an adolescent can be determined by a medical practitioner or person skilled in the art and can be lower or the same as that administered to an adult.
  • a compound of Formula (I), (II), (III), (III-A), or (III-B) (e.g., metformin) or compositions thereof, as described herein, can be administered in combination with one or more additional pharmaceutical agents (e.g., therapeutically and/or prophylactically active agents).
  • additional pharmaceutical agents e.g., therapeutically and/or prophylactically active agents.
  • the compounds or compositions can be administered in combination with additional pharmaceutical agents that improve their activity (e.g., activity (e.g., potency and/or efficacy) in treating a disease in a subject in need thereof, in preventing a disease in a subject in need thereof, improve bioavailability, improve safety, reduce drug resistance, reduce and/or modify metabolism, inhibit excretion, and/or modify distribution in a subject, biological sample, tissue, or cell.
  • a pharmaceutical composition described herein including a compound described herein and an additional pharmaceutical agent shows a synergistic effect that is absent in a pharmaceutical composition including one of the compound and the additional pharmaceutical agent, but not both.
  • compositions thereof can be administered concurrently with, prior to, or subsequent to one or more additional pharmaceutical agents, which may be useful as, e.g., combination therapies.
  • Pharmaceutical agents include therapeutically active agents.
  • Pharmaceutical agents also include prophylactically active agents.
  • Pharmaceutical agents include small organic molecules such as drug compounds (e.g., compounds approved for human or veterinary use by the U.S.
  • the additional pharmaceutical agent is a pharmaceutical agent useful for treating and/or preventing a disease (e.g., neurological disease).
  • Each additional pharmaceutical agent may be administered at a dose and/or on a time schedule determined for that pharmaceutical agent.
  • the additional pharmaceutical agents may also be administered together with each other and/or with the compound or composition described herein in a single dose or administered separately in different doses.
  • the particular combination to employ in a regimen will take into account compatibility of the compound described herein with the additional pharmaceutical agent(s) and/or the desired therapeutic and/or prophylactic effect to be achieved.
  • it is expected that the additional pharmaceutical agent(s) in combination be utilized at levels that do not exceed the levels at which they are utilized individually. In some embodiments, the levels utilized in combination will be lower than those utilized individually.
  • the additional pharmaceutical agents include, but are not limited to, anti-proliferative agents, anti-cancer agents, anti-angiogenesis agents, anti-inflammatory agents, immunosuppressants, anti-bacterial agents, anti-viral agents, cardiovascular agents, cholesterol-lowering agents, anti-diabetic agents, anti-allergic agents, contraceptive agents, pain-relieving agents, and a combination thereof.
  • additional pharmaceutical agents include, but are not limited to, cardiovascular agents, anti-diabetic agents, and agents for treating and/or preventing a neurological disease.
  • the additional pharmaceutical agents include, but are not limited to, anti-inflammatory agents or compounds (e.g., turmeric).
  • kits e.g., pharmaceutical packs.
  • the kits provided may comprise a pharmaceutical composition or compound described herein and a container (e.g., a vial, ampule, bottle, syringe, and/or dispenser package, or other suitable container).
  • a container e.g., a vial, ampule, bottle, syringe, and/or dispenser package, or other suitable container.
  • provided kits may optionally further include a second container comprising a pharmaceutical excipient for dilution or suspension of a pharmaceutical composition or compound described herein.
  • the pharmaceutical composition or compound described herein provided in the first container and the second container are combined to form one unit dosage form.
  • kits including a first container comprising a compound of Formula (I), (II), (III), (III-A), or (III-B) (e.g., metformin) or compositions thereof described herein.
  • the kits are useful for treating a neurological disease) in a subject in need thereof.
  • the kits are useful for preventing a neurological disease) in a subject in need thereof.
  • the kits are useful for reducing the level of one or more RAN proteins (e.g., reducing the expression of RAN proteins) in a subject, biological sample, tissue, or cell.
  • the kits are useful for reducing the accumulation of RAN proteins in a subject, biological sample, tissue, or cell.
  • the kits are useful for modulating (e.g., reducing or inhibiting) RAN protein translation in a subject, biological sample, tissue, or cell.
  • kits described herein further includes instructions for using a compound of Formula (I), (II), (III), (III-A), or (III-B) (e.g., metformin), or pharmaceutical composition thereof, included in the kit.
  • a kit described herein may also include information as required by a regulatory agency such as the U.S. Food and Drug Administration (FDA).
  • the information included in the kits is prescribing information.
  • the kits and instructions provide for treating a disease (e.g., a neurological disease) in a subject in need thereof.
  • the kits and instructions provide for preventing a disease (e.g., a neurological disease) in a subject in need thereof.
  • kits and instructions provide for reducing the level of one or more RAN proteins in a subject, biological sample, tissue, or cell. In certain embodiments, the kits and instructions provide for reducing the accumulation of RAN proteins in a subject, biological sample, tissue, or cell. In certain embodiments, the kits and instructions provide for modulating (e.g., reducing or inhibiting) RAN protein translation in a subject, biological sample, tissue, or cell.
  • a kit described herein may include one or more additional pharmaceutical agents described herein as a separate composition.
  • Metformin was evaluated for its effect on RAN protein translation in HEK293T cells that have been transfected with constructs containing CAG, CCTG or GGGGCC repeat expansion motifs.
  • Transfected HEK293T cells were treated with metformin.
  • Protein blots were run on protein lysates from HEK293T cells transfected with various repeat expansion constructs shown in FIG. 1 A .
  • FIG. 1 B the lanes labeled KMQ, show: RAN poly-Ser-Flag, RAN poly-Ala-HA, ATG initiated polyGln-Myc.
  • FIG. 1 B the lanes labeled KMQ, show: RAN poly-Ser-Flag, RAN poly-Ala-HA, ATG initiated polyGln-Myc.
  • the lanes labeled KMQ has a methionine encoding ATG immediately 5′ to the CAG repeat expansion and located within the polyGln reading frame.
  • the lanes labeled KKQ indicate the KKQ vector contains a CAG expansion without an AUG initiation codon, and indicates: RAN polySer-Flag, RAN polyAla-HA, RAN polyGln-Myc.
  • These constructs contain epitope tags that are incorporated into the C-terminal regions of the ATG-initiated poly-Gln and non-ATG initiated RAN proteins (poly-Gln, poly-Leu-Pro-Ala-Cys and poly-Gly-Pro) which are expressed across these repeat expansions.
  • the lane labeled CCTG expresses the following RAN proteins: RAN polyLPAC-Flag, RAN polyLPAC-HA, RAN polyLPAC-Myc.
  • the lane labeled G4C2 is designed to detect the following RAN proteins: RAN polyGP-Flag, RAN polyGR-HA, RAN polyGA-Myc.
  • the protein blots in FIG. 1 B show reduced RAN protein levels of the following RAN proteins of poly-LPAC (poly-Leucine-Proline-Alanine-Cysteine) in all three reading frames, poly-Ala, and poly-GP (poly glycine-proline).
  • FIG. 1 B shows that metformin inhibits RAN protein accumulation in cells transfected with exemplary repeat expansion constructs.
  • Metformin was evaluated for its effect on the steady state levels of glycine-proline (GP) RAN protein detected in vivo in proteins extracted from peripheral blood of a C9ORF72 expansion-positive study subject before and after treatment with metformin C9ORF72. These levels were measured in a human study subject before and after the subject was administered metformin (500 mg or 1000 mg per day Metformin Hydrochloride Extended Release Tablets) at different doses as prescribed by the subject's physician. Dose dependent reduction of glycine-proline (GP) RAN protein levels was observed in blood samples taken from a single human subject with a C9ORF72 repeat expansion compared to pretreatment levels.
  • metformin 500 mg or 1000 mg per day Metformin Hydrochloride Extended Release Tablets
  • FIG. 2 shows that metformin reduces the levels of RAN proteins generated by expression of C9ORF72 in vivo.
  • This Example describes activation of the PKR pathway by structured RAN-positive repeat expansion RNAs.
  • the activation leads to increased phospho-eIF2 ⁇ (p-eIF2 ⁇ ) and increased RAN protein levels. It was observed that inhibition of PKR decreased RAN protein levels in cell culture and a BAC transgenic mouse model of C9orf72 ALS/FTD (C9-BAC). It was also observed that metformin (and certain metformin derivatives, for example buformin and phenformin) inhibits phospho-PKR activation, decreases RAN protein levels and improves phenotypes in C9-BAC mice.
  • Gait Analysis Digital video images of the underside of the mouse were collected with a high-speed video camera from below the transparent belt of a motorized treadmill (DigiGaitTM Imaging system, Mouse Specific). Each mouse was allowed to explore the treadmill compartment with the motor speed set to 14 cm/s for 1 min then the motor speed was increased to 24 cm/s for video recording. Only video recordings in which the mouse walked straight ahead with a constant relative position with respect to the camera were used for analysis. Data from each paw was analyzed with DigiGait automated gait analysis software (Mouse Specifics).
  • Open Field Analysis Open field analysis was performed by testing mouse behavior during a 30 min session in a completely dark open chamber (17′′ ⁇ 17′′) (Med Associates). Approximately two hours before the start of analysis, mice were placed in the testing room to allow for acclimation to the room. Mice were then placed in the center of the darkened activity-monitoring chamber. The trace path and center time was recorded and analyzed with Activity Monitor (MED associates, Inc.) software.
  • Activity Monitor MED associates, Inc.
  • HEK293T cells were cultured in DMEM medium supplemented with 10% fetal bovine serum and incubated at 37° C. in a humid atmosphere containing 5% CO 2 .
  • DNA transfections were performed using Lipofectamine 2000 Reagent (Invitrogen) according to the manufacturer's instructions.
  • AAV vectors expressing the PKR under the control of the cytomegalovirus enhance/chicken beta actin (CBA) promoter, a woodchuck hepatitis virus post-transcriptional-regulatory element (WPRE), and the bovine growth hormone polyA were generated by Polyethylenimine Linear (PEI, Polysciences) transfection into HEK293T cells. Cells were co-transfected with AAV helper plasmids pDP8.ape to produce recombinant adeno-associated viral (rAAV) vector rAAV2/8.
  • CBA cytomegalovirus enhance/chicken beta actin
  • WPRE woodchuck hepatitis virus post-transcriptional-regulatory element
  • bovine growth hormone polyA bovine growth hormone polyA
  • Neonatal pups were injected within 0-12 hours after birth.
  • the naive pups were covered in aluminum foil and completely surrounded in ice for 3-4 minutes, resulting in the body temperature being lowered to ⁇ 10° C.
  • the pups were considered completely cryoanesthetized when all movement stops and the skin color changes from pink to purple.
  • 2 ⁇ l of virus (1013 viral genomes/ml) was slowly injected into the ventricle using 10 ⁇ l syringes (30 degree beveled). After injection pups were allowed to completely recover on a warming blanket and then returned to the home cage.
  • the subcellular distribution of polymeric proteins was assessed in transfected HEK293T cells by immunofluorescence.
  • Cells were plated on 8 well tissue-culture chambers and transfected with plasmids the next day. Forty-eight hours post-transfection, cells were fixed in 4% paraformaldehyde (PFA) in PBS for 30 min and permeabilized in 0.5% triton X-100 in PBS for 15 min on ice. The cells were blocked in 1% normal goat serum (NGS) in PBS for 30 min.
  • PFA paraformaldehyde
  • NGS normal goat serum
  • the cells were incubated for 1 hour at RT in blocking solution containing the rabbit anti-Myc (Abcam), mouse anti-HA (Covance), mouse anti-Flag (Sigma), rabbit ⁇ -GR and rabbit ⁇ -GR-CT primary antibodies at a dilution of 1:400.
  • the slides were washed three times in PBS and incubated for 1 hour at RT in blocking solution containing Goat anti-rabbit conjugated to Cy3 (Jackson ImmunoResearch, PA) and goat anti-mouse conjugated to Alexa Fluor 488 (Invitrogen) secondary antibodies at a dilution of 1:200.
  • the slides were washed three times in PBS and mounted with mounting medium containing DAPI (Invitrogen).
  • Imnumofluorescence in patient hippocampal tissue was performed on the 6 ⁇ m fresh frozen sections.
  • a similar protocol was used as in transfected cells, except 2% NGS was used as blocking buffer and higher dilution of antibodies was used (mouse ⁇ -GP 1:1000 and rabbit ⁇ -GP-CT 1:5000).
  • Transfected cells in each well of a six-well tissue-culture plate were rinsed with PBS and lysed in 300 ⁇ L RIPA buffer with protease inhibitor cocktail for 45 min on ice. DNA was sheared by passage through a 21-gauge needle. The cell lysates were centrifuged at 16,000 ⁇ g for 15 min at 4° C., and the supernatant was collected. The protein concentration of the cell lysate was determined using the protein assay dye reagent (Bio-Rad). Twenty micrograms of protein were separated in a 4-12% NuPAGE Bis-Tris gel (Invitrogen) and transferred to a nitrocellulose membrane (Amersham).
  • the membrane was blocked in 5% dry milk in PBS containing 0.05% Tween-20 (PBS-T) and probed with the anti-Flag (1:2000), anti-Myc (1:1000), anti-HA (1:1000), or rabbit polyclonal antibodies (1:1000) in blocking solution. After the membrane was incubated with anti-rabbit or anti-mouse HRP-conjugated secondary antibody (Amersham), bands were visualized by the ECL plus Western Blotting Detection System (Amersham).
  • Sequential extraction of patient frontal cortex autopsy tissue was performed as follows: tissue was homogenized in PBS containing 1% Triton-X100, 15 mM MgCl 2 , 0.2 mg/ml DNase I and protease inhibitor cocktail and centrifuged at 16,000 ⁇ g for 15 min at 4° C. The supernatant was collected. The pellet was resuspended in 2% SDS and incubated at room temperature for 1 hour, then centrifuged at 16,000 ⁇ g for 15 min at 4° C. The supernatant was collected and the 2% SDS insoluble pellet was resuspended in 8% SDS, 62.5 mM Tris-HCl pH 6.8, 10% glycerol, and 20% 2-mercaptoethanol for protein blotting.
  • Metformin Decreases RAN Translation and Mitigates Repeat-Induced PKR Activation
  • metformin decreases RAN protein levels in cells expressing CAG, CCUG or G 4 C 2 expansion RNAs ( FIG. 3 A ).
  • RAN protein inhibition by metformin is similar to the inhibition with PKR—K296R, indicating that metformin mitigates PKR activation induced by repeat expansion RNAs.
  • Transient transfections of expansion constructs treated with or without metformin were performed. Protein blots indicate that metformin decreases PKR phosphorylation at T446 and T451, sites which have been observed to be required for PKR activation ( FIG. 3 B ).
  • metformin and the related drugs phenformin and buformin mediate similar dose-dependent inhibition of G 4 C 2 repeat-expansion induced p-PKR levels and RAN polyGP levels ( FIG. 4 ).
  • metformin reduced the levels of several types of RAN proteins in mammalian cells and PKR was identified as a metformin target that inhibits PKR activation and eIF2 ⁇ phosphorylation.
  • Metformin Ameliorates Neuropathological and Behavioral Phenotypes in the C9-500 Mouse Model.
  • C9orf72 mice, C9-500 BAC and NT mice were treated for 3 months with or without metformin (5 mg/ml) in the drinking water.
  • metformin 5 mg/ml
  • treatment began at 2 months of age, before the onset of overt behavioral or pathological phenotypes.
  • a schematic depicting treatment regimens is shown in FIG. 3 C . DigiGait analyses of Group A mice at 5 months identified eight DigiGait parameters that differed between untreated C9 and NT cohorts.
  • C9 metformin treated mice six of these parameters improved compared to the C9 water treatment group ( FIGS. 3 E- 3 G ).
  • Group A metformin-treated C9 mice showed increased center time by open field testing, compared to untreated C9 mice.
  • C9 metformin treated animals showed decreased numbers of GA aggregates in the retrosplenial cortex compared to C9 controls in cohorts that began treatment at presymptomatic (8 wks, Group A) or symptomatic ages (6 mos, Group B) ( FIG. 3 D ). Decreases in soluble GP levels were observed in C9 metformin treated animals compared to C9 controls in the older Group B but not the younger Group A treatment cohorts ( FIGS. 3 H- 3 I ).
  • GFAP glial fibrillary acidic protein
  • data indicate that metformin reduces RAN protein levels in vitro and in vivo, and metformin treatment improves behavior and decreases neuroinflammation in C9 BAC transgenic mice.
  • data described in this example are consistent with a model in which repeat expansion RNAs lead to chronic activation of the PKR pathway, a condition which results in increased levels of p-eIF2 ⁇ , decreases in global protein synthesis and the upregulation of RAN translation ( FIG. 3 J ).
  • Metformin was evaluated for its effect on RAN protein translation in HEK293T cells that have been transfected with constructs containing CAG, CCTG or GGGGCC repeat expansion motifs.
  • Transfected HEK293T cells were treated with metformin.
  • Protein blots were run on protein lysates from HEK293T cells transfected with various repeat expansion constructs shown in FIG. 5 A .
  • FIG. 5 B the lanes labeled KMQ, show: RAN poly-Ser-Flag, RAN poly-Ala-HA, ATG initiated polyGln-Myc.
  • FIG. 5 B the lanes labeled KMQ, show: RAN poly-Ser-Flag, RAN poly-Ala-HA, ATG initiated polyGln-Myc.
  • the lanes labeled KMQ has a methionine encoding ATG immediately 5′ to the CAG repeat expansion and located within the polyGln reading frame.
  • the lanes labeled KKQ indicate the KKQ vector contains a CAG expansion without an AUG initiation codon, and indicates: RAN polySer-Flag, RAN polyAla-HA, RAN polyGln-Myc.
  • These constructs contain epitope tags that are incorporated into the C-terminal regions of the ATG-initiated poly-Gln and non-ATG initiated RAN proteins (poly-Gln, poly-Leu-Pro-Ala-Cys and poly-Gly-Pro) which are expressed across these repeat expansions.
  • the lane labeled CCTG expresses the following RAN proteins: RAN polyLPAC-Flag, RAN polyLPAC-HA, RAN polyLPAC-Myc.
  • the lane labeled G4C2 is designed to detect the following RAN proteins: RAN polyGP-Flag, RAN polyGR-HA, RAN polyGA-Myc.
  • the protein blots in FIG. 13 B show reduced RAN protein levels of the following RAN proteins of poly-LPAC (poly-Leucine-Proline-Alanine-Cysteine) in all three reading frames, poly-Ala, and poly-GP (poly glycine-proline).
  • FIG. 5 B shows that metformin inhibits RAN protein accumulation in cells transfected with exemplary repeat expansion constructs.
  • FIG. 5 B shows that metformin decreases polyAla, polyLPAC and polyGP RAN protein levels, but not polyGln levels in cells expressing CAG, CCUG or G 4 C 2 expansion RNAs.
  • exemplary compound metformin inhibits PKR activation induced by repeat expansion RNAs
  • repeat expansion transcripts were expressed with or without metformin.
  • Protein blots show that PKR metformin decreases PKR phosphorylation at the T446 and T451 sites, which are required for PKR activation ( FIG. 6 A ).
  • exemplary metformin and the exemplary related drugs phenformin and buformin show similar dose-dependent inhibition of G 4 C 2 repeat-expansion induced p-PKR levels and RAN polyGP levels (see FIG. 4 ).
  • exemplary compound metformin reduces the levels of several types of RAN proteins in mammalian cells and a novel function of metformin as a modulator of PKR phosphorylation has been identified.
  • Metformin was evaluated for its effect on the steady state levels of glycine-proline (GP) RAN protein detected in vivo in proteins extracted from peripheral blood of a C9ORF72 expansion-positive study subject before and after treatment with metformin C9ORF72. These levels were measured in a human study subject before and after the subject was administered metformin (500 mg or 1000 mg per day Metformin Hydrochloride Extended Release Tablets) at different doses as prescribed by the subject's physician. Dose dependent reduction of glycine-proline (GP) RAN protein levels was observed in blood samples taken from a single human subject with a C9ORF72 repeat expansion compared to pretreatment levels.
  • metformin 500 mg or 1000 mg per day Metformin Hydrochloride Extended Release Tablets
  • GP levels were measured in protein lysates from leukocytes isolated from peripheral blood and at multiple time points between 10 and 30 days after treatment with 500 or 1000 mg/day of metformin. * p ⁇ 0.05, *** p ⁇ 0.001, after correction for multiple comparisons.
  • C9-BAC and NT mice were treated for 3 months with or without metformin (5 mg/ml) in the drinking water ( FIG. 6 B ), a dose which has previously been shown to result in plasma levels ( ⁇ 10 uM) comparable to conventional human doses of 20 mg/kg/day used in diabetic patients (Chen, Y. et al. Antidiabetic drug metformin (GlucophageR) increases biogenesis of Alzheimer's amyloid peptides via up-regulating BACE1 transcription.
  • metformin 5 mg/ml
  • GlucophageR Antidiabetic drug metformin
  • Group A animals three months of treatment began at 2 months of age, before the onset of overt behavioral or pathological phenotypes.
  • Group B smaller cohorts of animals were treated for four months beginning at 6 months, an age at which behavioral phenotypes are evident 12 .
  • metformin did not change C9orf72 mRNA levels.
  • DigiGait analyses of Group A mice at 5 months identified eight parameters that differed between untreated C9 and NT cohorts.
  • C9 metformin treated mice six of these parameters improved compared to the C9 water treatment group ( FIG. 6 E ) including, brake, brake/stance and brake/stride ( FIG. 6 F ).
  • Group A metformin-treated C9 mice showed normalization or increased center time by open field testing, compared to untreated C9 mice.
  • GFAP glial fibrillary acidic protein
  • the invention encompasses all variations, combinations, and permutations in which one or more limitations, elements, clauses, and descriptive terms from one or more of the listed claims is introduced into another claim.
  • any claim that is dependent on another claim can be modified to include one or more limitations found in any other claim that is dependent on the same base claim.
  • elements are presented as lists, e.g., in Markush group format, each subgroup of the elements is also disclosed, and any element(s) can be removed from the group. It should it be understood that, in general, where the invention, or aspects of the invention, is/are referred to as comprising particular elements and/or features, certain embodiments of the invention or aspects of the invention consist, or consist essentially of, such elements and/or features.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
US16/650,721 2017-09-26 2018-09-26 Use of metformin and analogs thereof to reduce RAN protein levels in the treatment of neurological disorders Active 2039-03-21 US11903910B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US16/650,721 US11903910B2 (en) 2017-09-26 2018-09-26 Use of metformin and analogs thereof to reduce RAN protein levels in the treatment of neurological disorders

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762563588P 2017-09-26 2017-09-26
US16/650,721 US11903910B2 (en) 2017-09-26 2018-09-26 Use of metformin and analogs thereof to reduce RAN protein levels in the treatment of neurological disorders
PCT/US2018/052913 WO2019067587A1 (en) 2017-09-26 2018-09-26 USE OF METFORMIN AND ANALOGUES THEREOF TO REDUCE RAN PROTEIN RATES DURING TREATMENT OF NEUROLOGICAL DISORDERS

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2018/052913 A-371-Of-International WO2019067587A1 (en) 2017-09-26 2018-09-26 USE OF METFORMIN AND ANALOGUES THEREOF TO REDUCE RAN PROTEIN RATES DURING TREATMENT OF NEUROLOGICAL DISORDERS

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US18/403,100 Continuation US20240269093A1 (en) 2017-09-26 2024-01-03 Use of metformin and analogs thereof to reduce ran protein levels in the treatment of neurological disorders

Publications (2)

Publication Number Publication Date
US20200268691A1 US20200268691A1 (en) 2020-08-27
US11903910B2 true US11903910B2 (en) 2024-02-20

Family

ID=65903814

Family Applications (2)

Application Number Title Priority Date Filing Date
US16/650,721 Active 2039-03-21 US11903910B2 (en) 2017-09-26 2018-09-26 Use of metformin and analogs thereof to reduce RAN protein levels in the treatment of neurological disorders
US18/403,100 Pending US20240269093A1 (en) 2017-09-26 2024-01-03 Use of metformin and analogs thereof to reduce ran protein levels in the treatment of neurological disorders

Family Applications After (1)

Application Number Title Priority Date Filing Date
US18/403,100 Pending US20240269093A1 (en) 2017-09-26 2024-01-03 Use of metformin and analogs thereof to reduce ran protein levels in the treatment of neurological disorders

Country Status (6)

Country Link
US (2) US11903910B2 (fi)
EP (1) EP3688021A4 (fi)
JP (1) JP7350337B2 (fi)
AU (1) AU2018342105B2 (fi)
CA (1) CA3076214A1 (fi)
WO (1) WO2019067587A1 (fi)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6628285B2 (ja) 2013-03-14 2020-01-08 ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド Ａｌｓ関連ジアミノ酸リピート含有タンパク質
CA3019847A1 (en) 2016-04-04 2017-10-12 University Of Florida Research Foundation, Incorporated Manipulation of eif3 to modulate repeat associated non-atg (ran) translation
WO2018195110A1 (en) 2017-04-17 2018-10-25 University Of Florida Research Foundation, Incorporated Regolation of ran translation by pkr and eif2a-p pathways
US11903910B2 (en) 2017-09-26 2024-02-20 University Of Florida Research Foundation, Incorporated Use of metformin and analogs thereof to reduce RAN protein levels in the treatment of neurological disorders
WO2021007110A1 (en) * 2019-07-05 2021-01-14 University Of Florida Research Foundation, Incorporated Methods for treating ran protein-associated neurological diseases
CA3172328A1 (en) * 2020-03-27 2021-09-30 Haruhisa Inoue Nerve cell degeneration inhibitor
EP4440560A1 (en) 2021-12-01 2024-10-09 University Of Florida Research Foundation, Incorporated Small molecule inhibitors of repeat associated non-aug (ran) translation and combination therapies

Citations (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5011912A (en) 1986-12-19 1991-04-30 Immunex Corporation Hybridoma and monoclonal antibody for use in an immunoaffinity purification system
US6204008B1 (en) 1995-04-11 2001-03-20 Merck & Co., Inc. Bioprocess for production of dipeptide based compounds
WO2001075067A2 (en) 2000-03-31 2001-10-11 Hyseq, Inc. Novel nucleic acids and polypeptides
WO2001081581A2 (en) 2000-04-21 2001-11-01 Corixa Corporation Compositions and methods for the therapy and diagnosis of acne vulgaris
US6342581B1 (en) 1997-07-08 2002-01-29 Human Genome Sciences, Inc. Secreted protein HLHFP03
WO2002040672A2 (en) 2000-11-20 2002-05-23 Diadexus, Inc. Compositions and methods relating to breast specific genes and proteins
WO2002062945A2 (en) 2000-10-25 2002-08-15 Diadexus, Inc. Compositions and methods relating to lung specific genes and proteins
US20020165355A1 (en) 1997-08-29 2002-11-07 Innogenetics N.V. Methylated, SmD homologous peptides, reactive with the antibodies from sera of living beings affected with systemic lupus erythematosus
US20030233675A1 (en) 2002-02-21 2003-12-18 Yongwei Cao Expression of microbial proteins in plants for production of plants with improved properties
WO2005033321A2 (en) 2003-09-30 2005-04-14 The Trustees Of The University Of Pennsylvania Adeno-associated virus (aav) clades, sequences, vectors containing same, and uses therefor
US7008796B2 (en) 1997-09-18 2006-03-07 Mesoscale Technologies, Llc. Assay sonication apparatus and methodology
US20060068434A1 (en) 2004-09-21 2006-03-30 Jay Stoerker Methods and compositions for detecting cancer using components of the U2 spliceosomal particle
WO2006083800A2 (en) 2005-01-31 2006-08-10 University Of Iowa Research Foundation Nucleic acid silencing of huntington's disease gene
US20070004729A1 (en) 2001-09-21 2007-01-04 Timmer Richard T Methods and compositions of novel triazine compounds
US20070014810A1 (en) 2003-12-31 2007-01-18 Denise Baker Inducing cellular immune responses to human papillomavirus using peptide and nucleic acid compositions
US20070093426A1 (en) 2004-03-23 2007-04-26 Uri Wormser Histone H2A peptide derivatives and analogs and methods of use thereof
US20080188457A1 (en) 2007-02-02 2008-08-07 Braincells, Inc. Modulation of Neurogenesis with Biguanides and GSK3-beta Agents
US20080227699A1 (en) 2004-04-08 2008-09-18 Tomohiro Chiba Therapeutic Agent for Neurodegenerative Diseases
US20080248099A1 (en) 2005-11-11 2008-10-09 Ishii Douglas N Method for Treating Disease or Disorder of Adult Central Nervous System Associated with Tissue Shrinkage or Atrophy by Administration of Insulin
US7481997B1 (en) 2004-02-12 2009-01-27 Montana State University Snow mountain virus genome sequence, virus-like particles and methods of use
US20090074721A1 (en) 2005-06-06 2009-03-19 Vgx Pharmaceuticals, Inc. Methods for treating viral infection with oral or injectibel drug solution
US20090143418A1 (en) 2007-11-30 2009-06-04 The Regents Of The University Of Michigan Compositions and Methods for Preventing and Treating Hair Growth Cycle-Related Conditions
WO2009144480A1 (en) 2008-05-30 2009-12-03 University Court Of The University Of Aberdeen Treatment and diagnosis of behavioural disorders
US20090312395A1 (en) 2006-09-20 2009-12-17 Queen's University Of Belfast Assay
WO2010115033A2 (en) 2009-04-02 2010-10-07 Regents Of The University Of Minnesota Nucleotide repeat expansion-associated polypeptides and uses thereof
WO2010132982A1 (en) 2009-05-18 2010-11-25 Ottawa Hospital Research Institute Treatment of muscle disease characterized by insulin resistance
US20120076785A1 (en) 2009-02-18 2012-03-29 Genentech, Inc. Method for inhibiting neurodegeneration
US20120220534A1 (en) 2009-09-03 2012-08-30 University Of Tennessee Research Foundation Biomarker for neurodegeneration in neurological disease
WO2013030588A1 (en) 2011-08-31 2013-03-07 The University Of Manchester Method for diagnosing a neurodegenerative disease
US20130085169A1 (en) 2010-04-02 2013-04-04 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and compositions comprising ampk activator (metformin/troglitazone) for the treatment of myotonic dystrophy type 1 (dm1)
WO2013172537A1 (ko) 2012-05-15 2013-11-21 경상대학교산학협력단 메트포민 및/또는 타이모퀴논을 포함하는 임신중 알코올 노출에 의한 신경질환 치료 또는 예방용 약학적 조성물
US20140100282A1 (en) 2012-10-10 2014-04-10 Patrick S L Wong Intranasal administration of pharmaceutical agents for treatment of neurological diseases
WO2014114303A1 (en) 2013-01-22 2014-07-31 Deutsches Zentrum Für Neurodegenerative Erkrankungen Dipeptide-repeat proteins as therapeutic target in neurodegenerative diseases with hexanucleotide repeat expansion
WO2014114660A1 (en) 2013-01-22 2014-07-31 Deutsches Zentrum Für Neurodegenerative Erkrankungen E.V. (Dzne) Dipeptide-repeat proteins as therapeutic target in neurodegenerative diseases with hexanucleotide repeat expansion
WO2014116865A1 (en) 2013-01-24 2014-07-31 Mayo Foundation For Medical Education And Research Methods and materials for detecting c9orf72 hexanucleotide repeat expansion positive frontotemporal lobar degeneration or c9orf72 hexanucleotide repeat expansion positive amyotrophic lateral sclerosis
WO2014159247A1 (en) 2013-03-14 2014-10-02 University Of Florida Research Foundation, Inc. Di-amino acid repeat-containing proteins associated with als
US20140336133A1 (en) 2012-02-29 2014-11-13 Sangamo Biosciences, Inc. Methods and compositions for treating huntington's disease
EP2837390A1 (en) 2013-08-15 2015-02-18 Universitäts-Kinderspital beider Basel Combined Pharmaceutical Preparation for Use in Treating Neuromuscular Disorders
WO2016025692A1 (en) 2014-08-13 2016-02-18 The Scripps Research Institute Treatment of c9ftd/als by targeting rna expanded repeat sequences
US20160096800A1 (en) 2013-03-15 2016-04-07 The Regents Of The University Of California Modulators of the eif2alpha pathway
US20160346297A1 (en) 2015-05-27 2016-12-01 James Sheehan Pharmaceutical Compositions Affecting Mitochondrial Redox State and Methods of Treatment
WO2017176813A1 (en) 2016-04-04 2017-10-12 University Of Florida Research Foundation, Incorporated Manipulation of eif3 to modulate repeat associated non-atg (ran) translation
WO2018035408A1 (en) 2016-08-18 2018-02-22 Ovid Therapeutics Inc. Methods of treating developmental disorders with biguanides
US20180292416A1 (en) 2015-05-29 2018-10-11 University Of Florida Research Foundation, Incorporated Methods for diagnosing huntington's disease
WO2019060918A1 (en) 2017-09-25 2019-03-28 University Of Florida Research Foundation, Incorporated IMMUNOLOGICAL ASSAYS FOR DETECTION OF RAN PROTEINS
WO2019067587A1 (en) 2017-09-26 2019-04-04 University Of Florida Research Foundation, Incorporated USE OF METFORMIN AND ANALOGUES THEREOF TO REDUCE RAN PROTEIN RATES DURING TREATMENT OF NEUROLOGICAL DISORDERS
US20190153445A1 (en) 2009-04-17 2019-05-23 Oxford University Innovation Limited Composition For Delivery Of Genetic Material
US20200140846A1 (en) 2017-04-17 2020-05-07 University Of Florida Research Foundation, Incorporated Regulation of ran translation by pkr and eif2a-p pathways
WO2021007110A1 (en) 2019-07-05 2021-01-14 University Of Florida Research Foundation, Incorporated Methods for treating ran protein-associated neurological diseases
US11034974B2 (en) 2013-05-16 2021-06-15 University Of Florida Research Foundation Incorporated Hairpin MRNA elements and methods for the regulation of protein translation
US20220373559A1 (en) 2019-09-20 2022-11-24 University Of Florida Research Foundation, Incorporated Detection of antibodies against ran proteins from serum and tissue lysates

Patent Citations (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5011912A (en) 1986-12-19 1991-04-30 Immunex Corporation Hybridoma and monoclonal antibody for use in an immunoaffinity purification system
US6204008B1 (en) 1995-04-11 2001-03-20 Merck & Co., Inc. Bioprocess for production of dipeptide based compounds
US6342581B1 (en) 1997-07-08 2002-01-29 Human Genome Sciences, Inc. Secreted protein HLHFP03
US20020165355A1 (en) 1997-08-29 2002-11-07 Innogenetics N.V. Methylated, SmD homologous peptides, reactive with the antibodies from sera of living beings affected with systemic lupus erythematosus
US7008796B2 (en) 1997-09-18 2006-03-07 Mesoscale Technologies, Llc. Assay sonication apparatus and methodology
WO2001075067A2 (en) 2000-03-31 2001-10-11 Hyseq, Inc. Novel nucleic acids and polypeptides
WO2001081581A2 (en) 2000-04-21 2001-11-01 Corixa Corporation Compositions and methods for the therapy and diagnosis of acne vulgaris
JP2004520803A (ja) 2000-04-21 2004-07-15 コリクサ コーポレイション 尋常性挫瘡の治療および診断のための組成物および方法
WO2002062945A2 (en) 2000-10-25 2002-08-15 Diadexus, Inc. Compositions and methods relating to lung specific genes and proteins
JP2004518437A (ja) 2000-10-25 2004-06-24 ディアデクサス インコーポレーテッド 肺特異的遺伝子およびタンパク質に関する組成物および方法
WO2002040672A2 (en) 2000-11-20 2002-05-23 Diadexus, Inc. Compositions and methods relating to breast specific genes and proteins
US20070004729A1 (en) 2001-09-21 2007-01-04 Timmer Richard T Methods and compositions of novel triazine compounds
US20030233675A1 (en) 2002-02-21 2003-12-18 Yongwei Cao Expression of microbial proteins in plants for production of plants with improved properties
WO2005033321A2 (en) 2003-09-30 2005-04-14 The Trustees Of The University Of Pennsylvania Adeno-associated virus (aav) clades, sequences, vectors containing same, and uses therefor
US20070036760A1 (en) 2003-09-30 2007-02-15 The Trutees Of The University Of Pennsylvania Adeno-associated virus (aav) clades, sequences, vectors containing same, and uses therefor
US20070014810A1 (en) 2003-12-31 2007-01-18 Denise Baker Inducing cellular immune responses to human papillomavirus using peptide and nucleic acid compositions
US7481997B1 (en) 2004-02-12 2009-01-27 Montana State University Snow mountain virus genome sequence, virus-like particles and methods of use
US20070093426A1 (en) 2004-03-23 2007-04-26 Uri Wormser Histone H2A peptide derivatives and analogs and methods of use thereof
US20080227699A1 (en) 2004-04-08 2008-09-18 Tomohiro Chiba Therapeutic Agent for Neurodegenerative Diseases
US20060068434A1 (en) 2004-09-21 2006-03-30 Jay Stoerker Methods and compositions for detecting cancer using components of the U2 spliceosomal particle
WO2006083800A2 (en) 2005-01-31 2006-08-10 University Of Iowa Research Foundation Nucleic acid silencing of huntington's disease gene
US20090074721A1 (en) 2005-06-06 2009-03-19 Vgx Pharmaceuticals, Inc. Methods for treating viral infection with oral or injectibel drug solution
US20080248099A1 (en) 2005-11-11 2008-10-09 Ishii Douglas N Method for Treating Disease or Disorder of Adult Central Nervous System Associated with Tissue Shrinkage or Atrophy by Administration of Insulin
US20090312395A1 (en) 2006-09-20 2009-12-17 Queen's University Of Belfast Assay
US20080188457A1 (en) 2007-02-02 2008-08-07 Braincells, Inc. Modulation of Neurogenesis with Biguanides and GSK3-beta Agents
US20090143418A1 (en) 2007-11-30 2009-06-04 The Regents Of The University Of Michigan Compositions and Methods for Preventing and Treating Hair Growth Cycle-Related Conditions
WO2009144480A1 (en) 2008-05-30 2009-12-03 University Court Of The University Of Aberdeen Treatment and diagnosis of behavioural disorders
US20120076785A1 (en) 2009-02-18 2012-03-29 Genentech, Inc. Method for inhibiting neurodegeneration
WO2010115033A2 (en) 2009-04-02 2010-10-07 Regents Of The University Of Minnesota Nucleotide repeat expansion-associated polypeptides and uses thereof
US20120094299A1 (en) 2009-04-02 2012-04-19 Regents Of The University Of Minnesota Nucleotide repeat expansion-associated polypeptides and uses thereof
US20130115603A9 (en) 2009-04-02 2013-05-09 Regents Of The University Of Minnesota Nucleotide repeat expansion-associated polypeptides and uses thereof
US20190153445A1 (en) 2009-04-17 2019-05-23 Oxford University Innovation Limited Composition For Delivery Of Genetic Material
WO2010132982A1 (en) 2009-05-18 2010-11-25 Ottawa Hospital Research Institute Treatment of muscle disease characterized by insulin resistance
US8993633B2 (en) * 2009-05-18 2015-03-31 Fate Therapeutics, (Canada) Inc. Treatment of muscle disease characterized by insulin resistance
US20120220534A1 (en) 2009-09-03 2012-08-30 University Of Tennessee Research Foundation Biomarker for neurodegeneration in neurological disease
US20130085169A1 (en) 2010-04-02 2013-04-04 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and compositions comprising ampk activator (metformin/troglitazone) for the treatment of myotonic dystrophy type 1 (dm1)
WO2013030588A1 (en) 2011-08-31 2013-03-07 The University Of Manchester Method for diagnosing a neurodegenerative disease
US20140336133A1 (en) 2012-02-29 2014-11-13 Sangamo Biosciences, Inc. Methods and compositions for treating huntington's disease
WO2013172537A1 (ko) 2012-05-15 2013-11-21 경상대학교산학협력단 메트포민 및/또는 타이모퀴논을 포함하는 임신중 알코올 노출에 의한 신경질환 치료 또는 예방용 약학적 조성물
US20140100282A1 (en) 2012-10-10 2014-04-10 Patrick S L Wong Intranasal administration of pharmaceutical agents for treatment of neurological diseases
WO2014114660A1 (en) 2013-01-22 2014-07-31 Deutsches Zentrum Für Neurodegenerative Erkrankungen E.V. (Dzne) Dipeptide-repeat proteins as therapeutic target in neurodegenerative diseases with hexanucleotide repeat expansion
WO2014114303A1 (en) 2013-01-22 2014-07-31 Deutsches Zentrum Für Neurodegenerative Erkrankungen Dipeptide-repeat proteins as therapeutic target in neurodegenerative diseases with hexanucleotide repeat expansion
US20150361166A1 (en) 2013-01-22 2015-12-17 Deutsches Zentrum Für Neurodegenerative Erkrankungen E.V. (Dzne) Dipeptide-repeat proteins as therapeutic target in neurodegenerative diseases with hexanucleotide repeat expansion
US9448232B2 (en) 2013-01-24 2016-09-20 Mayo Foundation For Medical Education And Research Methods and materials for detecting C9ORF72 hexanucleotide repeat expansion positive frontotemporal lobar degeneration or C9ORF72 hexanucleotide repeat expansion positive amyotrophic lateral sclerosis
WO2014116865A1 (en) 2013-01-24 2014-07-31 Mayo Foundation For Medical Education And Research Methods and materials for detecting c9orf72 hexanucleotide repeat expansion positive frontotemporal lobar degeneration or c9orf72 hexanucleotide repeat expansion positive amyotrophic lateral sclerosis
EP2948471A1 (en) 2013-01-24 2015-12-02 Mayo Foundation for Medical Education and Research Methods and materials for detecting c9orf72 hexanucleotide repeat expansion positive frontotemporal lobar degeneration or c9orf72 hexanucleotide repeat expansion positive amyotrophic lateral sclerosis
US10295547B2 (en) 2013-03-14 2019-05-21 University Of Florida Research Foundation, Incorporated Use and treatment of di-amino acid repeat-containing proteins associated with ALS
US20200341012A1 (en) 2013-03-14 2020-10-29 University Of Florida Research Foundation,Incorporated Use and treatment of di-amino acid repeat-containing proteins associated with als
US20210285970A1 (en) 2013-03-14 2021-09-16 University Of Florida Research Foundation, Incorporated Use and treatment of di-amino acid repeat-containing proteins associated with als
JP2016515208A (ja) 2013-03-14 2016-05-26 ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド Ａｌｓ関連ジアミノ酸リピート含有タンパク質
US20160025747A1 (en) 2013-03-14 2016-01-28 University Of Florida Research Foundation, Inc. Use and treatment of di-amino acid repeat-containing proteins associated with als
US10663475B2 (en) 2013-03-14 2020-05-26 University Of Florida Research Foundation, Incorporated Use and treatment of di-amino acid repeat-containing proteins associated with ALS
US20190285652A1 (en) 2013-03-14 2019-09-19 University Of Florida Research Foundation, Incorporated Use and treatment of di-amino acid repeat-containing proteins associated with als
WO2014159247A1 (en) 2013-03-14 2014-10-02 University Of Florida Research Foundation, Inc. Di-amino acid repeat-containing proteins associated with als
US20160096800A1 (en) 2013-03-15 2016-04-07 The Regents Of The University Of California Modulators of the eif2alpha pathway
US11034974B2 (en) 2013-05-16 2021-06-15 University Of Florida Research Foundation Incorporated Hairpin MRNA elements and methods for the regulation of protein translation
EP2837390A1 (en) 2013-08-15 2015-02-18 Universitäts-Kinderspital beider Basel Combined Pharmaceutical Preparation for Use in Treating Neuromuscular Disorders
WO2016025692A1 (en) 2014-08-13 2016-02-18 The Scripps Research Institute Treatment of c9ftd/als by targeting rna expanded repeat sequences
US20160346297A1 (en) 2015-05-27 2016-12-01 James Sheehan Pharmaceutical Compositions Affecting Mitochondrial Redox State and Methods of Treatment
US20180292416A1 (en) 2015-05-29 2018-10-11 University Of Florida Research Foundation, Incorporated Methods for diagnosing huntington's disease
US10509045B2 (en) 2015-05-29 2019-12-17 University Of Florida Research Foundation, Incorporated Methods for diagnosing Huntington's disease
US20200241013A1 (en) 2015-05-29 2020-07-30 University Of Florida Research Foundation, Incorporated Methods for diagnosing huntington's disease
US20210236535A1 (en) 2016-04-04 2021-08-05 University Of Florida Research Foundation, Incorporated Manipulation of eif3 to modulate repeat associated non-atg (ran) translation
US20190142858A1 (en) 2016-04-04 2019-05-16 University Of Florida Research Foundation, Incorporated Manipulation of eif3 to modulate repeat associated non-atg (ran) translation
WO2017176813A1 (en) 2016-04-04 2017-10-12 University Of Florida Research Foundation, Incorporated Manipulation of eif3 to modulate repeat associated non-atg (ran) translation
EP3440100A1 (en) 2016-04-04 2019-02-13 University of Florida Research Foundation, Incorporated Manipulation of eif3 to modulate repeat associated non-atg (ran) translation
US20200206255A9 (en) 2016-04-04 2020-07-02 University Of Florida Research Foundation, Incorporated Manipulation of eif3 to modulate repeat associated non-atg (ran) translation
US10940161B2 (en) 2016-04-04 2021-03-09 University Of Florida Research Foundation, Incorporated Manipulation of EIF3 to modulate repeat associated non-ATG (RAN) translation
WO2018035408A1 (en) 2016-08-18 2018-02-22 Ovid Therapeutics Inc. Methods of treating developmental disorders with biguanides
US20200140846A1 (en) 2017-04-17 2020-05-07 University Of Florida Research Foundation, Incorporated Regulation of ran translation by pkr and eif2a-p pathways
US11345911B2 (en) 2017-04-17 2022-05-31 University Of Florida Research Foundation, Incorporated Regulation of RAN translation by PKR and eIF2A-P pathways
US20230002753A1 (en) 2017-04-17 2023-01-05 University Of Florida Research Foundation, Incorporated Regulation of ran translation by pkr and eif2a-p pathways
US20200232925A1 (en) 2017-09-25 2020-07-23 University of Florida Research Foundation,Incorporation Immunoassays for detection of ran proteins
WO2019060918A1 (en) 2017-09-25 2019-03-28 University Of Florida Research Foundation, Incorporated IMMUNOLOGICAL ASSAYS FOR DETECTION OF RAN PROTEINS
WO2019067587A1 (en) 2017-09-26 2019-04-04 University Of Florida Research Foundation, Incorporated USE OF METFORMIN AND ANALOGUES THEREOF TO REDUCE RAN PROTEIN RATES DURING TREATMENT OF NEUROLOGICAL DISORDERS
WO2021007110A1 (en) 2019-07-05 2021-01-14 University Of Florida Research Foundation, Incorporated Methods for treating ran protein-associated neurological diseases
US20220373559A1 (en) 2019-09-20 2022-11-24 University Of Florida Research Foundation, Incorporated Detection of antibodies against ran proteins from serum and tissue lysates

Non-Patent Citations (141)

* Cited by examiner, † Cited by third party
Title
[No Author Listed] EBNA1—Epstein-Barr nuclear antigen 1—Epstein-Barr virus (strain GD1) (HHV-4)—EBNA1 gene & protein, 2018 Jan. 2018. Retrieved from the internet under https://www.uniprot.org/uniprot/Q3KSS4 on Sep. 12, 2018. 6 pages.
[No Author Listed], Abstracts. Medgen. Mar. 4, 2016; 28(1):84-232. DOI: 10.1007/s11825-016-0083-5.
[No Author Listed], Amersham ECL Western Blotting Detection Reagent. Retrieved from the internet under https://www.cytivalifesciences.com/en/us/shop/protein-analysis/blotting-and-detection/blotting-standards-and-reagents/amersham-ecl-western-blotting-detection-reagent-p-05748 on Feb. 22, 2022, 6 pages.
Ash et al., Unconventional translation of C9ORF72 GGGGCC expansion generates insoluble polypeptides specific to c9FTD/ALS. Neuron. Feb. 20, 2013;77(4):639-46. doi: 10.1016/j.neuron.2013.02.004. Epub Feb. 12, 2013.
Ashizawa et al., GGCCTG repeats put a hex on Purkinje cells and motor neurons in SCA36. Neurology. Jul. 24, 2012;79(4):302-3. doi: 10.1212/WNL.0b013e31826043d9. Epub Jun. 27, 2012.
Ayhan et al., SCA8 RAN polySer protein preferentially accumulates in white matter regions and is regulated by eIF3F. EMBO J. Oct. 1, 2018;37(19). pii: e99023. doi: 10.15252/embj.201899023. Epub Sep. 11, 2018.
Baboonian et al., Cross reaction of antibodies to a glycine/alanine repeat sequence of Epstein-Barr virus nuclear antigen-1 with collagen, cytokeratin, and actin. Ann Rheum Dis. Nov. 1991;50(11):772-5.
Bae et al., Antibody-aided clearance of extracellular ?-synuclein prevents cell-to-cell aggregate transmission. J Neurosci. Sep. 26, 2012;32(39):13454-69.
Bañez-Coronel et al., A pathogenic mechanism in Huntington's disease involves small CAG-repeated RNAs with neurotoxic activity. PLoS Genet. 2012;8(2):e1002481. doi: 10.1371/journal.pgen.1002481. Epub Feb. 23, 2012.
Bañez-Coronel et al., RAN Translation in Huntington Disease. Neuron. Nov. 18, 2015; 88(4): 667-677. doi: 10.1016/j.neuron.2015.10.038.
Bañez-Coronel et al., Repeat-associated non-AUG (RAN) translation: insights from pathology. Lab Invest. Jul. 2019;99(7):929-942. doi: 10.1038/s41374-019-0241-x. Epub Mar. 27, 2019.
Bañez-Coronel et al., Sense and antisense RAN proteins in the CAG⋅CTG polyglutamine spinocerebellar ataxias. International Congress for Ataxia Research. Abstract ID 271. Nov. 1-4, 2022. 1 page.
Barzilai et al., Metformin as a Tool to Target Aging. Cell Metab. Jun. 14, 2016;23(6):1060-1065. doi: 10.1016/j.cmet.2016.05.011.
Batra et al. Human Molecular genetics 2010, 19 (1), R77-R82. *
Benkirane et al., Oncogenic potential of TAR RNA binding protein TRBP and its regulatory interaction with RNA-dependent protein kinase PKR. EMBO J. Feb. 3, 1997;16(3):611-24. doi: 10.1093/emboj/16.3.611.
Brooks et al., Spinal and bulbar muscular atrophy: a trinucleotide-repeat expansion neurodegenerative disease. Trends Neurosci. Oct. 1995;18(10):459-61. doi: 10.1016/0166-2236(95)94497-s.
Carroll et al., Potent and selective antisense oligonucleotides targeting single-nucleotide polymorphisms in the Huntington disease gene / allele-specific silencing of mutant huntingtin. Mol Ther. Dec. 2011;19(12):2178-85. doi: 10.1038/mt.2011.201. Epub Oct. 4, 2011.
Chen et al., Antidiabetic drug metformin (GlucophageR) increases biogenesis of Alzheimer's amyloid peptides via up-regulating BACE1 transcription. Proc Natl Acad Sci U S A. Mar. 10, 2009;106(10):3907-12. doi: 10.1073/pnas.0807991106. Epub Feb. 23, 2009.
Chen et al., Functional genomics in Drosophila models of human disease. Briefings in Functional Genomics. Aug. 22, 2012;11(5):405-415.
Cheng et al., C9ORF72 GGGGCC repeat-associated non-AUG translation is upregulated by stress through eIF2α phosphorylation. Nat Commun. Jan. 4, 2018;9(1):51. doi: 10.1038/s41467-017-02495-z.
Cleary et al. Human Molecular genetics 2013, 22 (1), R45-R51. *
Cleary et al., New developments in RAN translation: insights from multiple diseases. Curr Opin Genet Dev. Jun. 2017;44:125-134. doi: 10.1016/j.gde.2017.03.006. Epub Mar. 30, 2017. Author Manuscript, 18 pages.
Cleary et al., Repeat-associated non-ATG (RAN) translation in neurological disease. Hum Mol Genet. Oct. 15, 2013;22(R1):R45-51. doi: 10.1093/hmg/ddt371. Epub Aug. 4, 2013.
Donnelly et al., RNA toxicity from the ALS/FTD C9ORF72 expansion is mitigated by antisense intervention. Neuron. Oct. 16, 2013;80(2):415-28. doi: 10.1016/j.neuron.2013.10.015.
Duan et al., Generation of polyclonal antiserum for the detection of methylarginine proteins. J Immunol Methods. Mar. 30, 2007;320(1-2):132-42. Epub Feb. 6, 2007.
Duellman et al., Antigen-binding properties of monoclonal antibodies reactive with EBNA1 and use in immunoaffinity chromatography. PLoS One. 2009;4(2):e4614. doi: 10.1371/journal.pone.0004614. Epub Feb. 26, 2009.
EP 14776090.4, Sep. 30, 2016, Extended European Search Report.
EP 17779695.0, Jan. 7, 2020, Extended European Search Report.
EP 17779695.0, Oct. 18, 2019, Supplementary Partial European Search Report.
EP 18860923.4, Nov. 26, 2021, Extended European Search Report.
Extended European Search Report, dated Dec. 17, 2020, in connection with Application No. EP 18786964.9.
Extended European Search Report, dated Jan. 7, 2020, in connection with Application No. EP 17779695.0.
Extended European Search Report, dated Jun. 11, 2021, in connection with Application No. EP 18859783.5.
Extended European Search Report, dated Nov. 26, 2021, in connection with Application No. EP 18860923.4.
Extended European Search Report, dated Sep. 30, 2016, in connection with Application No. EP 14776090.4.
Foretz et al., Metformin: from mechanisms of action to therapies. Cell Metab. Dec. 2, 2014;20(6):953-66. doi: 10.1016/j.cmet.2014.09.018. Epub Oct. 30, 2014.
Gantois et al., Metformin ameliorates core deficits in a mouse model of fragile X syndrome. Nat Med. Jun. 2017;23(6):674-677. doi: 10.1038/nm.4335. Epub May 15, 2017.
Gkogkas et al., Pharmacogenetic inhibition of eIF4E-dependent Mmp9 mRNA translation reverses fragile X syndrome-like phenotypes. Cell Rep. Dec. 11, 2014;9(5):1742-1755. doi: 10.1016/j.celrep.2014.10.064. Epub Nov. 26, 2014.
Gómez-Tortosa et al., C9ORF72 hexanucleotide expansions of 20-22 repeats are associated with frontotemporal deterioration. Neurology. Jan. 22, 2013;80(4):366-70. doi: 10.1212/WNL.0b013e31827f08ea. Epub Jan. 2, 2013.
Green et al., RAN translation at C9orf72-associated repeat expansions is selectively enhanced by the integrated stress response. Nat Commun. Dec. 8, 2017;8(1):2005. doi: 10.1038/s41467-017-02200-0.
Hock et al., Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Neuron. May 22, 2003;38(4):547-54.
International Preliminary Report on Patentability, dated Apr. 21, 2022, in connection with Application No. PCT/US2020/054976.
International Preliminary Report on Patentability, dated Apr. 7, 2022, in connection with Application No. PCT/US2020/051670.
International Preliminary Report on Patentability, dated Apr. 9, 2020, in connection with Application No. PCT/US2018/052745.
International Preliminary Report on Patentability, dated Apr. 9, 2020, in connection with Application No. PCT/US2018/052913.
International Preliminary Report on Patentability, dated Dec. 14, 2017, in connection with Application No. PCT/US2016/034738.
International Preliminary Report on Patentability, dated Mar. 31, 2022, in connection with Application No. PCT/US2020/051671.
International Preliminary Report on Patentability, dated Oct. 18, 2018, in connection with Application No. PCT/US2017/026020.
International Preliminary Report on Patentability, dated Oct. 31, 2019, in connection with Application No. PCT/US2018/028015.
International Preliminary Report on Patentability, dated Sep. 24, 2015, in connection with Application No. PCT/US2014/022670.
International Search Report and Written Opinion, dated Apr. 23, 2021, in connection with Application No. PCT/US2020/054976.
International Search Report and Written Opinion, dated Aug. 22, 2014, in conenction with Application No. PCT/US2014/022670.
International Search Report and Written Opinion, dated Dec. 31, 2020, in connection with Application No. PCT/US2020/051670.
International Search Report and Written Opinion, dated Dec. 6, 2019, in connection with Application No. PCT/US2018/052745.
International Search Report and Written Opinion, dated Feb. 9, 2021, in connection with Application No. PCT/US2020/051671.
International Search Report and Written Opinion, dated Jan. 15, 2019, in connection with Application No. PCT/US2018/052913.
International Search Report and Written Opinion, dated Jul. 27, 2018, in connection with Application No. PCT/US2018/028015.
International Search Report and Written Opinion, dated Jul. 7, 2017, in connection with Application No. PCT/US2017/026020.
International Search Report and Written Opinion, dated Sep. 21, 2016, in connection with Application No. PCT/US2016/034738.
Invitation to Pay Additional Fees, dated Feb. 19, 2021, in connection with Application No. PCT/US2020/054976.
Invitation to Pay Additional Fees, dated Mar. 30, 2023, in connection with Application No. PCT/US2022/051530.
Invitation to Pay Additional Fees, dated Nov. 30, 2020, in connection with Application No. PCT/US2020/051671.
Jawaid et al., ALS disease onset may occur later in patients with pre-morbid diabetes mellitus. Eur J Neurol. May 2010;17(5):733-9. doi: 10.1111/j.1468-1331.2009.02923.x. Epub Jan. 13, 2010.
Jin et al., Metformin Protects Cells from Mutant Huntingtin Toxicity Through Activation of AMPK and Modulation of Mitochondrial Dynamics. Neuromolecular Med. Dec. 2016;18(4):581-592. doi: 10.1007/s12017-016-8412-z. Epub May 25, 2016.
Kearse et al., CGG Repeat-Associated Non-AUG Translation Utilizes a Cap-Dependent Scanning Mechanism of Initiation to Produce Toxic Proteins. Mol Cell. Apr. 21, 2016;62(2):314-322. doi: 10.1016/j.molcel.2016.02.034. Epub Mar. 31, 2016.
Kioumourtzoglou et al., Diabetes Mellitus, Obesity, and Diagnosis of Amyotrophic Lateral Sclerosis: A Population-Based Study. JAMA Neurol. Aug. 2015;72(8):905-11. doi: 10.1001/jamaneurol.2015.0910. Author Manuscript, 15 pages.
Koide et al., Unstable expansion of CAG repeat in hereditary dentatorubral-pallidoluysian atrophy (DRPLA). Nat Genet. Jan. 1994;6(1):9-13. doi: 10.1038/ng0194-9.
Koob et al., An untranslated CTG expansion causes a novel form of spinocerebellar ataxia (SCA8). Nat Genet. Apr. 1999;21(4):379-84. doi: 10.1038/7710.
Leitman et al., ER stress-induced eIF2-alpha phosphorylation underlies sensitivity of striatal neurons to pathogenic huntingtin. PLoS One. Mar. 3, 2014;9(3):e90803. doi: 10.1371/journal.pone.0090803.
Liu et al., C9orf72 BAC Mouse Model with Motor Deficits and Neurodegenerative Features of ALS/FTD. Neuron. May 4, 2016;90(3):521-34. doi: 10.1016/j.neuron.2016.04.005. Epub Apr. 21, 2016.
Ma et al. Neuroscience Letters 2007, 411, 98-103. *
Ma et al., Metformin therapy in a transgenic mouse model of Huntington's disease. Neurosci Lett. Jan. 10, 2007;411(2):98-103. doi: 10.1016/j.neulet.2006.10.039. Epub Nov. 15, 2006.
Memmott et al., Metformin prevents tobacco carcinogen-induced lung tumorigenesis. Cancer Prev Res (Phila). Sep. 2010;3(9):1066-76. doi: 10.1158/1940-6207.CAPR-10-0055. Epub Sep. 1, 2010.
Mirkin, S. Nature 2007, 447, 932-940. *
Moon et al., Neuronal Regulation of eIF2α Function in Health and Neurological Disorders. Trends Mol Med. Jun. 2018;24(6):575-589. doi: 10.1016/j.molmed.2018.04.001. Epub Apr. 30, 2018.
Mori et al., The C9orf72 GGGGCC repeat is translated into aggregating dipeptide-repeat proteins in FTLD/ALS. Science. Mar. 15, 2013;339(6125):1335-8. doi: 10.1126/science.1232927. Epub Feb. 7, 2013. Supplementary information included.
Nguyen et al., Repeat-Associated Non-ATG Translation: Molecular Mechanisms and Contribution to Neurological Disease. Annu Rev Neurosci. Jul. 8, 2019;42:227-247. doi: 10.1146/annurev-neuro-070918-050405. Epub Mar. 25, 2019. Author Manuscript, 24 pages.
Pakos-Zebrucka et al., The integrated stress response. EMBO Rep. Oct. 2016;17(10):1374-1395. doi: 10.15252/embr.201642195. Epub Sep. 14, 2016.
Park et al., TAR RNA-binding protein is an inhibitor of the interferon-induced protein kinase PKR. Proc Natl Acad Sci U S A. May 24, 1994;91(11):4713-7. doi: 10.1073/pnas.91.11.4713.
PCT/US2014/022670, Aug. 22, 2014, International Search Report and Written Opinion.
PCT/US2014/022670, Sep. 24, 2015, International Preliminary Report on Patentability.
PCT/US2016/034738, Dec. 14, 2017, International Preliminary Report on Patentability.
PCT/US2016/034738, Sep. 21, 2016, International Search Report and Written Opinion.
PCT/US2017/026020, Jul. 7, 2017, International Search Report and Written Opinion.
PCT/US2017/026020, Oct. 18, 2018, International Preliminary Report on Patentability.
PCT/US2018/028015, Jul. 27, 2018, International Search Report and Written Opinion.
PCT/US2018/028015, Oct. 31, 2019, International Preliminary Report on Patentability.
PCT/US2018/052745, Apr. 9, 2020, International Preliminary Report on Patentability.
PCT/US2018/052745, Dec. 6, 2019, International Search Report and Written Opinion.
PCT/US2018/052913, Apr. 9, 2020, International Preliminary Report on Patentability.
PCT/US2018/052913, Jan. 15, 2019, International Search Report and Written Opinion.
PCT/US2020/051670, Apr. 7, 2022, International Preliminary Report on Patentability.
PCT/US2020/051670, Dec. 31, 2020, International Search Report and Written Opinion.
PCT/US2020/051671, Feb. 9, 2021, International Search Report and Written Opinion.
PCT/US2020/051671, Mar. 31, 2022, International Preliminary Report on Patentability.
PCT/US2020/051671, Nov. 30, 2020, Invitation to Pay Additional Fees.
PCT/US2020/054976, Apr. 21, 2022, International Preliminary Report on Patentability.
PCT/US2020/054976, Apr. 23, 2021, International Search Report and Written Opinion.
PCT/US2020/054976, Feb. 19, 2021, Invitation to Pay Additional Fees.
PCT/US2022/051530, Mar. 30, 2023, Invitation to Pay Additional Fees.
Perez et al., CCG⋅CGG interruptions in high-penetrance SCA8 families increase RAN translation and protein toxicity. EMBO Mol Med. Nov. 8, 2021;13(11):e14095. doi: 10.15252/emmm.202114095. Epub Oct. 11, 2021.
Satoh et al., Dystrophic neurites express C9orf72 in Alzheimer's disease brains. Alzheimers Res Ther. Aug. 16, 2012;4(4):33. doi: 10.1186/alzrt136. 13 pages.
Sha et al., Treatment implications of C9ORF72. Alzheimer's Res Ther. Nov. 2, 2012;4(6):46. doi: 10.1186/alzrt149. eCollection 2012.
Shoesmith et al., Amyotrophic lateral sclerosis: update for family physicians. Can Fam Physician. Dec. 2006;52(12):1563-9.
Sonenberg et al., Regulation of translation initiation in eukaryotes: mechanisms and biological targets. Cell. Feb. 20, 2009;136(4):731-45. doi: 10.1016/j.cell.2009.01.042.
Soragni et al., Repeat-Associated Non-ATG (RAN) Translation in Fuchs' Endothelial Corneal Dystrophy. Invest Ophthalmol Vis Sci. Apr. 1, 2018;59(5):1888-1896. doi: 10.1167/iovs.17-23265.
Supplementary Partial European Search Report, dated Oct. 18, 2019, in connection with Application No. EP 17779695.0.
Taylor et al., Decoding ALS: from genes to mechanism. Nature. Nov. 10, 2016;539(7628):197-206. doi: 10.1038/nature20413. Author Manuscript, 28 pages.
Tian et al., Expanded CUG repeat RNAs form hairpins that activate the double-stranded RNA-dependent protein kinase PKR. RNA. Jan. 2000;6(1):79-87. doi: 10.1017/s1355838200991544.
Todd et al., CGG repeat-associated translation mediates neurodegeneration in fragile X tremor ataxia syndrome. Neuron. May 8, 2013;78(3):440-55. doi: 10.1016/j.neuron.2013.03.026. Epub Apr. 18, 2013. Erratum in: Neuron. Jul. 24, 2013;79(2):402.
Todd et al., Insights into the pathogenic mechanisms of Chromosome 9 open reading frame 72 (C9orf72) repeat expansions. J Neurochem. Aug. 2016;138 Suppl 1:145-62. doi: 10.1111/jnc.13623. Epub Jun. 15, 2016.
Trouth et al., Myasthenia gravis: a review. Autoimmune Dis.; 2012:874680. doi: 10.1155/2012/874680. Epub Oct. 31, 2012.
Tsuji, S., Dentatorubral-pallidoluysian atrophy. Handb Clin Neurol. 2012; 103:587-94. doi: 10.1016/B978-0-444-51892-7.00041-3.
U.S. Appl. No. 14/775,278, filed Sep. 11, 2015, Ranum et al.
U.S. Appl. No. 15/577,995, filed Nov. 2, 2017, Ranum et al.
U.S. Appl. No. 16/091,444, filed Oct. 4, 2018, Ranum et al.
U.S. Appl. No. 16/362,908, filed Mar. 25, 2019, Ranum et al.
U.S. Appl. No. 16/605,992, filed Oct. 17, 2019, Ranum et al.
U.S. Appl. No. 16/650,016, filed Mar. 24, 2020, Ranum et al.
U.S. Appl. No. 16/695,717, filed Nov. 26, 2019, Ranum et al.
U.S. Appl. No. 16/851,690, filed Apr. 17, 2020, Ranum et al.
U.S. Appl. No. 17/761,764, filed Mar. 18, 2022, Ranum et al.
U.S. Appl. No. 17/762,543, filed Mar. 22, 2022, Ranum et al.
U.S. Appl. No. 17/767,549, filed Apr. 8, 2022, Ranum et al.
U.S. Appl. No. 17/826,224, filed May 27, 2022, Ranum et al.
Vaughn et al., Inhibition of PKR protects against tunicamycin-induced apoptosis in neuroblastoma cells. Gene. Feb. 15, 2014;536(1):90-6. doi: 10.1016/j.gene.2013.11.074. Epub Dec. 14, 2013.
Vishwakarma et al., Current molecular insight to reveal the dynamics of CAG repeating units in spinocerebellar ataxia. Intractable Rare Dis Res. May 2018;7(2):79-86. doi: 10.5582/irdr.2018.01039.
Wang et al., Comparative Analysis of VOCs in Exhaled Breath of Amyotrophic Lateral Sclerosis and Cervical Spondylotic Myelopathy Patients. Sci Rep. 2016;6:26120. Published May 23, 2016. doi: 10.1038/srep26120.
Welnowska et al., Translation of Viral mRNA without Active eIF2: The Case of Picornaviruses. PLoS One. 2011; 6(7): e22230. EPub Jul. 14, 2011. doi: 10.1371/journal.pone.0022230.
Wieben et al., Amplification-free long-read sequencing of TCF4 expanded trinucleotide repeats in Fuchs Endothelial Corneal Dystrophy. PLoS One. Jul. 5, 2019;14(7):e0219446. doi: 10.1371/journal.pone.0219446.
Wojciechowska et al., RAN translation and frameshifting as translational challenges at simple repeats of human neurodegenerative disorders. Nucleic Acids Res. 2014;42(19):11849-11864. doi:10.1093/nar/gku794.
Xiao et al., Isoform-specific antibodies reveal distinct subcellular localizations of C9orf72 in amyotrophic lateral sclerosis. Ann Neurol. Oct. 2015;78(4):568-83. doi: 10.1002/ana.24469. Epub Aug. 29, 2015.
Yanagisawa et al., Protein Binding of a DRPLA Family Through Arginine-Glutamic Acid Dipeptide repeats is Enhanced by Extended polyglutamine. Human Molecular Genetics. 2000;9(9):1433-1442.
Yu et al., Developing therapeutic antibodies for neurodegenerative disease. Neurotherapeutics. Jul. 2013;10(3):459-72. doi: 10.1007/s13311-013-0187-4.
Zhang et al., Aggregation-prone c9FTD/ALS poly(GA) RAN-translated proteins cause neurotoxicity by inducing ER stress. Acta Neuropathol. 2014;128:505-24.
Zhou et al., Antibodies inhibit transmission and aggregation of C9orf72 poly-GA dipeptide repeat proteins. EMBO Mol Med. May 2017;9(5):687-702. doi: 10.15252/emmm.201607054.
Zhu et al., Suppression of PKR promotes network excitability and enhanced cognition by interferon-γ-mediated disinhibition. Cell. Dec. 9, 2011;147(6):1384-96. doi: 10.1016/j.cell.2011.11.029.
Zu et al., Metformin inhibits RAN translation through PKR pathway and mitigates disease in C9orf72 ALS/FTD mice. Proc Natl Acad Sci U S A. Aug. 4, 2020;117(31):18591-18599. doi: 10.1073/pnas.2005748117. Epub Jul. 20, 2020. Supplementary Materials, 33 pages.
Zu et al., Non-ATG-initiated translation directed by microsatellite expansions. Proc Natl Acad Sci U S A. Jan. 4, 2011;108(1):260-5. doi: 10.1073/pnas.1013343108. Epub Dec. 20, 2010.
Zu et al., RAN proteins and RNA foci from antisense transcripts in C9ORF72 ALS and frontotemporal dementia. Proc Natl Acad Sci U S A. 2013;110(51):E4968-E4977. doi:10.1073/pnas.1315438110.
Zu et al., RAN Translation Regulated by Muscleblind Proteins in Myotonic Dystrophy Type 2. Neuron. Sep. 13, 2017;95(6):1292-1305.e5. doi: 10.1016/j.neuron.2017.08.039.

Also Published As

Publication number Publication date
WO2019067587A1 (en) 2019-04-04
EP3688021A4 (en) 2021-12-29
US20240269093A1 (en) 2024-08-15
AU2018342105A1 (en) 2020-04-02
AU2018342105B2 (en) 2023-11-16
JP7350337B2 (ja) 2023-09-26
CA3076214A1 (en) 2019-04-04
JP2020535165A (ja) 2020-12-03
EP3688021A1 (en) 2020-08-05
US20200268691A1 (en) 2020-08-27

Similar Documents

Publication Publication Date Title
US11903910B2 (en) Use of metformin and analogs thereof to reduce RAN protein levels in the treatment of neurological disorders
US20240091213A1 (en) Compounds for tau protein degradation
US10975055B2 (en) Inhibitors of interleukin-1 receptor-associated kinases and uses thereof
US20160168165A1 (en) Myc modulators and uses thereof
US11905285B2 (en) Inhibitors of plasma kallikrein and uses thereof
US20190000860A1 (en) Use of compositions modulating chromatin structure for graft versus host disease (gvhd)
US10865213B2 (en) Max binders as MYC modulators and uses thereof
US20230167081A1 (en) 5-amino-2-piperidinon-3-yl-1-oxoisoindoline derivatives for degradation of ikzf2 degraders
US20220242872A1 (en) E3 ligase binders and uses thereof
US20130096129A1 (en) Activators of class i histone deacetlyases (hdacs) and uses thereof
US9550744B2 (en) Vitamin C prodrugs and uses thereof
US20180362574A1 (en) Methods for treating polycystic kidney disease and polycystic liver disease
US20220152036A1 (en) COMPOUNDS FOR USES IN PHARMACOLOGICAL INDUCTION OF HBF FOR TREATMENT OF SICKLE CELL DISEASE AND ß-THALASSEMIA
US11919886B2 (en) 4,9-dioxo-4,9-dihydronaphtho[2,3-B]furan-3-carboxamide derivatives and uses thereof for treating proliferative diseases and infectious diseases
EP4440560A1 (en) Small molecule inhibitors of repeat associated non-aug (ran) translation and combination therapies
WO2024086705A2 (en) Bicyclic enhancers of the particulate guanylyl cyclase receptor a
WO2024151519A2 (en) Pparg modulators
US20230382865A1 (en) Histone demethylase 5 inhibitors and uses thereof
US20240246952A1 (en) Small molecule modulators of glucocerebrosidase activity and uses thereof
WO2024086717A2 (en) Heteroaryl enhancers of the particulate guanylyl cyclase receptor a

Legal Events

Date Code Title Description
FEPP Fee payment procedure

Free format text: ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: BIG.); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

FEPP Fee payment procedure

Free format text: ENTITY STATUS SET TO SMALL (ORIGINAL EVENT CODE: SMAL); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

STPP Information on status: patent application and granting procedure in general

Free format text: APPLICATION DISPATCHED FROM PREEXAM, NOT YET DOCKETED

AS Assignment

Owner name: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED, FLORIDA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:RANUM, LAURA;ZU, TAO;REEL/FRAME:054893/0775

Effective date: 20190425

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS

STPP Information on status: patent application and granting procedure in general

Free format text: PUBLICATIONS -- ISSUE FEE PAYMENT VERIFIED

STCF Information on status: patent grant

Free format text: PATENTED CASE